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Abstract 
Introduction: Sustained attention is known to be dysfunctional in psychotic disorders. 
Sustained attention is the ability to remain focused on a specific time-locked stimulus 
within a task. We aimed to determine whether there are specific group differences 
between CON and three psychotic disorders: SCZ, MPD and BPD, then to determine 
differences between these psychotic disorders. This included differences in behavioural 
performance and prominent electrophysiological event-related potential (ERP) wave 
components during cueing and target processing of a visual sustained attention task. 
Further we aimed to characterize ERP waveform component relationships across and within 
these groups for demographics, substance use, behavioural performance, and clinical 
variables, the last limited to the psychotic groups. Lastly, we investigated the effects of 
prescribed medications on ERP wave components within the psychotic groups. 
Methodology: 103 participants (29 schizophrenia (SCZ), 28 bipolar disorder with a history of 
psychosis (BPD), 21 methamphetamine-induced psychotic disorder (MPD), and 30 controls 
(CON)) underwent electroencephalography (EEG) record while completing a visual 
continuous performance task. Participants were presented with 60 trials with three 
consecutive S’s, the presentation of the third S required a behavioural response. Prominent 
ERP waveform components were extracted from cues and target stimulus. Group 
differences were determined by ANOVA with Bonferroni post-hoc correction or 
multivariate Kruskal-Wallis test dependent on data distribution. Relationships between ERP 
wave components were determined appropriate with Spearman’s Rank order correlation 
analyses.  
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Results: (1) MPD reported higher use of substances compared to CON, SCZ and BPD. SCZ 
behavioural performance was poorer compared to CON which was shown by their longer 
response times, reduced accuracy and increased errors of omission. Clinically, MPD was 
found to have a shorter duration of illness compared to SCZ. Then SCZ was found to have 
more positive symptoms compared to BPD whereas BPD had more negative symptoms 
compared to SCZ. For the first cue, wave component differences were found only over the 
left hemisphere, for P100 amplitude over the frontal cortex, P300 amplitude over the 
central cortex, and N170 amplitude over the parietal cortex. For the presentation of the 
second cue, differences noted for all groups were localised to the frontal and central brain 
regions, for P100 and N170 ERP waveforms. For the target stimulus wave component 
differences were found over the prefrontal, frontal and parietal brain regions, within CON, 
SCZ, BPD and MPD. (2) For the first cue, education positively correlated with the N170 left 
parietal amplitude in CON and P300 right parietal amplitude in MPD. During the second 
cue, the left parietal N170 latency in SCZ correlated positively with education and the left 
central P300 latency correlated negatively with education in MPD. The age on the day of 
testing correlated positively with the target left frontal P300 latency in MPD. For the first 
cue, substance use positively correlated with the left and right parietal P300 latency and 
negatively for the right parietal P100 amplitude in SCZ. In MPD, a negative correlation was 
noted across left and right prefrontal N170 and P300 amplitudes, and positive correlation 
for the left prefrontal P300 latency in MPD. For the target stimulus, correlations were 
evident for the left and right parietal N70, N170 amplitudes, P300 latency, the right parietal 
P100 amplitude and left central P300 latency in SCZ. For the first cue, in SCZ PANSS total 
score correlated positively with left and right central P300 amplitudes and the left parietal 
P300 amplitude. For the second cue; in MPD, the PANSS negative symptom score, positively 
correlated with the P100 and N170 left parietal amplitude, left and right parietal P150 
amplitude, left central and right parietal P300 amplitude. For the target, the Hamilton 
depression rating scale correlated positively with the left and right frontal P300 amplitude 
in MPD and then negatively with the right parietal P300 amplitude in SCZ. Behavioural 
performance in CON, positively correlated with the left parietal N70, P100, P150 and N170 
amplitude the number of correct responses, and left central N170 amplitude. While the 
number of impulsive responses correlated negatively with the left parietal N70, P100, P150 
and N170 and the left central N170 amplitude of CON. For the second cue, behavioural 
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performance was related to the fronto-parietal relationship across all groups. For the target 
stimulus, impulsive responses positively correlated with the left parietal N70 latency in SCZ. 
Overall response time negatively correlated with the right parietal P300 latency for SCZ. (3) 
Medication was found to affect ERP wave components during the sustained visual attention 
task. For the first cue FGA’s increased the left central P100 amplitude in both SCZ and BPD 
and decreased the left parietal P100 amplitude in SCZ only. The use of antipsychotics 
increased the right parietal N70 and left central P100 amplitudes in BPD, specifically the 
right prefrontal N170 amplitude was increased with the use of SGA’s. Then clozapine use 
increased the left frontal P100 amplitude in SCZ. For the second cue, SGA’s decreased the 
right parietal P150 amplitude in SCZ but in MPD the right parietal P150 amplitude was 
increased with haloperidol use, and FGA. SGA’s increased the left parietal P300 latency in 
BPD and sodium valproate decreased the left prefrontal P300 latency. For the target 
stimulus, SGA’s decreased the right parietal P100, P150 and left parietal P150 amplitudes 
and increased the left central P300 latency in BPD. 
Conclusion: (1) sustained attentional performance is poorer in SCZ. Our study adds to 
previous studies showing attention processing deficits in SCZ, are evident during cueing of a 
sustained attention tasks; (2) substance use was found to slow cognitive processing, 
education improved executive function and information processing, and symptom severity 
was associated with dysfunction of prefrontal and frontal cortices; (3) antipsychotic 
medication was related to improved processing of salient information. These data support 
the current literature and provide novel insights to the attentional processing deficits 
during cueing in the psychotic disorders
http://etd.uwc.ac.za/
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Chapter 1 Literature review 
1.1 Background 
Mental illnesses have been around for centuries; however it was not until the nineteenth 
century that they were contextualised and characterised by symptom(s) and course 
(Farreras, I. G, 2017). By the twentieth century research into the etiology of psychiatric 
disorders became increasingly important (Kessler 2000). There have been continual 
improvements in the clinical diagnostics as can be seen in the revisions of the diagnostic 
statistical manual of mental disorders (DSM) (American Psychiatric Association 2013b), and 
are seen to aid treatment approaches (Saddichha et al. 2008). Current psychiatric 
medications serve to manage symptoms, e.g. antipsychotic medication in the treatment of 
psychosis, rather than a cure thereof (Perez et al. 2016). This limitation has led to new 
approach to psychiatric disorders where we search for biological mechanisms, with the 
hope of improving treatment regimens and development of new drug treatments, to 
ultimately improve patient prognosis (The National Institute of Mental Health 2015).  
Schizophrenia spectrum disorders, i.e. psychotic disorders (Trotman et al. 2013), are known 
to affect 1% of the world’s population (Mandelli et al. 2014; Rudolph et al. 2015). Psychosis 
is the active state of a psychotic disorder whereby the person undergoes an episode of 
severe behavioural changes, impaired cognitive functioning and a distorted sense of reality 
(Quach et al. 2016). Psychosis significantly reduces individuals’ ability to make good 
judgements, alters the ability to think clearly, behave appropriately and function (Serper & 
Berenbaum 2008). The typical characteristic symptoms of psychosis experienced are 
hallucinations and/ or delusions which they believe are real (Quach et al. 2016). 
Importantly psychosis are not only symptoms related to hallucinations/delusions, referred 
to as positive symptoms, but these individuals also experience negative symptoms, e.g. 
social withdrawal, and cognitive symptoms which  greatly impact daily activities and are a 
burden to the individual and family members involved (Perez et al. 2016). Approximately 21 
million individuals are diagnosed with schizophrenia (SCZ) (World Health Organization 
2008). SCZ does not affect a specific race or nationality (Chong et al. 2016), and occurs 
equally in men and females. However the peak age of onset in females occurs 5- 7 years 
later than males; 10–25 years in males and 25–35 years in females (Tandon et al. 2013; Hu 
http://etd.uwc.ac.za/
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et al. 2016). The exact reason to why this occurs is not completely certain (Hu et al. 2016). 
Some  hypothesize that the later onset of SCZ in females is due to the hormones present in 
women during puberty, and protective effect of the hormone estrogen (Erick Messias, 
Chuan-Yu Chen 2009; Kirkbride et al. 2012; Perez et al. 2016).   
Patients diagnosed with SCZ can be hospitalized several times in their lifetime (Erick 
Messias, Chuan-Yu Chen 2009). A drop in re- hospitalisation has been seen with good 
clinical management and support from family (Mccormick et al. 2015). It is reported that up 
to 10% of patients diagnosed with SCZ commit suicide (Rössler et al. 2005), the 
development of persecutory delusions and use of substances of abuse, e.g. cannabis, have 
been shown to  increase violence in SCZ (Spitzer et al. 1978). 
The presentation of psychosis is not limited to the schizophrenia spectrum of disorders, and 
can also be apparent in Bipolar disorder (BPD) and methamphetamine-induced psychotic 
disorder (MPD) (Grant et al. 2012; Soh et al. 2015). Like SCZ, BPD is a challenge and a 
lifelong struggle which affects the individual as well as their family (Hall et al. 2014). BPD, 
previously known as manic- depressive illness is a psychiatric disorder which classically 
presents with polarity of mood, i.e. mania and depression (Laxman et al. 2008). Individuals 
with BPD may also present with both mood polarities at one time and this is referred to as a 
mixed episode (Johnson & Leahy 2003). The presentation of psychosis in BPD can present in 
any mood state or episode, or when euthymic, i.e. stable mood state (Park et al. 2004). 
There are no restrictions to the race, nationality, social or educational class of an individual 
(Young & Grunze 2013). BPD affects 60 million individuals worldwide (World Health 
Organization 2017), it is expected that individuals with a diagnosis of severe BPD will spend 
20-50% of their lifetime in care (Young & Grunze 2013), due to cyclical nature of the 
disorder (0.4 episodes per year) (Ayano 2016), with episodes typically lasting between 2 to 
7 months (Young & Grunze 2013). A higher incidence of suicide, greater than 10%, is 
reported for BPD (Price & Marzani-Nissen 2012; Ayano 2016). Patients diagnosed with BPD 
are typically between the ages of 17 and 21 years old (Ayano 2016), and generally chronic, 
i.e. lifelong (Mccormick et al. 2015).  There are some cases where BPD starts in childhood 
but the diagnosis is difficult as the symptoms can present as attention deficit hyperactivity 
disorder or as other developmental disorders (Johnson & Leahy 2003). There is no bias to 
whether more men or women are being diagnosed with BPD (Price & Marzani-Nissen 
http://etd.uwc.ac.za/
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2012). However, it was found that more women experience a higher number of depressive 
episodes and men experience a higher number of manic episodes (Ayano 2016).   
With respect to methamphetamine (MA), in the Western Cape of South Africa 33% of 
individuals are reported to have used methamphetamine, and 15% of psychiatric hospital 
admission are a result of  MA psychosis (Corrigall et al. 2007; Lategan et al. 2016). MPD in 
the Western Cape exceeds reports from Asia, reported to be 10% (Farrell et al. 2002), 
worldwide 16 million people are reported to use MA (Bousman et al. 2009). One out of 
every four individuals using MA are female (Bousman et al. 2009; Zarrabi et al. 2016). The 
high incidence of MA abuse has been related to its recreational use or individuals testing 
the product and ultimately enjoying the high and eventually becoming addicted to the drug. 
The high levels of MA can cause; pulmonary oedema and congestion, heart failure and 
cerebrovascular haemorrhage, ultimately leading to death (Petit et al. 2012). The clinical 
presentation of psychosis in MPD is very similar to that of SCZ (Glasner-Edwards & Mooney 
2014).  
1.2 Diagnostic criteria for schizophrenia, bipolar disorder and methamphetamine induced 
psychotic disorder  
Diagnostically the psychotic disorder spectre comprises of: schizophrenia, brief psychotic 
disorder, schizotypal personality disorder, delusional disorder, schizophreniform disorder, 
schizoaffective disorder, catatonic, substance or medication induced psychotic disorder and 
psychosis due to a general medical condition (Mandelli et al. 2014). An example of 
substance -induced psychosis is MPD (Rusyniak 2012). Further, Bipolar I disorder may 
present with psychosis or psychotic symptoms, and some view Bipolar I as a psychotic 
disorder (Craddock et al. 2005).  
1.2.1 Schizophrenia diagnosis 
SCZ has an array of symptoms linked to it which are divided into three categories: positive, 
negative, and cognitive disturbances (Hill et al. 2010). The positive symptoms include: (1) 
delusions which can present as religiosity, paranoia, ideas of reference, thought disorder, 
thought control, or grandiosity; (2) hallucinations which can be present via any sense, 
predominantly visual and auditory, however patients may present with tactile, olfactory, or 
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gustatory. The negative symptoms include: apathy, absent, blunted or incongruous 
emotional responses, reductions in speech, social withdrawal, impaired attention, 
anhedonia, and sexual problems (American Psychiatric Association 1994). According to the 
DSM IV, if the patient presents with auditory hallucinations or bizarre delusions they will 
likely receive a diagnosis of SCZ (American Psychiatric Association 1994). Prior to the onset 
of symptoms, social and occupational dysfunction can occur, these are referred to as 
prodromal symptoms. Prodromal symptoms generally appear 1-6 months prior to psychotic 
episode, however this period can also be longer. The onset occurs between the age of 15 
and 45 years of age (Tandon et al. 2009), onset beyond 45 years old has been linked to 
neurodegeneration and aging (Chan 2017). 
1.2.2 Bipolar disorder 
BPD is a mental illness characterized by severe depression along with elevated or irritable 
mood states, i.e. mania (Anticevic et al. 2015). BPD was first known as a mood disorder as 
individuals presented with alterations in mood whereby periods of euphoria is achieved 
with a sudden change to major depression (Young & Grunze 2013). BPD is separated into 
two diagnostic categories; bipolar disorder type I and bipolar disorder type II. BPD type I is 
the more severe of the two. BPD type I patients display full mania alternating between 
periods of depression (Khaleghi et al. 2015). BPD type II differs to BPD type I due to the 
absence of a full manic episode, as they experience hypomanic episode which are not as 
severe (Ayano 2016), and do not necessarily require hospitalization (Mccormick et al. 
2015). Manic states are accompanied by pressured speech, altered sleeping patterns due to 
a decreased need for sleep, increased libido, grandiosity, reckless behaviour and severe 
thought disturbances with the presence or absence of psychosis (Mccormick et al. 2015).  
1.2.3 Methamphetamine- induced psychotic disorder  
Methamphetamine (MA) also known by its many street names; speed, ice, kryptonite and 
crystal meth, is a drug which stimulates the central nervous system (Buxton & Dove 2008; 
Petit et al. 2012). It was originally synthesized as an ephedrine in the early 1900’s. It was 
only in the late 1960’s that the drug become heavily abused in California through backyard 
MA laboratory production. The drug is presented as a powder or liquid and a more potent 
form of the drug was developed which was in the form of crystals (Petit et al. 2012). MA 
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can be ingested orally, through nasal insufflation/ snorting, vaginally and rectally, through 
intravenous injection, and via the inhalation of smoke vapours (Allerton & Blake 2008). 
Users of MA also describe to feel increased libido, endless energy, and increased 
productivity. Tweaking can be experienced, which  refers to hallucinating crawling insects 
on the skin, which can result in scratching and picking skin resulting in scabs and scarring 
(Petit et al. 2012). Tweaking is more noticeable in long term MA users where dose of use 
has been escalated to achieve the desired effect of the drug (Buxton & Dove 2008). When 
the effects of MA wear off, feelings of anxiety and depression kick in (Scott et al. 2007). 
As per DSM-IV, after intoxication and withdrawal if psychotic symptoms persist between 1 
and 4 weeks the diagnosis MPD may be given (American Psychiatric Association 1994). The 
presentation of psychosis has been linked to heavy drug use however can also be present 
with low MA abuse, and is suggested to stimulate an underlying psychotic disorder (Perry & 
Juhl 1977; Hermens et al. 2009; Shariat & Elahi 2010; Zarrabi et al. 2016).  
Individuals admitted to psychiatric hospitals for MPD tend to be re- diagnosed with SCZ if 
they present with another psychotic episode that cannot be related to the use of MA, after 
6 months of having their first psychotic episode (American Psychiatric Association 1994). 
This change in diagnosis is largely due to the similarity of symptoms between SCZ and MPD 
(American Psychiatric Association 1994). Bell, conducted a clinical study which involved 
fourteen cases of patients diagnosed with SCZ who were actively using MA at regular 
intervals for years. It was found that after years of MA use, similarities in presentation 
between MPD and SCZ were evident (Bell 1965). The symptoms of psychosis lasted for 
months following the initial diagnosis. After observation, Bell concluded that MPD produces 
a model of psychosis similar to SCZ than that produced by any other hallucinogenic drug 
(Bell 1965). In the recent years many other studies have investigated the similarities 
between MPD and SCZ. Supporting Bell, several studies report similarities between positive 
symptoms of SCZ in MPD  (Hermens et al. 2009; Shariat & Elahi 2010; Bramness et al. 2012; 
Medhus et al. 2015; Barnhorst 2015; Zarrabi et al. 2016; Paulus 2017). An interesting 
caveat, is the reported similarity between BPD and MPD, as delusions of grandeur and 
aggression are often reported in both (Zarrabi et al. 2016). 
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1.3 Dopamine in psychotic disorders 
In psychiatric disorders, neurotransmission is dysfunctional, medication prescribed aims to 
improve neurotransmission (Mikkelsen et al. 1987; Gil-da-Costa et al. 2013). In psychosis 
and psychotic illnesses, the dopamine systems are strongly suggested to be the primary 
neurotransmitter system that is dysfunctional (Mikkelsen et al. 1987), and primary drugs, 
antipsychotics which act on the dopamine systems are prescribed.  
The dopamine (DA) system is important in the control of muscle movement, cognitive 
function and reward mechanisms (Gurevicha et al. 2016). DA, a monoamine, is synthesized 
within dopaminergic neurons. Once the neuron is excited DA is released from the neuronal 
terminal via exocytosis into the synapse and acts by; binding to the post-synaptic DA 
receptors (D1 receptor), then regulated by pre-synaptic neuron DA auto-receptors (D2 
receptor), and recycled by re-uptake at pre-synaptic neuron via dopamine transporter 
(DAT) (Jan 2013). Methamphetamine stimulates the dopaminergic systems in four ways: (1) 
directly stimulates dopamine receptors and with higher affinity; (2) increases the release of 
dopamine; (3) prevents and reverses dopamine reuptake; (4) reduces the breakdown of DA 
and MA by reduction of monoamine oxidase (Jaber et al. 1996; Paulus 2017).  
The DA system consists of four different pathways; mesolimbic, mesocortical, nigrostriatal 
and tuberoinfundibular. Both mesolimbic and mesocortical pathways originate from the 
ventral tegmental area in the brainstem and are important in cognitive regulation and 
function (Emilien et al. 1999). Positive symptoms in schizophrenia are thought to be caused 
by increased dopamine in the mesolimbic pathway (Guzman & Farinde 2016). The 
dysfunction of the mesocortical pathway is associated with cognitive decline and negative 
symptoms in schizophrenia (Guzman & Farinde 2016). The onset of negative symptoms and 
cognitive decline is said to be from the reduced activation of the D1 receptor in the 
prefrontal cortex (Brisch 2014). The nigrostriatal pathway is involved in controlling muscle 
movement by regulating the release of dopamine to the neostriatum (Jibson 2017). The 
process occurs from the transport of DA from the substantia nigra to the neostriatum. By 
stopping the release of DA to the neostriatum with DA antagonists, extrapyramidal 
symptoms especially Parkinsonism become apparent. Within the tuberoinfundibular 
pathway DA inhibits the production of prolactin inhibiting factor. The DA produced within 
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the hypothalamus and transported to the pituitary gland via the tuberoinfundibular 
pathway. Therefore, the blocking of the D2 receptors results in an increase in the 
production of prolactin from the pituitary gland, causing hyperprolactinemia (Guzman & 
Farinde 2016). 
A primary theory which addresses the development of schizophrenia states that symptoms 
of schizophrenia are caused by overactive neuronal activity which is highly dependent on 
dopamine – the dopamine hypothesis of schizophrenia (Spitzer et al. 1978; Basset et al. 
2014). This theory suggests that elevated dopamine activating the D2 receptors results in 
more positive symptoms in SCZ and decreased activation of D1 receptors results in more 
negative symptoms and cognitive dysfunction (Spitzer et al. 1978; Zacher & Holmes 2012; 
Brisch 2014).  
 
Figure 1.1 Dopaminergic pathways. Dopamine is produced and released via four different pathways: 
mesolimbic tract, mesocortical tract, tuberoinfundibular tract and the nigrostriatal tract. Source of image from 
(S. M. Stahl 2008). 
DA has two families of receptors; D1- like dopamine receptor family and D2- like dopamine 
receptor family (Shin & Chung 2012). The D1-like dopamine receptor family consists of D1 
http://etd.uwc.ac.za/
8 
 
and D5 receptors whereas the D2-like dopamine receptor family consists of D2, D3, and D4 
receptors (Gurevicha et al. 2016). Both D1 and D2 receptors are the most abundant DA 
receptors (Jaber et al. 1996; Gurevicha et al. 2016). D1 receptors have been linked to 
cognitive impairment when too much DA is release (Stigge-Kaufman 2005). It is known that 
cognitive dysfunction is a core feature in patients diagnosed with SCZ (Li et al. 2016). A 
relationship between increased DA binding to the prefrontal cortex D1 receptors and 
cognitive dysfunction has been found in patients diagnosed with SCZ (Brisch 2014).  
The D2 receptors are G protein family receptors which functions in intracellular signal 
transduction to regulate DA concentration within the neuron (Emilien et al. 1999; Zhen et 
al. 2015). Dysfunction of the D2 receptor has been found to increase dopamine 
concentration in psychiatric disorders such as SCZ and depression (Schwalbe et al. 2017). 
This is supported by the remission of psychotic symptoms with administration of first 
generation antipsychotics (FGA, also referred to as typical antipsychotics) and second 
generation antipsychotics (SGA, also referred to as atypical antipsychotics) (Saddichha et al. 
2008), which primarily and selectively block the dopamine D2 post synaptic receptors in the 
brain (Sampaio et al. 2017). Most FGA prescriptions are for the blocking of D2 receptors to 
effectively target the positive symptoms of SCZ. However the blocking of D2 receptors by 
FGA’s can cause too little DA to be taken up thus resulting in negative symptoms (Li et al. 
2016).  
1.4 Pharmacological treatment of psychosis 
The first antipsychotic medication, chlorpromazine (CP) (Drake & Mueser 2002; Gowda et 
al. 2017),  a typical antipsychotic (FGA), was developed in the 1950’s, aside serving as a 
chronic medication it is effective in emergency situations and upon admission to calm 
actively psychotic patients (Abou-Setta et al. 2012; Campillo et al. 2015). Specifically, CP 
attenuates acute psychotic symptoms including agitation and excitement, as well as 
attenuating positive symptoms, i.e. hallucinations and delusions (Ban 2007). CP is 
considered to be a low- potency FGA as it has a lower risk of side effects compared to other 
FGA’s,  e.g. haloperidol (Jibson 2015). FGA’s such as CP and  haloperidol act by inhibiting the 
Cytochrome P450 2D6 enzyme interrupting DAT, thus calming an agitated patient (Campillo 
et al. 2015; Jibson 2015). Cytochrome P450 2D6 is an enzyme which metabolizes both m-
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tyramine and p- tyramine, hydroxytryptamines and neurosteroids into dopamine in the 
brain and liver (Wang et al. 2009). 
FGAs have been shown to suppress the positive symptoms (i.e. hallucinations, delusions 
and disorganization) of SCZ (Hill et al. 2010). However, studies have shown that high doses 
of FGA’s i.e. chlorpromazine can also worsen cognitive performance (Weickert & Goldberg 
2005; Hill et al. 2010). Aside the mode of action in antagonizing the D2 receptors, 
chlorpromazine is also a potent muscarinic receptor antagonist (Jibson 2015). The action of 
chlorpromazine antagonizing the muscarinic receptors and D2 receptors, can cause 
potential cognition slowing (Weiss et al. 2002). Psychiatric patients who were prescribed 
lower dosages of FGA showed mild to moderate cognitive improvement, a reduction in 
speed and motor performance was still noted (Weickert & Goldberg 2005).  
Treatment with FGA can result in the development of extrapyramidal side effects (Divac et 
al. 2014). In vitro studies conducted to understand the mechanisms of FGA’s showed that 
when more than 80% of the D2 receptors are blocked with antipsychotic medications, 
extrapyramidal side effects are present (Ananth et al. 2001). These extrapyramidal side 
effects in FGA can include; rigidity, bradykinesia, tremor, akathisia and tardive dyskinesia 
(Jibson 2015). The understanding of how extrapyramidal side effects are caused was found 
by conducting in vivo animal studies, by injecting with a D2 receptor antagonist, which 
induced the rats to catalepsy state (Ananth et al. 2001).  
Anticholinergics (i.e. orphenadrine) help to counter or reduce the extrapyramidal side 
effects (Hill et al. 2010). This occurs by the blocking of muscarinic receptors with 
anticholinergic drugs, thus preventing the acetylcholine activity and decreasing muscle 
rigidity and tremor (Rehse et al. 2016). It has also been used in the treatment of 
parkinsonism due to the muscle relaxant properties (Campillo et al. 2015; Lertxundi et al. 
2017). Parkinsonism occurs as a result of substantia nigra striatal dopamine degeneration 
resulting in the bradykinesia, tremor and rigidity seen in some patients suffering from this 
side effect (Emilien et al. 1999; Shin & Chung 2012). Even though anticholinergics help 
counter the side effects of FGA’s, it has its’ own disadvantages. Anticholinergics can cause 
side effects which include; dry or sticky lips, pale and cool dry skin, urinary disorders, 
increased anxiety, rapid breathing, cardiac arrhythmia, tachycardia and shallow breathing 
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(Mintzer & Burns 2000; Hu et al. 2016). Then the use of anticholinergics in combination 
with FGA’s have been shown to cause adverse effects on cognitive function (Hill et al. 
2010). Further, high doses of FGA’s can be fatal which stimulated the development of a new 
line of antipsychotics, atypical antipsychotics (SGAs) having reduced extrapyramidal side 
effects (Jibson 2015; Jibson 2017; Sampaio et al. 2017).  
SGA’s are atypical antipsychotics which were modelled from the FGA chlorpromazine (Divac 
et al. 2014). SGA’s were developed in the 1980’s, e.g. risperidone and olanzapine 
(Watanabe et al. 2010; Abou-Setta et al. 2012) which are effective in the treatment of 
positive and negative symptoms within SCZ, bipolar mania, acute agitation and other 
psychiatric conditions such as major depression (Zhang et al. 2013; Jibson 2017). SGA’s 
function by acting as a serotonin- dopamine antagonist (targeting the 5-HT2A receptor) and 
a D2 receptor antagonist (Hill et al. 2010; Mauri et al. 2014; Guzman & Farinde 2016). 
Compared to FGA’s, SGA’s bind with lower affinity to the  D2 receptors (Ananth et al. 2001). 
In a situation where hallucinogens (i.e. lysergic acid diethylamide or LSD) is used, psychotic 
symptoms can present and persist (Geyer & Vollenweider 2008). In the case where a 
patient is presenting with psychosis as the result of 5- HT2A hallucinogen, serotonin 
antagonists can be prescribed to reduce the presence of psychotic symptoms (Pytliak et al. 
2011). Of the current SGA’s available, risperidone was found to have a higher risk of 
extrapyramidal side effects (Jibson 2017). Other SGA’s such as clozapine, and quetiapine 
are known to have anticholinergic properties (Jibson 2017). Quetiapine is used as a first line 
treatment in BPD and SCZ (Gianfrancesco et al. 2005; Calabrese et al. 2017) and has a high 
affinity for muscarinic receptors and low affinity for D2 receptors (Nielsen et al. 2015). 
Quetiapine was found to decrease stress induced cell proliferation in the hippocampal 
region in the brain of patients suffering from a psychiatric disorder (Rief et al. 2016). 
Clozapine, compared to quetiapine, is generally used as a last choice antipsychotic 
treatment especially for patients who are not responding to first line treatments (Marder et 
al. 1991). The side effects of clozapine extend even further; induced ocular blindness is a 
side effect of clozapine which can fortunately be reversed through treatment with 
risperidone (Gowda et al. 2017). However, cardiometabolic adverse effects and weight 
gain, remain a concern for SGAs  (Jibson 2017). The cardiovascular diseases associated with 
psychiatric disorders are caused by the induction of vasodilation and natriuresis (Emilien et 
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al. 1999). When increased levels of DA are released into the blood stream, stimulation of 
the α-adrenergic receptors occurs causing a rise in blood pressure. Due to the increase in 
cardiovascular diseases and obesity in individuals with a psychiatric disorder, methods and 
other medications need to be developed to reduce the side effects of SGA medication 
(Saddichha et al. 2008).  
Both FGA’s and SGA’s have their pros and cons, and all might not work due to the patient 
having drug resistance (Abou-Setta et al. 2012; Leucht et al. 2013). However, even though 
SGA’s are more efficient, they can be quite costly compared to FGA’s (Leucht et al. 2013). 
Also, the long term use of FGA’s and SGA’s can cause the development of metabolic 
syndrome, which is currently affecting most prescribed antipsychotic medications for long 
periods of time (De Hert et al. 2008; Seow et al. 2017). Metabolic syndrome causes the 
individual to have increased risk for diabetes and cardiovascular disease which can 
essentially lead to death (Graham et al. 2008).   
There are currently different treatment guidelines for the management of manic and 
depressive episodes. These treatment guidelines help by reducing the reoccurrence or 
frequency of acute episodes (Rief et al. 2016). Currently to prevent both manic and 
depressive episodes in patients diagnosed with BPD, monotherapy with first-line 
treatments, including SGAs are administered (Ketter et al. 2016). There is currently ongoing 
research into the reduction of hospital admissions through the use of long- acting injections 
(Kisely et al. 2015). The production of long- acting injections (i.e. risperidone and 
olanzapine) is highly recommended for the prevention of mania  (Abou-Setta et al. 2012). 
Depot injections are also seen as a treatment option in the psychotic disorders, due to 
severity of illness or non-compliance to medication (Wingård et al. 2017). Depot 
antipsychotic medications are administered intramuscular to psychiatric patients (Roberts 
& Geppert 2004). Theoretically, depot antipsychotics have a greater effectiveness 
compared to oral antipsychotic medications as it does not go through the harsh acids in the 
stomach (Citrome et al. 2010). With increasing the effectiveness of treatment, costs 
involved in the management of the psychiatric disorders can be reduced (Kisely et al. 2015). 
Examples of depot antipsychotic medications include Flupentixol, Zuclopenthixol and 
Fluphenazine which are typical antipsychotics (Guzman & Farinde 2016).  
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1.5 Gene and environmental interaction 
Genetic and environmental factors influence whether an individual will develop psychosis 
(Olvet & Hajcak 2009; Perez et al. 2016). Previous genetic studies have shown there is an 
increased risk in developing a mental illness if there is a family history of psychotic 
disorders (Ayano 2016). SCZ is known to be highly heritable, evidenced by genetic twin and 
family history studies (Mandelli et al. 2014). Individuals from parents with diagnosis of SCZ 
and monozygotic twins have a 40% chance of inheriting the mental disorder. A similar 
effect was seen in patients diagnosed with BPD (Juli et al. 2012). BPD genetic studies in 
siblings and twins have shown that children from parents with diagnosis of BPD are more 
susceptible to developing BPD or unipolar disorder. Monozygotic twins are at a higher risk 
(40-70%) of developing BPD compared to dizygotic twins (Craddock et al. 2005). Children 
born from a parent diagnosed with BPD has a 10% chance of developing BPD themselves or 
another psychotic disorder (Juli et al. 2012; Ayano 2016). However, the development of 
other psychotic disorders does not follow the Mendelian pattern of inheritance. Genetic 
twin studies have revealed insight into the strong genetic components to developing BPD. 
The twin studies have shown that monozygotic twins have a 75% concordance compared to 
dizygotic twins (10.5% concordance) in developing BPD (Juli et al. 2012). Adoption studies 
have shown that the child of a BPD parent still has the risk of developing BPD even though 
they are not living with their biological parents (Ayano 2016). This shows that an individual 
who carries the susceptibility genes is still at risk of developing BPD irrespective of their 
environment (Juli et al. 2012). However, this does not mean that environmental influences 
can’t increase the risk of developing a psychiatric disorder. 
A prime example of the environmental interaction crossed with genetic vulnerability is the 
abuse of methamphetamine, which causes overstimulation of the DA systems. Psychosis 
due to MA abuse, is suggested to result from hereditary pre-disposition to psychiatric 
disorders and drug use (Perry & Juhl 1977; Hermens et al. 2009; Shariat & Elahi 2010; 
Zarrabi et al. 2016). Other environmental risk factors may seem less direct and include 
adverse psychosocial influences, e.g. childhood trauma, including physical and sexual 
trauma (Tsuang et al. 2004; Perez et al. 2016) or dysfunctional relationship pattern through 
development, which can also promote the use and abuse of substances (Schmidt 2007; 
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Adzic 2012; National Institute of Health and Clinical Excellence 2014; Quach et al. 2016). 
Other environmental influences can include: access to good nutrition and stress during the 
mothers’ pregnancy (Mansur et al. 2012), e.g. malnutrition of the mother can starve the 
baby in utero, potentially causing hormone and chemical imbalances as well as 
underdevelopment of the brain and other organs (Schmidt 2007). Also, mothers who use 
substances during pregnancy can increase their child’s risk for developing serious 
neurodevelopmental disorders (American Psychiatric Association 2013a).  
Another gene- environmental interaction, which continues to increase is social adversity, 
e.g. refugee or asylum seekers, and urbanisation (LaPorte et al. 1994; Hermens et al. 2009; 
Tandon et al. 2009; Adzic 2012; Mandelli et al. 2014; Basset et al. 2014; Tsuang et al. 2004; 
Seredenina et al. 2017; Kirkbride et al. 2012). Social adversity mechanisms have been found 
to be the link between genetic and environmental interaction which aid in the development 
of psychosis. In addition, it has been noted in both men and women that have moved from 
rural to urban areas  show greater susceptibility to the  impact of the high prevalence and 
availability of drugs, and high levels of substance- induced psychosis have been reported 
(Kirkbride et al. 2012; Perez et al. 2016).  
Prognosis related environmental risk factors for those with diagnosis of SCZ are also 
apparent. Patients may go untreated, e.g. limited infrastructure within health care system 
or family are unable to pay costs of treatment or therapy, or stop taking their medication as 
they feel better or do not want to be controlled by taking medication, particularly apparent 
in paranoid patients with a psychotic disorder (Hyman et al. 2001; Chong et al. 2016). 
1.6 Cognitive deficits in schizophrenia, bipolar I disorder, and methamphetamine induced 
psychotic disorder  
Areas of the brain associated with cognitive deficits are generally the frontal and parietal 
lobes. The frontal lobe is associated with cognitive functioning, and not limited to, 
attention, reasoning, planning and problem solving. Deficits within the frontal lobe can lead 
impaired cognitive function (Dias et al. 2011). The parietal lobe is associated with, but not 
limited to, orientation, recognition, perception of stimuli, and their association. Deficits 
within the parietal lobe can lead to the inability to recognize salient stimuli such as faces, 
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letters and patterns. It is known that mental disorders are characterised by cognitive 
dysfunctions (Rief et al. 2016). Cognitive deficits are seen as the primary limitation to 
integration of individuals with a diagnosis of SCZ into society (Hill et al. 2010). Specific 
cognitive deficits highlighted include delayed memory recall, reduced processing speed, 
poor attention and concentration and impaired executive functioning (Harvey 2011). 
Negative symptoms associated with SCZ have been found to correlate with the cognitive 
decline of the affected individuals over time (Nielsen et al. 2015). This correlation can 
however be influenced by age, predisposition due to genetics, and environmental 
influences.  
Cognitive dysfunction are also seen in patients with mood disorders i.e. BPD and depression 
(Harvey 2011). However, the severity of cognitive impairment is greater in SCZ compared to 
BPD (Trivedi 2006). Within BPD, cognitive dysfunctions include attention, executive 
function, learning, memory, and psychomotor speed (Martínez-Arán et al. 2004; Reddy et 
al. 2014). These cognitive dysfunctions are found to be worse in patients presenting with 
active BPD symptoms of depression, mania and residual dysthymia compared to BPD 
patients in a period of euthymia (Harvey 2011). Impulsivity associated with sustained 
attention deficits, are comparable in BPD and SCZ (Dickman 2000; Camelo et al. 2013). 
Specific neurotransmitter systems (i.e. dopamine and serotonin) have been related to 
impulse behaviour (Atmaca 2014), it has also been suggested that impulsivity in SCZ and 
BPD are influenced by antipsychotic medications (Reddy et al. 2014).  
There are many debates on the effect that MA has on neurocognitive function however, 
many studies reveal contradictory results regarding cognitive dysfunction in MPD (Scott et 
al. 2007; Hart et al. 2012; Paulus 2017). Psychostimulants, e.g. MA, have been shown to 
displace DA at receptor level due to its’ higher affinity at DA receptors. The high affinity of 
MA decreases the function of DA, from over activation of the DA system (Breier et al. 1997; 
Rusyniak 2012). As the individual uses higher doses of MA, the production of DA is 
decreased, in an attempt to attenuate over activation of the DA system (Jan 2013). 
Methamphetamine has been noted to affect executive function (Rusyniak 2012). 
Impairments in executive functioning affect strategic planning, behavioural initiation, and 
goal- directed behaviour (Mahurin et al. 1998). These traits along with impulsivity, are often 
described in SCZ and BPD (Koob & Volkow 2010). Koob and Volkow, (2010) stated drug 
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addiction is associated with impulsivity and compulsive behaviour. Sensitisation of the 
dopaminergic system has been suggested to underlie behavioural and drug addictions 
(Carter et al. 2011). In MPD cognitive deficits were found to persist long after 
methamphetamine use (Scott et al. 2007), and this is apparent within frontostriatal and 
frontolimbic systems (Petit et al. 2012).  
We do not fully understand the biological mechanisms which lead to the cognitive 
symptoms apparent in psychosis. Attempts to understand the underlying mechanisms of 
cognitive dysfunction in the psychotic disorders is continual, in the clinical research setting 
and by use of animal models (Emilien et al. 1999; Weiss et al. 2002; Harvey 2011). Sadly, 
cognitive dysfunction in psychotic illnesses is not treated with current medication regimes 
(Featherstone et al. 2007). And the duration of antipsychotic treatment and high doses of 
antipsychotic medication have been shown to aid in the decline of cognitive function 
(Rehse et al. 2016), albeit more apparent for FGA’s versus SGA’s (Hill et al. 2010). With the 
development of SGA’s, the dosage of antipsychotic medication was lower, and is more 
efficient in helping treat negative symptoms and cognitive impairment (Sampaio et al. 
2017), apparent for olanzapine and risperidone  (Weiss et al. 2002; Weickert & Goldberg 
2005). It is purported that most SCZ patients who are receiving managed treatment can live 
a productive life if their cognitive impairment is not severe (Harvey 2011).  
1.7 Sustained attention deficits in schizophrenia, bipolar I disorder, and 
methamphetamine induced psychotic disorder 
Attention is a key cognitive function that has been shown to be dysfunctional in SCZ and 
other psychotic disorders (Rief et al. 2016). Attention is a resource demanding process in 
which the brain decides what to process, i.e. salient versus non-relevant information (Shipp 
2004). It is accepted that there are four different types of attention: sustained attention, 
divided attention, selective attention, and alternating attention. Sustained attention 
determines the efficiency of divided and selective attention (Sarter et al. 2001). As an 
example, sustained attention can be seen as the ability to maintain focus on a specific time 
locked stimulus within a task (Featherstone et al. 2007). The theory of sustained attention, 
is currently suggested to be reliant on the mindfulness theory stating that errors created 
with sustained attentional tasks are related to mind wondering causing a shift in focus on 
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internal thoughts (Helton et al. 2009). There are four neurotransmitter systems which are 
involved in sustaining attentional processes: the primary system involved is the locus 
coeruleus norepinephrine system, however the raphe serotonin system, acetylcholine 
system, and mesocortical and mesolimbic dopamine systems are also involved (Okena et al. 
2006; Javitt 2009). 
Of particular relevance, in the psychotic disorders, is the role of dopaminergic dysfunction 
that underlies attentional deficits. (Hart et al. 2012). Dopaminergic dysfunction was found 
to be related to the efficiency of D2 receptors (Cohen et al., 1998) and the functioning of 
the basal ganglia (Sotoyama et al., 2011). The basal ganglia are the globus pallidus, dorsal 
and ventral striatum,  ventral pallidum, corpus striatum, the substantia nigra and the 
subthalamic nucleus striatum..  The basal ganglia is involved in voluntary movement, 
cognition, reaction time and emotion (Gruendler et al. 2011). The basal ganglia has a limbic 
sector (mesolimbic pathway) which is involved in reward learning and interacts with the 
prefrontal cortex to control attentional processing (Van Schouwenburg et al. 2015). Ikuta et 
al., (2014) conducted a study which addressed sustained attention and the basal ganglia 
region in first episode psychosis. The study revealed hyperactivation of the globus pallidus 
during attentional tasks prior to the onset of psychosis (Ikuta et al. 2014). Antipsychotic 
medication has been shown to improve attentional processing in psychotic disorders 
(McGurk et al. 2004). An example of tasks which test for sustained and selective attentional 
processing deficits include the continuous performance task (CPT) (Perlstein et al. 1998; 
Filbey et al. 2008), which can be presented visually or auditory (Huang et al. 2007). The 
visual system consist of two pathways, the magnocellular and parvocellular system, which 
processes the visual environment (Johnson et al. 2005). In patients with SCZ, cortical visual 
processing is impaired causing difficulties in object recognition, reading and motion 
detection (Javitt 2009). Event- related potentials (ERPs) have been used to determine and 
understand visual processing impairments. Furthermore, ERPs have been used to study 
attention more specifically the neural circuitry involved in attention (Luck et al. 2000). 
1.8 What is Event related potential (ERP)?  
It is possible to investigate cortical processing of task stimuli via record ERPs (Luck et al. 
2000; Saavedra & Bougrain 2012). An ERP is the electrophysiological response to a time- 
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locked stimulus, recorded during electroencephalography (EEG) (Huang et al. 2007; Dufau 
et al. 2009). The ERP refers to a specific window of time immediately before (-200ms) the 
stimulus of interest and shortly thereafter (+800ms). Within the ERP there are positive and 
negative deflections. These positive and negative deflections represent wave components 
of the ERP. The time at which they occur (latency reported in msec) and the size of the 
deflection (amplitude reported in Hz) are measures extracted from the ERP and are related 
to specific cognitive processes (Saavedra & Bougrain 2012). There have been many studies 
conducted focusing on the ERPs for visual related tasks (Mangun & Hillyard 1991; Van Der 
Lubbe & Woestenburg 1997; Hillyard & Anllo-Vento 1998; Luck 1998; De Pascalis & 
Speranza 2000; Radin 2004; Pourtois et al. 2008; Takeda et al. 2008; Nemrodov et al. 2011; 
Huang et al. 2011; Saavedra & Bougrain 2012; Howells et al. 2014; Dundas et al. 2014; 
Vareka et al. 2014; Oribe et al. 2015; Frey et al. 2016; San Martín et al. 2016; Luck et al. 
2000). Within these studies,  typical wave components  include: P100, P150, N170 and P300 
(Onitsuka et al. 2013), e.g. the P100 waveform is a positive (P) wave component that occurs 
approximately 100 msecs after the presentation of the stimulus To produce a reliable ERP 
for a specific stimulus a grand mean average is obtained (an average of at least 20 ERPs 
which are overlaid), this is to remove artefact, i.e. cortical activity, which is not related to 
the stimulus of the task being completed. There are several prominent wave components 
related to visual attention processes.  
The N70 ERP waveform reflects somatosensory processing which occurs before the 
occurrence of the visual P150 ERP (Adams et al. 2017). The N70 ERP waveform is of small-
amplitude with a negative (N) deflection that occurs approximately 70 msec after the visual 
presentation of a stimulus. The standard window in which the peak occurs is between 60 
and 110 msec  (Antal et al. 2004; Heimrath et al. 2012; Chapman et al. 2013). The N70 is 
associated with the activation of the striatal cortex and also reflects the extrastriata 
activity, which is posterior to the visual cortex (Saint-Amour et al. 2005). The N70 ERP 
waveform has been studied in somatosensory based tasks (Saint-Amour et al. 2005; Arnfred 
et al. 2000; Bolton & Staines 2011; Arnfred 2005), effects of medication on ERPs in 
Alzheimer’s disease (Chapman et al. 2013), and in EEG studies using transcranial magnetic 
stimulation (Heimrath et al. 2012; Antal et al. 2004). There are very few studies which have 
addressed the N70 ERP in SCZ, BPD and MPD. In one study frontal (EEG ERPs recorded from 
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electrodes positioned over the frontal cortex) N70 amplitude was observed to be greater in 
SCZ compared to controls during the presentation of a primed stimulus (Arnfred et al. 
2006). The N70 has been shown to be integrally involved in visual- spatial attention (Balslev 
et al. 2013; Adams et al. 2017), further research is required to understand the potential 
differences between the psychotic disorders. 
The second waveform of interest is the P100 ERP waveform which is a small-amplitude, 
positive deflection that occurs approximately 100 msec after the presentation of the target 
(Burra et al. 2017). The P100 is also noted as the first positive peak after the N70 ERP 
waveform (Antal et al. 2004), or as an early P150 which starts a few milliseconds before the 
initial start of the P150 (Coch & Mitra 2010). The P100 is associated with attention- 
demanding tasks (Bolton & Staines 2011), yet the exact link to cognitive process(es) remain 
unknown (Campanella et al. 2006). The P100 has been hypothesized to reflect facial 
processing while the later N170 is related to the structural coding of the face (Hileman et al. 
2011). The initial processing by the P100 followed by the N170 indicates that the P100 is 
involved in cueing. An attention based study showed that the right central P100 amplitude 
is greater when an individual attended to a specific stimuli compared to when a stimuli was 
ignored (Bolton & Staines 2011). This same result was repeated within another visual 
attention based task involving a sequential string of letters and distractor (Biehl et al. 2013).  
Studies on the P100 in SCZ report attenuated P100 amplitude while in BPD it is enhanced 
(Campanella et al. 2006; Earls et al. 2016). The P100 amplitude and latency deficits in SCZ 
were linked to the parietal cortex (Johnson et al. 2005). These P100 differences in patients 
with SCZ are sensory processing deficits, that are likely to impact attentional processes 
(Sulejmanpašić et al. 2017). Sensory processing deficits include the brain not processing; 
sight, smell, hearing, touch and taste (Campanella et al. 2006). More frequently, visual tasks 
use facial emotion- based tasks to determine global processing of visual perception. Overall 
SCZ was found to have an attenuated P100 amplitude for non- facial and facial cues 
compared to healthy controls (Onitsuka et al. 2013), suggesting deficits in the absence of 
specific types of stimuli. In BPD the P100 amplitude was shown to be increased compared 
to controls (CON) based on the data collected from a visual based task involving faces 
exerting emotion, and this has been related to emotional dysregulation in BPD and 
impairment of prefrontal cortical processing (Berchio et al. 2017). How the P100 amplitude 
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is related to attentional processing that does not carry emotional valence in BPD needs 
further investigation. Patients having decreased concentration and impaired sensory 
processing have been noted to have attenuated P100 amplitude and lengthened latency 
(Wahlstrom 2014). Even though very little research has been conducted on MPD, EEG 
analysis of MA users were shown to have slower and poorer performance in attentional 
tasks compared to controls (Ceballos et al. 2009). The P100 may be a useful marker in 
distinguishing sensory processing deficits that affect attentional processing in SCZ and BPD. 
It would further be interesting to see if MPD P100 amplitude was attenuated or greater, 
and if P100 latency is lengthened or decreased, to see if the P100 plays a role in attentional 
dysfunction seen in MPD. 
The N170 was first discovered upon the visual presentation of faces (Luck 2005; Dundas et 
al. 2014). It was later found that the N170 appeared after the presentation of known words 
(Luck 2005). The N170 ERP waveform is a negative deflection that occurs approximately 170 
msec after stimulus presentation (Feuerriegel et al. 2015). The N170 was found to be right 
lateralized (Hileman et al. 2011) however, there are instances where the N170 amplitude 
was found bilaterally in relation to expert or executive functioning. Tanaka et al. (2001) 
showed that the amplitude does remain slightly attenuated in the left hemisphere 
compared to the right hemisphere. Furthermore, studies involving emotional based tasks in 
the form of faces have shown that within BPD the amplitude for happy faces were larger 
than that of sad faces (Feuerriegel et al. 2015; Minami et al. 2015). Deficits in facial 
processing have been linked to underlying decision or semantic processing (Campanella et 
al. 2006). In healthy individuals with typical development, the N170 latency is delayed and 
the amplitude is increased (Hileman et al. 2011). The N170 has been previously found to 
have an attenuated amplitude in patients with SCZ during the presentation of neutral and 
emotional facial images (Onitsuka et al. 2013; Feuerriegel et al. 2015; Cao et al. 2015; 
Maher et al. 2016). Further studies in SCZ revealed that there are reductions in N170 
amplitudes which was not apparent in their first- degree family members (Onitsuka et al. 
2013). In early onset SCZ transient visual evoked potential studies addressed the P100 and 
N170 early visual cortical responses and found attenuated amplitudes (Butler & Javitt 
2005). Studies conducted between BPD and SCZ revealed the N170 latency was delayed 
compared to CON during word and facial processing (Wynn et al. 2013). Then in a different 
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study looking at word processing, the N170 latency was shortened indicating 
deficits/absence of earlier sensory processing (Strelets et al. 2015). Currently the 
knowledge available within the N170 ERP waveform mostly covers facial and emotion 
processing within CON, SCZ and BPD, very few address attentional processing (Okumura et 
al. 2015). Decreased N170 amplitudes in SCZ and BPD support deficits in understanding or 
processing of emotions. Okumura et al, (2015) found that the same results collected for 
letter and word coding are consistent with left lateral N170 amplitude and latency in early 
visual processing. Then, more research is needed to investigate N170 differences within 
MPD, and to see whether N170 amplitude and latency are similar in SCZ and BPD when 
processing non- emotional stimuli 
The P300 event-related potential waveform is thought to represent cortical updating 
processes (Sur & Sinha 2009). The P300 ERP waveform is a large- amplitude, positive 
deflection that occurs approximately 300 msec post stimulus presentation. The P300 
waveform has been studied in a mix of visual and auditory tasks in healthy control and in 
individuals with various mental disorders. The P300 has been widely studied in SCZ (Roth et 
al. 2007; Oribe et al. 2015; Dufau et al. 2009). These studies show that the P300 waveform 
in SCZ is usually attenuated (small amplitude) and delayed (longer latency) in response to 
target stimuli (Ethridge et al. 2015; VanMeerten et al. 2016). Both Ethridge et al (2015) and 
VanMeerten et al, (2016) suggest that P300 attenuated amplitude and delayed latency 
provides insight into the potential mechanisms involved in attentional processing within 
SCZ and BPD. 
P300 studies within BPD are few. However, from the few studies conducted a reduction in 
P300 amplitude has been reported in patients diagnosed with BPD (Turetsky et al. 2007; 
Ethridge et al. 2015). Both studies revealed that attentional processing is altered, as seen by 
the P300 waveform differentially in BPD and SCZ (Tekok-Kilic et al. 2001; Kuperberg 2004; 
Johannesen et al. 2013; Ethridge et al. 2015), finding P300 amplitude is globally reduced in 
SCZ, then BPD show reduced parietal P300 amplitudes, when compared with controls, then 
no P300 latency differences were reported. Reduced P300 amplitude is associated with the 
visual and attention processing within SCZ and BPD. In SCZ and BPD, the reduced 
amplitudes, and at different cortical regions, frontal vs. parietal, are suggested to reflect 
primary cognitive deficit related to these psychotic disorders (Turetsky et al. 2007; Roth et 
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al. 2007; Chun et al. 2013). To date no studies have been conducted in MPD and it would be 
interesting to see if they too show deficits in their P300 waveform.   
To address the limited literature on attentional processing deficits across the psychotic 
disorders, and clear absence of studies in MPD, we developed a visual continuous 
performance task to investigate voluntary sustained attention (Helton et al. 2009). First, to 
address response to target stimuli and prominent ERP wave components, as described 
above. Second, to address the potential role of cueing ERP wave components in attentional 
dysfunction, which has not been formally addressed across the psychotic disorders, this 
was based on previous work by our laboratory (Howells et al. 2012), which found significant 
differences in how BPD processed cueing information.  
Sustained attention is known to be dysfunctional in psychotic disorders (Rief et al. 2016). 
Sustained attention is the ability to remain focussed on a specific time- locked stimulus 
within a task (Featherstone et al. 2007). Many studies have looked at sustained attention in 
SCZ (Johnson et al. 2005; Campanella et al. 2006; Earls et al. 2016; Sulejmanpašić et al. 
2017) and BPD (Martínez-Arán et al. 2004; Harvey 2011). However, very few studies have 
investigated sustained attention in MPD (Yvonne 2006; Fassbender et al. 2015). Through 
using a visual sustained attention focused continuous performance task (CPT), we aimed to: 
(1) determine whether there are specific group differences between CON, SCZ, MPD and 
BPD. This included differences in (a) behavioural performance while completing the task 
and (b) prominent electrophysiological event- related potential (ERP) wave components 
during cueing and target processing.  
(2) Few studies have investigated the relationship between ERP waveform components 
with demographic, drug use, clinical variables, and behavioural performance. In this study 
we aimed to characterize relationships that are apparent across groups and determine 
whether there are unique relationships with specific psychotic disorders. Due to the limited 
studies addressing the potential interaction of demographics, drug use and clinical 
variables, this study strictly characterized these relationships.   
(3) Despite the current knowledge to the positive and negative effects of psychotropic 
medication, very few studies have addressed the effects they have on behavioural 
performance and ERP wave components. In a review conducted by (Amato et al. 2017) it 
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was evident that effects of medication on neurological systems within psychotic disorders 
are unclear. This limitation is due to most studies only focusing on a single psychotic 
disorder and comparing it to a healthy control group. By incorporating more than one 
psychotic group, effects of medication can be investigated across the psychotic disorders to 
distinguish whether there are differences. With this study we aim to investigate medication 
use and its’ potential effect, by grouping those ‘on’ compared them to those ‘off’ a specific 
psychotropic medication, this was made possible by including three psychotic disorders.  
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 Chapter 2 Methodology 
2.1 Participants 
A total of 103 participants were recruited for this study. This included the recruitment of 
participant with diagnosed psychotic disorders: schizophrenia (SCZ, N= 27), bipolar I 
disorder with a significant history of psychosis (BPD, N= 28), methamphetamine induced 
psychotic disorder (MPD, N= 21), and socio-demographic matched controls (CON, N= 27).  
2.2 Inclusion of participants 
All participants were between the ages of 18 and 40. All participants were interviewed, 
using the Structured Clinical Interview for Diagnostic Systematic Manual- IV (SCID-DSM-IV) 
(American Psychiatric Association 1994). For the psychiatric groups, only outpatients were 
recruited. Individuals recruited for SCZ group had clear diagnosis of schizophrenia as other 
disorders from the schizophrenia spectrum were excluded, e.g. schizoaffective and 
schizophreniform (American Psychiatric Association 1994).  Individuals recruited for BPD 
group had clear diagnosis of Bipolar I disorder with a significant history of psychosis 
(American Psychiatric Association 1994), and currently euthymic (e.g. no presentation of 
mood polarity) (Mccormick et al. 2015). Individuals recruited for MPD group were included 
if it was clear that the cause of the psychosis was a result of methamphetamine use 
(American Psychiatric Association 2013a). Individuals recruited for CON group were 
included if there was an absence of mental illness, including psychosis or psychotic 
symptoms (DSM Axis I disorders) (American Psychiatric Association 1994). Further, 
participants were not recruited if they presented with an active mood state, e.g. depression 
or anxiety, to reduce potential interference on ERP waveforms (Stigge-Kaufman 2005). 
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2.3 Exclusion of participants 
Participants were excluded if they reported a history of: electroconvulsive shock therapy; 
transcranial magnetic stimulation; epilepsy, including childhood epilepsy or known family 
history; major brain trauma or brain surgery including stroke or brain aneurism; any chronic 
medical illness that required medical care or prescription medication, e.g. fibromyalgia, 
diabetes, known HIV positive status; history of psychosis as a result of a general medical 
condition; females that were pregnant or breastfeeding; and any individual who presented 
with clinically apparent mental dysfunction. 
Further exclusion criterion were applied as the research participants also underwent 
magnetic resonance imaging as a separate part of the umbrella project, these additional 
exclusion criteria are as follows: physiological implant (e.g. pacemaker, cochlear implant, 
aneurism clip); extensive tattoos on upper body; piercings that could not be removed; 
possible shrapnel or bullets in the body; any form of severe motoric disturbances above a 
very minimal tremor, e.g. no tardive dyskinesia, akathisia, etc.  
2.4 Ethical considerations 
Ethical clearance for the research study was obtained from the University of Cape Town’s 
Health Sciences Research Ethics Committee (HREC Ref No: 192/2010) and was conducted in 
accordance with the Declaration of Helsinki. Furthermore, approval was obtained from the 
Western Cape Provincial Government and respective hospitals (appendix B). Importantly, 
this was a multimodal imaging study, of which the EEG and ERPs were collected during a 
sustained attention task. For this thesis, only the ERPs was analysed. 
Participation in the current study was voluntary and participants were allowed to exit the 
study at any time during their participation. Prior to participating in the study participants 
were required to sign informed consent (appendix A).  
2.5 Study procedures 
Participants were required to present at 08h00. This study included several brain imaging 
modalities, including EEG recordings and MRI scan. The focus of my study was the ERP 
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analysis from the EEG recording. All ERP recordings were collected between 11h00- 12h00 
during a working week day. In addition, participants completed several subjective 
questionnaires during the day and if from a psychotic group they also completed several 
clinical scales with a clinician after the battery of brain imaging modalities.  
2.6 Demographic information, clinical scales, and subjective questionnaires 
The following demographic information was collected: gender, date of birth, education, and 
handedness. The clinical demographic information related to psychotic groups included: 
age of onset of the disease, duration of illness, and current medication regime.  
The Psychotic symptom related clinical scale included the Positive and negative syndrome 
scale (PANSS)– which is an operationalised and drug- sensitive instrument used to assess 
positive and negative symptoms in schizophrenia (Kay et al. 1982). The positive symptom 
subscale includes delusions, conceptual disorganization, hallucinatory behaviour, 
excitement, grandiosity, suspiciousness, and hostility. The negative symptom subscale 
addresses emotional withdrawal, poor rapport, passive/apathetic social withdrawal, 
difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped 
thinking and assesses for blunted affect. Lastly, the general psychopathology subscale 
assesses somatic concern, tension, mannerisms and posturing, anxiety, feelings of guilt, 
depression, motor retardation, uncooperativeness, unusual thought content, 
disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor 
impulse control, preoccupation, and active social avoidance. The PANSS scale uses a rating 
of 1 to 7 to score an individual for each section. The rating scale meaning is as follows; 1 = 
absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderate- severe, 6 = severe, and 7 = 
extreme. For the results of the PANSS scale, a score of the ratings across items are between 
7- 49 for the Positive and Negative Scales and 16-112 for the general psychopathology 
scales.  
Then three mood related clinical scales were included; the Calgary depression scale (CDS) 
which is a scale used to measure the level of depression in schizophrenia (Addington et al. 
1990), the Hamilton depression rating scale (HAM-D)– a clinical scale used to assess 
symptoms of depression (Hamilton 1960) and the Young Mania Rating scale (YMRS)– used 
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to determine the severity of manic symptoms (Young et al. 1978). The CDS scale was found 
to be more specific to depression in SCZ compared to the HAM-D scale, as it helps 
distinguish depression from negative symptoms of SCZ (Grover et al. 2017). The CDS scale 
comprises of 9 items to which if a patient describes 6 or more, the patient is said to have a 
major depressive disorder. The HAM-D scale consists of 17 items, of which each item is 
rated on either a 5- point scale (0−4) or 3- point scale (0−2). A score of more than 7 
indicates the presence of depression. The severity of the depression is graded as mild 
(score of 8–13), moderate (score of 14– 18), severe (score of 19–22) and very severe (score 
of > 23). Lastly, the young mania rating scale comprises of 11 items which are divided into 
four questions scored (0-8) and 7 items scored (0-4). The final scoring of the scale is; mania 
(YMRS = 12), depression (YMRS = 3), or euthymia (YMRS = 2).  
Further, the Clinical Global impression severity scale (CGI-S) was used to determine illness 
severity in psychiatry (Aas 2011). The scale is rated 1-7; 1=normal, not at all ill, 2=borderline 
mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most 
extremely ill patients. Lastly the Global assessment of functioning (GAF) was used. The GAF 
is a scoring system used to briefly assesses the patients’ global functioning by also 
considering the patient’s history, psychosocial circumstances, symptoms, behaviour, and 
the impact of the symptoms on the patient’s ability to function (Busner & Targum 2007). 
The scale is scored out of 100; a score of 1-30 is a possible patient for inpatient care, an 
individual with a score of 31-69 is a potential candidate for outpatient care, and a patient 
with a score of 70 and higher may be a patient who is functioning too well for the need of 
any treatment (Aas 2011) (Appendix C). 
2.7 Electroencephalography hardware 
EEG data was recorded using the Biopac MP150 data acquisition system with ten 100C 
biopotential amplifiers attached (Biopac Systems Incorporated 2012). The 100C amplifiers 
are biopotential transducers used to amplify voltages smaller than 0.01 volts (10 
microvolts), i.e. electrical brain signals measured in microvolts (µV) collected via the EEG 
electrodes of the EEG cap (Biopac Systems Incorporated 2012). The EEG lycra cap used to 
collect the EEG recordings had a standard 10/20 system containing recessed pure tin 
electrodes (Electro-cap international inc n.d.). A referential linked ear referencing montage 
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was incorporated using a pair of 9mm Electro-Cap Tin Ear Electrodes. The Electrodes 
contained a plastic covered spring clip back to hold the electrodes in place. The ten 100C 
EEG amplifiers were connected using jumper cables for referencing to linked ear electrodes. 
EEG channels recorded from included: pre-frontal (Fp1, Fp2), frontal (F3, F4), temporal (F7, 
F8), central (C3, C4) and parietal (P3, and P4).  
Then an electrooculography (EOG) 100C amplifier was also attached to the Biopac MP150 
system, to permit the removal of eye related activity from the EEG recordings. Similarly to 
the EEG 100C amplifier, the EOG 100C amplifier is used to amplify voltages smaller than 
0.01 volts (10 microvolts). Electrooculography (EOG) is a technique used to measure the 
resting state of the retina (Siddiqui & Shaikh 2013). Two 4 mm Ag-AgCl lead shielded 
electrodes which was placed 1 cm below and 1 cm to the outer edge of the right eye. 
Lastly, participants were grounded using electromyography (EMG) positioned on the 
forearm. Grounding the participants through EMG recording, prevents the loss of the signal 
of interest by reducing powerline noise interference as well as static energy (Costa et al. 
2016). This set-up was defined by the overarching research project which incorporated 
additional electrophysiological measurements, Cortical Inhibition and Attentional 
modulation: A study of Psychosis (CIAM – HREC/192). The setup for CIAM – HREC/192 
consisted of magnetic resonance spectroscopy (MRS) to assess the level of brain chemicals, 
electroencephalography to assess electrical activity, and using electroencephalography with 
transcranial magnetic stimulation to assess changes in electrical activity. 
2.8 Electroencephalography software 
The MP150 system data were collected using Biopac software Acqknowledge 4.1 data 
acquisition and analysis software (Figure 2.1). The software allows for instant viewing, 
measure, replay and transforming and analysis of the EEG data recorded (Biopac Systems 
Incorporated 2012). The ten 100 C biopotential amplifiers attached to the Biopac MP150 
system included an electrooculography amplifier (EOG= channel A12), electromyography 
(EMG= channel A11) and ten EEG 100C amplifiers connected to collect data for the 
prefrontal (Fp1 = channel A1, Fp2 = channel A2), frontal  (F3 = channel A3, F4 = channel A4), 
temporal (F7 = channel A5, F8 = channel A6), central (C3 = channel A7, C4 = channel A8) and 
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parietal (P3 = channel A9 and P4 = channel A10). All the channels were run at a sampling rate 
of 500Hz.  
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Figure 2.1 Acqknowledge electroencephalography channels of interest. The data collected for EEG analysis 
included twelve different channels; pre-frontal (Fp1 = channel A1, Fp2 = channel A2), frontal (F3 = channel A3, 
F4 = channel A4), temporal (F7 = channel A5, F8 = channel A6), central (C3 = channel A7, C4 = channel A8) and 
parietal (P3 = channel A9 and P4 = channel A10), electromyography (EMG=channel A11) channel which served 
as ground, and electrooculography (EOG= channel A12). Acqknowledge 4.1 software was used to collect the 
data. Electrodes F7 and F8 were not analysed during the final analysis. 
2.9 Behavioural task software 
Eprime 2.0 is software, used to design behavioural tasks, collect behavioural performance, 
and conduct behavioural analyses. E- Studio, the design tool within Eprime, was used to 
design the visual continuous performance task used. Eprime records data in milliseconds 
(msec) and was designed to send digital inputs of stimuli to Acqknowledge 4.1 (Figure 2.2) 
(Schnieder et al, 2012). 
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Figure 2.2 Representation of the cues in the Continuous Performance task. The digital channels for trigger 
collection included eight different channels; correct responses (digital channel D0), eCue- Ss (digital channel 
D1), eTrick- S (digital channel D2), eNon- ta target (digital channel D3) target (digital channel D4), cues (digital 
channel D5), trick- S (digital channel D6) and non- target (digital channel D7). All channels were collected at 
500Hz. 
2.10 Voluntary sustained attention task: a visual continuous performance task (S-S-S) 
The continuous performance task (CPT) involves the presentation of three consecutive S’s 
within a series of randomized letters of the alphabet. The purpose of the CPT task is to 
measure the participants’ ability to sustain attention during the completion of a task which 
contains a cueing process, target and non- stimuli. Participants were presented with 60 
trials with three consecutive S’s, the presentation of the third S required a behavioural 
response. In addition, 40 single S’s or trick S’s were embedded in the task with inter-stimuli 
letters. The task contained 20 letters of the alphabet and excluded the vowels, A, E, I, O, U 
as well as the letter X. Each letter was presented for 500 msec with a 100 msec inter-
stimulus interval before the next stimulus (Figure 2.3). However, the participant was able to 
shorten the presentation of the third S if a response was given before the 500 msec time 
limit (Figure 2.2, channel D4).  
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(a)
(b) 
Figure 2.3 Representation of the visual Continuous Performance task. The continuous performance task was 
designed as a time- locked response task, where the letters appeared in a randomized order. Each letter was 
presented individually, appearing for 500 msec and disappearing for 100 msec before the next stimulus. (a) 
The trick stimulus was presented to distract the participant from the presentation of the three consecutive 
S’s. (b) The presentation of the three consecutive S’s occurred as cue 1, cue 2 and the target S. The participant 
was able to shorten the presentation of the third S if a response was given before the 500 msec time limit. 
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2.11 Electroencephalography set up 
Prior to starting the EEG, the placement of the electrodes and CPT task was re-explained to 
ensure that the participant knew what the EEG consisted of. The participant was asked to 
sit at a desk with a desktop computer screen in front of them. An alcohol swab was used to 
clean natural oils and loose skin cells of from the forehead and on the side and below the 
right eye. Two sponge discs, used to support the Electrode Cap International (ECI) electrode 
lycra cap, were positioned on the forehead. Earrings were asked to be removed prior to 
attachment of the earlobe reference electrodes. An electrode gel was placed inside the 
4mm EOG electrodes prior to attaching the electrodes with a double- sided adhesive disk 
on the side and 1cm below the right eye. The ECI electrode lycra cap was pulled onto the 
participants head and positioned, electrode gel was inserted into the hollow EEG electrodes 
using a blunt needle and syringe. Lastly, the EMG electrode was placed on the participant’s 
forearm. 
After completion of the EEG setup, the Acqknowledge 4.1 software was opened and the E- 
prime experiment file was loaded. The participant was asked to relax while the researcher 
observed the electrode channels. The channels were observed for any flat lined signals or 
channels with a lot of activity (“noisy” channels). If any noisy channels were present; the 
electrodes were checked for any bubbles in the electrode gel, hair which could be 
obstructing the connection from electrode to scalp or more gel was applied. Once all 
electrodes were producing excellent signal the EEG record was initiated, and participant 
completed the visual CPT.  
2.12 Electroencephalography analysis 
Preceding frequency and ERP extraction, the raw EEG data were corrected for EOG artefact 
using an automated independent component analysis (ICA) within the data collection 
software package, Acqknowledge 4.1 (Figure 2.4). It is important to apply ICA for EOG 
artefact removal when extracting ERPs from a data set, due to eye blinking emitting a 
positive peak at 300 msec (previously discussed in section 1.8) (Bonfiglio et al. 2009). All 
files which were EOG corrected were saved as Matlab coded file (extension .mat).  
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(c)
(d) 
Figure 2.4 Acqknowledge EOG removal.  The raw electroencephalography data collected during completion 
of the continuous performance task was EOG corrected through the Acqknowledge 4.1 software to remove 
eye movement from the data which could false results when analysing the ERPs. (a) Electrooculography 
removal was conducted by clicking the analysis tab in Acqknowledge 4.1 – scrolling to electrooculography- 
then clicking remove EOG artefacts. (b) The EOG channel was selected from the command box to select the 
channel which recorded electrooculography. (c) The channels (pre-frontal (Fp1 = channel A1, Fp2 = channel 
A2), frontal (F3 = channel A3, F4 = channel A4), temporal (F7 = channel A5, F8 = channel A6), central (C3 = 
channel A7, C4 = channel A8) and parietal (P3 = channel A9 and P4 = channel A10)) to be denoised from EOG 
were selected from the command box. (d) The process of EOG artefact removal was initiated.  
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2.13 Event Related Potential extraction 
The ERP waveforms extracted were from the pre- frontal (Fp1, Fp2) frontal (F3 and F4), 
central (C3 and C4), and parietal lobes (P3 and P4). The ERPs were extracted using an ERP 
extraction Matlab tool with simple graphical user interface (GUI) (Matlab, Mathworks, MA, 
USA, developed in-house) (Figure 2.5). Setting for ERP window: 1000 msec epoch; 200 msec 
before and 800 msec after, target stimulus. An artefact rejection limit of ±100µV was set to 
each extraction. This ensured that there was removal of an ERP with substantial distortion 
or artefact that may reduce the signal to noise ratio of the ERP waveform.  
 
Figure 2.5 Event related potential Matlab Graphical User Interface. The program was specifically made to 
extract the ERP data from EOG corrected data. A 100µV artefact rejection limit and a fixed baseline length of 
200 msec was used for the ERP analysis. The time was set to 200 msec backward and 800 msec forward to 
capture a 1000 msec epoch. The cues and target were analysed separately. 
To identify robust ERP waveform components from the data collected, grand averages ERP 
waveforms were created for each group and plotted on an XY lined scatter plot. The 
amplitude (μV) and latency (msec) values were extracted for each robustly identified ERP 
wave component. The windows used to extract the ERP waveforms from each channel are 
presented in table 2.1. 
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Table 2.1 Epochs used for the extraction of ERP waveforms from each channel 
for all four stimuli; first cue, second cue,  and target stimulus. 
Target Fp1 Fp2 F3 F4 C3 C4 P3 P4 
N70       20-150 20-150 
P150       70-200 70-200 
P100   50-150 50-150 50-150 50-150 50-150 50-150 
N170 100-200 100-200 100-200 100-200 100-250 100-250 100-250 100-250 
P300 200-400 200-400 200-400 200-400 300-500 300-500 250-500 250-500 
 
The ERP waveforms extracted from the first cue, second cue, and target stimulus included 
the N70 (20-150 msec window) and early positive P150 (70-200 msec window) for the 
parietal electrodes (P3 and P4). The N70 is a small-amplitude, positive deflection that occurs 
approximately 70 msec after each cue, and target. The P150 is a small-amplitude, positive 
deflection that occurs approximately 150 msec after each cue, and target. The P100 (50-150 
msec window) was extracted for the frontal (F3 and F4), central (C3 and C4) and parietal (P3 
and P4) electrodes. The P100 is a small-amplitude, positive deflection that occurs 
approximately 100 msec after each cue, and target. The early N150 (100- 200 msec 
window- Fp1, Fp2, F3 and F4; 100-250 msec window- C3, C4, P3 and P4) was extracted for the 
frontal, central and parietal electrodes. The N150 is a small-amplitude, positive deflection 
that occurs approximately 150 msec after each cue, and target.  The P300 ERP waveform 
was extracted for the frontal (200-400 msec window- Fp1, Fp2, F3 and F4), central (300-500 
msec window- C3 and C4) and the parietal (250-500 msec window- P3 and P4) electrodes. 
The P300 is a small-amplitude, positive deflection that occurs approximately 300 msec after 
each cue, and target. 
A further visual inspection was conducted by plotting the participant data for each stimulus 
separately on a µV vs msec line graph (Figure 2.6). The visual inspection consisted of 
looking at each participants’ data throughout the stimuli data extracted, to exclude 
participants with results which contained more than two sets of arbitrary data within each 
channel.  
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Figure 2.6 Exclusion of data. Event- related potential data was analysed using visualization through a 
“microvolt vs time” line graph to exclude data which did not conform to the averaged event- related potential 
waveforms. In this case, the event-related potential data moved at a steady decline and had no form. An 
example is seen by the bold black line. 
2.14 Statistical analysis 
Statistica (Dell, 2016) was used to conduct the statistical analysis on the data collected. A 
descriptive statistical analysis was applied to the data to determine normality using the 
Shapiro Wilks W test. Analysis of the Shapiro Wilks W test, the parametric and non- 
parametric data was determined using a P- value less than 0.05 as the limit for parametric 
data (P<0.05). The data obtained were both parametric and non-parametric.  
To characterize our population, group differences in demographics (age on the day of 
testing, duration at school, tertiary education, total years of education, weight, height, BMI 
and handedness), drug use (total substance use and individual drug use of tobacco, alcohol, 
cannabis, cocaine, methamphetamine, inhalants, sedatives, hallucinogen, opioids, and 
mandrax), and behavioural performance (correct responses, overall response time, errors 
of commission, errors of omission, and responses to distractor stimuli, i.e. trick S responses) 
are reported between the four groups.  
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Then differences in clinical scale scores Positive and Negative Symptom Scale for 
Schizophrenia (PANSS) total score, PANSS positive symptom subscale, PANSS negative 
symptom subscale, PANSS general psychopathology subscale, Calgary depression rating 
scale, Hamilton depression rating scale, Young mania rating scale, clinical global impression 
of illness severity scale, global assessment of functioning scale, and the Simpson angus 
scale for parkinsonism), duration of illness, and medication variables where statistical 
analysis was viable, i.e. n was sufficient to perform sound statistical analysis, 
(chlorpromazine equivalents, use of any antipsychotic, 1st generation antipsychotics (FGA), 
prominently used FGAs (haloperidol), 2nd generation antipsychotics (SGA), prominently 
used SGAs (clozapine, risperidone), mood stabilizers, lithium, sodium valproate, 
serotonin/norepinephrine reuptake inhibitors, and anticholinergics) are reported for the 
three psychotic groups. 
Then three different analyses were conducted to determine the aims of the current thesis:  
(1) A group analysis across the four groups (CON, SCZ, BPD and MPD) to determine whether 
group differences in (a) behavioural performance and (b) event related potential wave 
components amplitudes and latencies. This was achieved by first conducting an analysis of 
distribution for each variable, using Shapiro-Wilks test. That data which was of normal 
distribution underwent univariate one- way analysis of variance (ANOVA). When the 
ANOVA yielded significance, these variables underwent post-hoc testing with Bonferroni 
correction to determine whether there were specific group differences (p < 0.05). That data 
which was not of normal distribution underwent multiple independent Kruskal-Wallis 
ANOVA, which provided the overall ANOVA test result and between group differences. 
These differences are reported where the ANOVA yielded significance (p < 0.05).  
(2) ERP wave-component amplitude and latency correlation analyses were performed for 
(a) all four groups (CON, SCZ, BPD, MPD) with demographics, drug use, and behavioural 
performance data, and (b) within the psychotic groups (SCZ, BPD, MPD) for clinical variables 
(clinical scales, duration of illness and chlorpromazine equivalent). Due to the data 
distribution non-parametric correlation analysis was performed, using Spearman’s, rank 
order (Rho > ±0.5 and p-value < 0.01). Due to the correlation analysis taking an exploratory 
approach, with limited event-related potential studies in these disorders investigating the 
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interaction of demographics and clinical variables, we applied greater stringency in 
reporting. The strength of relationship was increased to ±0.5 (Rho; (Mukaka 2012)) and 
increased the probability of the relationship being repeated by lowering the P- value to 0.01 
(Dahiru 2008). Caution is still needed when these data are interpreted as the sample size is 
limited, however do provide insight to future studies and more complex statistical analysis. 
Further, the statistical package used, Statistica, does not have the function to permit co-
variate analysis within non-parametric ANOVAs.   
(3) The last analysis was performed to determine the potential difference ‘on’ or ‘off’ 
psychotropic medications by grouping all the psychotic groups and comparing those ‘on’ a 
specific medication to those ‘off’ that specific medication. The analysis included medication 
which was prescribed to at least 8 of the 76 participants with a diagnosis of a psychotic 
disorder. This permitted us to determine group differences by those on a medication and 
off a medication (number on: number off). The following medications were investigated: 
any antipsychotic prescribed (62:14); 1st generation antipsychotics prescribed (35:41); 
haloperidol (22:54); 2nd generation antipsychotics prescribed (33:43); clozapine (10:66); 
risperidone (15:61); mood stabilizers (33:44); lithium (14:62); sodium valproate (22:54); and 
anticholinergic (orphenadrine; 15:61), refer to Table 3.5.  
The group difference ‘on’ and ‘off’ a specific medication was also determined within an 
individual psychotic group when at least 8 of the individuals were either off or on a 
medication. This permitted us to determine differences within SCZ for 1st generation 
antipsychotic prescribed (9:18), 2nd generation antipsychotic prescribed (18:9), and 
clozapine (9:18). Then within BPD for any antipsychotic prescribed (20:8), 1st generation 
antipsychotic prescribed (10:18), 2nd generation antipsychotic prescribed (10:18), lithium 
(13:15), and sodium valproate (15:13). And within MPD for haloperidol (13:8), and 
anticholinergics (8:13). Univariate analysis was applied to the parametric data by one- way 
analysis of variance (ANOVA), and non- parametric data Mann- Whitney U testing was 
applied.   
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 Chapter 3 Results 
3.1 Participant demographics 
To characterize our population, group differences in demographics, drug use, and 
behavioural performance are reported between the four groups (CON, SCZ, BPD, MPD). 
Then differences in clinical scale scores, duration of illness, and medication variables where 
statistical analysis was viable, i.e. n was sufficient to perform sound statistical analysis, are 
reported for the three psychotic groups (SCZ, BPD, MPD). 
3.1.1 Participant characteristics 
A total of 103 participants between the ages of 19 and 40 were recruited for the present 
study. The individuals diagnosed with a psychiatric disorder consisted of 27 (females n=11, 
males n=16) participants diagnosed with schizophrenia (SCZ), 28 (females n=12, males n= 
16) participants diagnosed with bipolar I mood disorder with a history of psychosis and 21 
(females n=9, males n=12) participants diagnosed with methamphetamine induced 
psychotic disorder (MPD). Then 27 (females n=15, males n=12) controls (CON) were 
recruited. 
An attempt was made to balance the demographic information across groups, however the 
following demographic differences were found CON (H3,103=12.96, P=0.004) were younger 
in age compared to SCZ (P=0.041) and BPD (P=0.036). MPD (H3,103=11.50, P=0.009) reported 
fewer years at school compared to CON (P=0.043). Then MPD (H3,103=10.96, P=0.011) 
reported shorter total duration at school going compared to CON (P=0.017) and BPD 
(P=0.041). No significant group difference was noted for time spent at a tertiary institution. 
There were differences in weight (H3,103=18.88, P<0.001), SCZ weighed more than MPD 
(P=0.049) and CON (P=0.019), then BPD weighed more than MPD (P=0.010) and CON 
(P=0.003). Differences in BMI were also found (H3,103=24.18, P<0.001), where SCZ BMI was 
greater than MPD (P=0.010) and CON (P=0.006), then BPD BMI was greater than MPD 
(P=0.001) and CON (P<0.001), Table 3.1. 
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3.1.2 Drug use 
The ASSIST, a public health tool to assess drug use, was performed across all groups. The 
total substance involvement (TSI) score (H3,103=34.83, P<0.001) was higher in MPD 
compared to CON (P<0.001), SCZ (P<0.001) and BPD (P<0.001). Tobacco ASSIST score 
(H3,103=24.74, P<0.001) was higher in MPD compared to CON (P<0.001), SCZ (P=0.021) and 
BPD (P=0.028). Cannabis ASSIST score (H3,103=16.94, P<0.001) was higher in MPD 
compared to CON (P=0.005), SCZ (P=0.002) and BPD (P=0.012). Methamphetamine ASSIST 
score (H3,103=63.31, P<0.001) was higher in MPD compared to CON (P<0.001), SCZ 
(P<0.001) and BPD (P<0.001). Differences were found for the opioid ASSIST score 
(H3,103=16.16, P=0.001), specific group differences were not evident. Mandrax ASSIST 
score (H3,103=36.49, P<0.001) was higher in MPD compared to CON (P<0.001), SCZ 
(P=0.012) and BPD (P<0.001). No significant differences were evident for the alcohol 
ASSIST, cocaine ASSIST, inhalant ASSIST, sedative ASSIST and hallucinogen ASSIST scores, 
Table3.4.
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Table 3.1 Demographic information  
 
Table 3.2 Behavioural performance  
Median Range Median Range Median Range Median Range
Age on day of imaging (yrs) * 25,00 19-33 29,00 20-39 30.5 21-40 26,05 19-35 H₃, ₁₀₃=12,96; P=0,004 CON  vs SCZ P=0,041; CON vs BPD P=0,036
Duration at school (yrs) 12,00 8-14 12,00 7-14 12,00 9-12 # 10,24 7-12 H₃, ₁₀₃=11,50; P=0,009 MPD vs CON P=0,043
Tertiary education (yrs) 0,00 0-10 0,00 0-6 1.5 0-8 0,57 0-4,5 ns
Total duration of education (yrs) 12,00 8-12 12,00 7-18 13.5 9-20 @ 10,80 7-16,5 H₃, ₁₀₃=10,96; P=0,011 MPD vs CON P=0,017; MPD vs BPD P=0,041
Weight (kg) * 68,40 55-84 80,00 50-136 83,85 52,7-110 & 68,77 47,5-98 H₃, ₁₀₃=18,88; P<0,001 CON vs SCZ P=0,019; CON vs BPD P=0,003; MPD vs SCZ P=0,049; MPD vs BPD P=0,010
BMI * 23,19 18,16-30,85 28,07 17,30-47,46 29,26 19,35-39,17 & 23,34 18,5-30,6 H₃, ₁₀₃=24,18; P<0,001 CON vs SCZ P=0,006; CON vs BPD P<0,001; MPD vs SCZ P=0,010; MPD vs BPD P=0,001
Handedness (left:right)
12 females/16 males
n = 21 
9 females/12 males
Post hoc analysis
Control Schizophrenia Bipolar I disorder 
Methamphetamine induced 
psychosis 
n = 27 Kruskal Wallis (H-test)
1:26
15 females/12 males
n = 27 
11 females/16 males
n = 28
3:24 2:26 3:19
 
*
 CON vs SCZ and BPD; 
#
 CON vs MPD; 
@
 MPD vs CON and BPD 
&  
MPD vs SCZ and BPD. ⁿˢ Non- significant. Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
Median Range Median Range Median Range Median Range
Continuous Performance Task 
Correct responses (χ/60) 59,00 18-60 * 48,50 15-60 58,00 13-60 50,00 16-60 H₃, ₁₀₂=13,81; P=0,003 CON  vs SCZ P=0,003
Overall response time (msec) 209,00 84-533 * 465,50 57-1044 302,50 134-674 283,00 105-677 H₃, ₁₀₂=18,93; P<0,001 CON  vs SCZ P<0,001
Errors of commission 0,00 0-28 5,00 0-33 1,00 0-46 5,00 0-44 ns
Total number of omissions 0,00 0-24 # 3,00 0-45 0,00 0-18 0,00 0-12 H₃, ₁₀₂=17,12;P<0,001 CON  vs SCZ P=0,002; SCZ vs BPD P=0,014
Total number of trick S responses 0,00 0-13 0,00 0-11 0,00 0-4 0,00 0-5 ns
9 females/12 males11 females/16 males 12 females/16 males
 *  CON vs SCZ #  SCZ vs CON and BPD.  ⁿˢ Non- significant. Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
Kruskal Wallis (H-test)
Control Schizophrenia Bipolar I disorder 
Methamphetamine induced 
psychosis 
Post hoc analysisn = 27 n = 27 n = 28 n = 21 
15 females/12 males
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3.1.3 Clinical scales 
Clinical scales were only performed in the psychotic groups to analyse differences in clinical 
symptoms. The PANSS scale scores were assessed, as a total score, and its subscale scores: 
positive, negative and general psychopathology. PANSS total score (H2,76=13.28, P=0.001) 
was attenuated (lower) in BPD compared to SCZ (P=0.013) and MPD (P=0.041). PANSS 
positive score (H2,76=10.06, P=0.006) was poorer (higher) in SCZ compared to BPD 
(P=0.015). PANSS negative score (H2,76=23.53, P<0.001) was attenuated (lower) in BPD 
compared to SCZ (P<0.001) and MPD (P<0.001). The general psychopathology score 
(H2,76=7.14, P=0.028) was poorer (higher) in SCZ compared to BPD (P=0.028). Clinical global 
impression score (H2,76=10.69, P=0.004) was poorer (higher) in SCZ compared to BPD 
(P=0.006). Global assessment of function scores (H2,76=6.72, P=0.034) was poorer (lower) in 
SCZ compared to BPD (P=0.031). Extrapyramidal side effects score, using the Simpson 
Angus scale for Parkinsonism, (H2,76=14.24, P<0.001) was higher in SCZ compared to BPD 
(P=0.006). No significant differences were found between groups for mood scales (Young 
Mania Rating Scale, Hamilton Depression Rating Scale, and Calgary Depression Rating Scale 
for Schizophrenia), Table 3.3. 
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Table 3.3 Clinical scales performed in psychotic disorders  
 
Table 3.4 Drug use   
 
Median Range Median Range Median Range Median Range
Positive & Negative Syndrome Scale
Total score 43 30-100 48 30-100 * 35 30-73 45 30-77 H₂,₇₆=13,28; P= 0,001 BPD vs SCZ P=0,001; BPD vs MPD P=0,041
Positive symptoms 8 7-25 # 12 7-24 7 7-25 7 7-19 H₂,₇₆=10,06; P= 0,006 BPD vs SCZ P=0,015
Negative symptoms 11 7-30 13 7-30 * 9 7-20 12 7-27 H₂,₇₆=23,53; P<00,01 BPD vs SCZ P<0,001; BPD vs MPD P<0,001
General psychopathology 22 16-50 # 23 16-50 19 16-37 22 16-38 H₂,₇₆=7,14; P= 0,028 BPD vs SCZ P=0,028
Calgary depression for schizophrenia 1 0-13 2 0-8 0 0-13 1 0-9 ns
Hamilton depression rating scale 1 0-20 2 0-10 0 0-20 2 0-5 ns
Young mania rating scale 2 0-16 3 0-15 1 0-16 2 0-12 ns
Clinical global impression of illness severity 2 1-4 # 3 1-4 2 1-4 2 1-4 H₂,₇₆=10,69; P= 0,004 BPD vs SCZ P=0,006
Global assessment of functioning scale 65 5-90 # 60 30-85 71 5-85 65 31-90 H₂,₇₆=6,72; P= 0,034 BPD vs SCZ P=0,031
Simpson Angus scale for parkinsonism 0 0-16 # 1 0-16 0 0-1 0 0-9 H₂,₇₆=14,24; P<0,001 BPD vs SCZ P=0,006
Kruskal Wallis (H-test)
 * BPD vs  SCZ, and MPD ;# SCZ vs  BPD. ⁿˢ Non- s igni ficant. Non- parametric Kruskal  Wal l i s  (H- test), Signi ficance P<0,05.
Psychotic groups 
combined
Schizophrenia Bipolar I disorder 
Methamphetamine 
induced psychosis Post Hoc Analysis
n=76 n=27 n=28 n=21
Median Range Median Range Median Range Median Range
Total substance involvement score 16 0-49 26 0-121 22 0-80 * 54 0-139 H₃, ₁₀₃=34,83; P<0,001 MPD vs CON P<0,001; MPD vs SCZ P<0,001; MPD vs BPD P<0,001
Tobacco score 3,00 0-31 9,00 0-38 9,00 0-39 * 21,00 0-34 H₃, ₁₀₃=24,74; P<0,001 MPD vs CON P<0,001; MPD vs SCZ P=0,021; MPD vs BPD P=0,028
Alcohol score 5,00 0-22 3,00 0-29 6,50 0-24 6,00 0-24 ns
Cannabis score 3 0-9 3 0-20 3 0-24 * 9 0-28 H₃, ₁₀₃=16,94; P<0,001 MPD vs CON P=0,005; MPD vs SCZ P=0,002; MPD vs BPD P=0,021
Cocaine score 0 0-6 0 0-1 0 0-3 0 0-9 ns
Methamphetamine score 0 0-3 0 0-29 0 0-3 * 11 0-41 H₃, ₁₀₃=63,31; P<0,001 MPD vs CON P<0,001; MPD vs SCZ P<0,001; MPD vs BPD P<0,001
Inhalants score 0 0-3 0 0-6 0 0-0 0 0-3 ns
Sedatives sleeping pill score 0 0-3 0 0-6 0 0-16 0 0-6 ns
Hallucinogens score 0 0-5 0 0-3 0 0-8 0 0-3 ns
Opioids score 0 0-3 0 0-6 0 0-3 0 0-3 H₃, ₁₀₃=16,16; P=0,001 %
Mandrax score 0 0-3 0 0-6 0 0-3 * 3 0-15 H₃, ₁₀₃=36,49; P<0,001 MPD vs CON P<0,001; MPD vs SCZ P=0,012; MPD vs BPD P<0,001
   *  MPD vs all other groups;  % Denotes significant differences but not between groups. ⁿˢ Non- significant. Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
Schizophrenia Bipolar I disorder 
Post Hoc Analysis
n=27 n=27 n=28 n=21
Methamphetamine induced 
psychosis 
Controls
Kruskal Wallis (H-test)
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3.1.4 Illness duration and medication  
Analysis was conducted on the medication used within psychotic groups to determine 
whether medication effects were specific to clinical diagnosis. Within the psychotic group’s, 
differences were found for years with clinical diagnosis: years with diagnosis (H2,76=13.77, 
P=0.001) was shorter in MPD compared to SCZ (P=0.004) and BPD (P=0.002). Few studies 
have addressed illness duration across psychotic disorders. However, our results supports 
literature  in that age, illness duration and medication can alter brain function (Tan et al. 
2016). 
First generation antipsychotics (FGAs; H2,76=10.50, P=0.005) were prescribed more in MPD 
compared to SCZ (P=0.033) and BPD (P=0.047). The FGA haloperidol (H2,76=15.82, P<0.001) 
was prescribed more in MPD compared to SCZ (P=0.007) and BPD (P=0.047). Second 
generation antipsychotics (SGAs; H2,76=9.77, P=0.007) were prescribed more for SCZ 
compared to MPD (P=0.033). Differences were found for clozapine (H2,76=14.85, P<0.001), 
however specific group differences were not evident.  
Mood stabilizers (H2,76=38.22, P<0.001) were prescribed more in BPD compared to MPD 
(P<0.001) and SCZ (P<0.001). The mood stabilizer lithium (H2,76=22.94, P<0.001) was 
prescribed more in BPD compared to SCZ (P=0.019) and MPD (P=0.016). Then sodium 
valproate (H2,76=13.35, P=0.001) was prescribed more to BPD compared to MPD (P=0.025).  
Differences were found in anticholinergic’s (i.e. orphenadrine) prescription (H2,76=7.20, 
P=0.027) however specific group differences were not evident. Furthermore, no differences 
were found for the chlorpromazine equivalent, i.e. antipsychotic dose, Table 3.5. 
3.2 Group differences in behavioural performance and event-related potential wave 
components 
To address the first aim, a group analysis across the four groups (CON, SCZ, BPD and MPD) 
to determine whether group differences in (a) behavioural performance and (b) event 
related potential wave components amplitudes and latencies, this included prominent 
wave components during the cueing process and target stimulus. 
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3.2.1 Behavioural performance group differences 
The participants were asked to complete the Continuous Performance Task (CPT) where the 
behavioural performance data revealed several group differences, Table 3.2. For number of 
correct responses, i.e. accuracy, (H3,102=13.81, P=0.003) SCZ made fewer correct responses 
than CON (P=0.003). Response times (H3,102=18.93, P<0.001) were longer in SCZ than CON 
(P<0.001). Errors of omission (H3,102=17.12, P<0.001) SCZ made more compared to CON 
(P=0.002) and BPD (P=0.014). 
3.2.2 Continuous performance event-related potential group differences 
Several significant group differences in ERP wave components were found during the CPT. 
These differences were apparent for the cueing stimuli (first cue the first S presented and 
second cue the second S presented) and target stimulus (third S presented), figure 2.3. 
3.2.2.1 First cue event-related potential wave component group differences 
During the presentation of the first cue significant differences were found for the left 
frontal P100 amplitude (F3(H3,103)=8.78, P=0.024) and left central P300 amplitude 
(C3(H3,103)=9.18, P=0.026) however with post hoc analysis no significant group differences 
were evident. Then left parietal N170 amplitude (P3(H3,103)=9.83, P=0.020) was smaller for 
SCZ compared to MPD (P=0.019), Figure 3.1. 
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Table 3.5 Medication  
Median Range Median Range Median Range Median Range
Duration of psychotic disorders (yrs) 5 0,25-20 6 1-20 6 0,60-16 * 1 0,25-13 H₂,₇₆=13,77; P= 0,001 MPD vs SCZ P=0,004; MPD vs BPD P=0,002
Chlorpromazine equivalents 100 0-1500 200 0-1500 87,5 0-600 100 0-450
Prescribed medications
Any antipsychotic ns
1st generation antipsychotics * H₂,₇₆=10,50; P= 0,005 MPD vs SCZ P=0,033; MPD vs BPD P=0,047
Haloperidol * H₂,₇₆=15,82; P<0,001 MPD vs SCZ P=0,007; MPD vs BPD P=0,047
Chlorporomazine ns
Sulpiride ns
Depot (Flupentixol:Zuclopenthixol: 
Fluphenazine)
ns
2nd generation antipsychotics # H₂,₇₆=9,77; P=0,007 MPD vs SCZ P=0,033 
Clozapine H₂,₇₆=14,85; P<0,001 %
Olanzapine ns
Risperidone ns
Quetiapine ns
Moodstabilizers ns
Lithium & H₂,₇₆=38,22; P<0,001 BPD vs SCZ P<0,001; BPD vs MPD P<0,001
Sodium valproate & H₂,₇₆=22,94; P<0,001 BPD vs SCZ P=0,019; BPD vs MPD P=0,016
Lamotrigine $ H₂,₇₆=13,35; P= 0,001 BPD vs MPD P=0,025
Serotonin/Norepinephrine reuptake inhibitors 
(Fluoxetine:Citalopram:Amitriptyline)
ns
Anticholinergics - Orphenadrine H₂,₇₆=7,20; P=0,027 %
Psychotic groups 
combined
Schizophrenia Bipolar I disorder 
Methamphetamine 
induced psychosis 
n=76 n=27 n=28 n=21
Post Hoc AnalysisKruskal Wallis (H-test)
1:1:1
18
9
2
5
2
20
10
6
2
6
5
4
25
2
2:3:1
22
9
3
0
0
1:1:0
20
16
13
2
0
2
2:0:0
0
0
2
2:2:15:5:1
33
14
22
5
0
0
10
1
15
2
62
35
22
4
2
   * MPD vs  SCZ, and BPD; # SCZ vs  MPD ;% Denotes  s igni ficant di fferences  but not between groups; & BPD vs  SCZ, and  MPD  ;$ BPD vs  MPD. ⁿˢ Non- s igni ficant.  Non- parametric Kruskal  Wal l i s  (H- test), Signi ficance P<0,05.
4:1:2
33
10
2
15
6
0
2
0
131
5
0
1:0:1
5
15 25 8
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Figure 3.1 Grand mean event-related potentials of the first cue for the continuous performance task (-200 msec prior and 800 msec post cue presentation) for bilateral pre-frontal (Fp1 
and Fp2), frontal (F3 and F4), central (C3 and C4), and parietal (P3 and P4), left and right electrodes respectively. *Differences in P100 waveform (50-150msec) amplitude were found for 
however post hoc analysis did not show any specific group differences for left frontal (F3) and left central (C3) electrode. #Left parietal (P3) N170 waveform (100-250msec) amplitude was 
smaller for SCZ compared to MPD (P= 0.019). CON – control; SCZ- schizophrenia; BPD- bipolar with a history of psychosis; MPD- methamphetamine-induced psychotic disorder. Data 
represent the median with range of group grand mean average ERPs, Significance P<0.05  
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3.2.2.2 Second cue event-related potential wave component group differences 
Several differences in amplitude were found for the second cue P100 wave component; left 
frontal amplitude (F3(F3,102)=4.22; P=0.007) in SCZ was greater compared to CON (P=0.020) 
and BPD (P=0.045), right frontal amplitude (F4(F3,102)=4.10; P=0.008) in SCZ was greater 
compared to CON (P=0.030) and BPD (P=0.025), left central  amplitude (C3(H3,103)=8.71; 
P=0.033) in SCZ  was greater compared to CON (P=0.045), and the right central amplitude 
(C4(H3,103)=11.53; P=0.009)  in SCZ was greater compared to CON (P=0.022). 
Several differences were found for N170 latency and amplitude; left pre-frontal latency 
(Fp1(H3,103)=12.60; P=0.005) was shorter in CON compared to SCZ (P=0.008) and MPD 
(P=0.024). Then right central amplitude (C4(F3,102)=2.93, P=0.037) in CON was smaller 
compared to SCZ (P=0.042). Then differences were found between groups for the right pre- 
frontal latency (Fp2(H3,103)=8.55; P=0.035) and right frontal amplitude (F4(F3,102)=2.90, 
P=0.038) however with post-hoc analysis specific group differences were not evident, 
Figure 3.2. 
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Figure 3.2 Grand mean event-related potentials of the second cue for the continuous performance task (-200 msec prior and 800 msec post presentation) for bilateral pre-frontal (Fp1 
and Fp2), frontal (F3 and F4), central (C3 and C4), and parietal (P3 and P4), left and right electrodes respectively. #Differences in P100 waveform (50-150msec) amplitude were found for; 
left frontal (F3) in SCZ > CON and SCZ > BPD, right frontal (F4) in SCZ > CON and SCZ > BPD, left central (C3) in SCZ > CON, and the right central (C4) in SCZ > CON. *Differences were found for 
N170 waveform (100-250msec) latency and amplitude; left pre-frontal latency (Fp1) CON < SCZ and CON < MPD. Then right central amplitude (C4) in CON < SCZ. After post hoc analysis, no 
significant differences were found between groups in the right pre- frontal (Fp2) and left frontal (F3). CON – control; SCZ- schizophrenia; BPD- bipolar with a history of psychosis; MPD- 
methamphetamine-induced psychotic disorder. Data represent the median with range of group grand mean average ERPs, Significance P<0.05.  
* 
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3.2.2.3 Target stimulus event-related potential wave component group differences 
For the target stimulus, significant differences ERP wave components were found. For N70 
wave component: right parietal N70 latency differed (F4(H3,103)=8.19; P=0.042), no specific 
group differences were found with post hoc analysis. Left frontal P100 amplitude 
(F3(H3,103)=11.68; P=0.008) in SCZ was greater than CON (P=0.005). Right frontal P100 
amplitude (F4(H3,103)=14.99; P=0.001) in SCZ was greater than CON (P=0.001) and BPD 
(P=0.022).  
The left prefrontal N170 latency (Fp1(H3,103)=11.60; P=0.008) was shorter for CON compared 
to SCZ (P=0.034) and MPD (P=0.041). The right prefrontal N170 amplitude (Fp2(F3,102)=3.77; 
P=0.013) in SCZ was greater than CON (P=0.046), BPD (P=0.043) and MPD (P=0.044). The 
left frontal N170 amplitude (F3(F3,102)=2.81; P=0.043) in SCZ was greater than CON 
(P=0.027); right frontal N170 amplitude (F4(F3,102)=4.18; P=0.007) in SCZ was greater than 
CON (P=0.006).  
Then right prefrontal P300 latency (Fp2(H3,103)=12.34; P=0.006) was shorter for CON 
compared to SCZ (P=0.038) and MPD (P=0.017), Figure 3.3.  
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Figure 3.3 Grand mean event-related potentials of the target stimulus for the continuous performance task (-200 msec prior and 800 msec post presentation) for bilateral pre-frontal 
(Fp1 and Fp2), frontal (F3 and F4), central (C3 and C4), and parietal (P3 and P4), left and right electrodes respectively. *Differences in P100 waveform (50-150msec) left frontal P100 
amplitude (F3) in SCZ > CON and SCZ > BPD. however, post hoc analysis did not show any specific group differences for right frontal N70 latency (F4). @Differences were found for N170 
waveform (100-250msec) latency and amplitude; the left prefrontal latency (Fp1) and CON < MPD. The right prefrontal (Fp2) amplitude in SCZ > CON, SCZ > BPD and SCZ > MPD. The left 
frontal amplitude (F3) in CON < SCZ; right frontal amplitude (F4) in CON < SCZ.# Differences were found for P300 waveform (200-400msec) right prefrontal P300 latency (Fp2) was 
specifically shorter for CON < SCZ and CON < MPD. CON – control; SCZ- schizophrenia; BPD- bipolar with a history of psychosis; MPD- methamphetamine-induced psychotic disorder. Data 
represent the median with range of group grand mean average ERPs, Significance P<0.05. 
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3.3 Event related potential wave component correlation analysis 
To address the second aim, to characterize event related potential wave component 
amplitude and latency relationships,  correlation analyses were performed on (a) all four 
groups (CON, SCZ, BPD, MPD) with demographics, drug use, and behavioural performance 
data, and  (b) within the psychotic groups (SCZ, BPD, MPD) for clinical variables (clinical 
scales, duration of illness, and medication prescribed). 
3.3.1 Event-related potential wave component correlates with demographics 
When group demographics were combined several correlations were found with ERP wave 
components of the CPT, significance P<0.01. The first of the spearman’s rank correlation 
between ERPs and demographics was over all groups combined. Then the same analysis 
was looked at within each group (appendix E and appendix F).  
Within CON for education, duration at school correlated with the first cue left parietal N170 
amplitude (P3RSpearman’s=0.51, p=0.005). Then tertiary education correlated with the first cue 
left parietal N170 amplitude (P3RSpearman’s=0.53, p=0.003). For physical characteristics, 
weight correlated with the first cue left central P300 latency (C3RSpearman’s=0.55, p=0.002).  
Within SCZ for education, duration at school correlated with: target stimulus left parietal 
N170 latency (P3RSpearman’s=0.56, p=0.002). The total years at school and total duration of 
education correlated with the second cue left parietal N170 latency (P3RSpearman’s=0.58, 
p=0.001), and second cue left parietal N170 latency (P3RSpearman’s=0.57, p=0.001). 
Within MPD for age, the age on day of testing correlated with: target stimulus left frontal 
P300 latency (F3RSpearman’s=-0.56, p=0.008), first cue right parietal N70 latency 
(P4RSpearman’s=0.55, p=0.009), and first cue right parietal P300 amplitude (P4RSpearman’s=0.72, 
p=0.001). For education, the duration of education correlated with: the second cue left 
central P300 latency (C3RSpearman’s=-0.55, p=0.009). Tertiary education correlated with: 
target stimulus right central P100 latency (C4RSpearman’s=0.60, p=0.003) and first cue right 
parietal P300 amplitude (P4RSpearman’s=0.68, p=0.006). For physical characteristics, BMI 
correlated with the second cue right frontal P100 latency (F4RSpearman’s=-0.55, p=0.009). 
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3.3.2 Event-related potential wave component correlates with drug use 
Within CON for ASSIST scores i.e. measure of drug use, total substance involvement 
correlated with: first cue left parietal N170 latency (P3RSpearman’s=-0.50, p=0.007), and target 
stimulus left parietal P300 (P3RSpearman’s=-0.54, p=0.003). Tobacco ASSIST correlated with: 
first cue left prefrontal N170 latency (Fp1RSpearman’s=-0.50, p=0.007), and target stimulus left 
parietal P300 amplitude (P3RSpearman’s=-0.58, p=0.001). Alcohol ASSIST correlated with: 
second cue left parietal N170 amplitude (P3RSpearman’s=0.55, p=0.002), and target stimulus 
right prefrontal P300 amplitude (Fp2RSpearman’s=-0.51, p=0.006). Cannabis ASSIST correlated 
with: target stimulus right frontal P100 latency (F4RSpearman’s=-0.55, p=0.002), second cue 
right frontal P100 latency (F4RSpearman’s=-0.54, p=0.003), second cue right parietal N70 
amplitude (P4RSpearman’s=0.50, p=0.007), first cue left central N170 latency (C3RSpearman’s=-
0.52, p=0.004); second cue right parietal N170 amplitude (P4RSpearman’s=0.53, p=0.003), and 
target stimulus right frontal P300 amplitude (F4RSpearman’s=-0.50, p=0.007). Cocaine ASSIST 
correlated with and first cue right prefrontal N170 amplitude (Fp2RSpearman’s=0.50, p=0.007). 
Methamphetamine ASSIST correlated with the second cue left central N170 amplitude 
(C3RSpearman’s=0.52, p=0.004). Hallucinogen ASSIST correlated with the second cue: left 
parietal N70 amplitude (P3RSpearman’s=-0.50, p=0.007), left parietal P100 amplitude 
(P3RSpearman’s=0.52, p=0.004); right parietal P100 amplitude (P4RSpearman’s=0.49, p=0.008), and 
left parietal P150 amplitude (P3RSpearman’s=-0.52, p=0.004). 
Within SCZ for ASSIST scores, total substance involvement correlated with: target stimulus 
left parietal N70 amplitude (P3RSpearman’s=-0.61, p<0.001), target stimulus right parietal N70 
amplitude (P4RSpearman’s= -0.55, p=0.002), target stimulus right parietal P100 amplitude 
(P3RSpearman’s=-0.57, p=0.001), first cue left parietal P100 latency (P3RSpearman’s=-0.50, 
p=0.007), target stimulus left parietal  N170 amplitude (P3RSpearman’s=-0.56, p=0.002), target 
stimulus right parietal N170 amplitude (P4RSpearman’s=-0.55, p=0.002), second cue left 
parietal P300 latency (P3RSpearman’s=0.53, p=0.004), second cue right parietal P300 latency 
(P4RSpearman’s=0.50, p=0.007), target stimulus left parietal P300 latency (P3RSpearman’s=0.55, 
p=0.002), and target stimulus right parietal P300 latency (P4RSpearman’s= 0.56, p=0.002). 
Tobacco ASSIST correlated with: target stimulus left parietal N70 amplitude (P3RSpearman’s=-
0.56, p=0.002), target stimulus right parietal N70 amplitude (P4RSpearman’s=-0.51, p=0.005), 
first cue left frontal P100 amplitude (F3RSpearman’s=0.50, p=0.007), first cue left parietal P100 
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amplitude (P3RSpearman’s=0.61, p<0.001), first cue left parietal P100 latency (P3RSpearman’s=-
0.51, p=0.006); target stimulus right parietal P100 amplitude (P3RSpearman’s= -0.57, p=0.001), 
right frontal P100 amplitude (F4RSpearman’s=0.61, p<0.001), first cue left frontal N170 latency 
(F3RSpearman’s=0.54, p=0.003), target stimulus left central P300 latency (C3RSpearman’s=0.61, 
p<0.001), second cue right parietal P300 latency (P4RSpearman’s=0.54, p=0.003), target 
stimulus right parietal P300 latency (P4RSpearman’s=0.58, p=0.001), and target stimulus left 
parietal P300 latency (P3RSpearman’s=0.60, p<0.001). Cannabis ASSIST correlated with the 
second cue right parietal P100 amplitude (P4RSpearman’s=-0.50, p=0.007). Alcohol ASSIST 
correlated with the target stimulus left frontal N170 amplitude (F3RSpearman’s=0.55, p=0.002). 
Within BPD for ASSIST scores, total substance involvement correlated with the second cue 
left frontal N170 amplitude (F3RSpearman’s=0.52, p=0.004). Tobacco ASSIST correlated with the 
first cue right central N170 amplitude (C4RSpearman’s=0.50, p=0.005).  
Within MPD for ASSIST scores, total substance involvement correlated with: second cue left 
prefrontal P300 latency (Fp1RSpearman’s=0.55, p=0.008). Tobacco ASSIST correlated with: first 
cue right central P300 latency (C4RSpearman’s=0.62, p=0.002). Alcohol ASSIST correlated with: 
first cue right frontal N170 amplitude (F4RSpearman’s=0.58, p=0.004), second cue left 
prefrontal N170 amplitude (Fp1RSpearman’s=0.76, p<0.001), second cue right prefrontal N170 
amplitude (Fp2RSpearman’s=-0.63, p=0.002), second cue left prefrontal P300 amplitude 
(Fp1RSpearman’s=-0.72, p<0.001), and second cue right prefrontal P300 amplitude 
(Fp2RSpearman’s=-0.66, p=0.001). Methamphetamine ASSIST correlated with the target 
stimulus left parietal N170 amplitude (P3RSpearman’s=-0.56, p=0.007).  
3.3.3 Event- related potential wave component correlates with behavioural performance  
Within CON for behavioural performance, number of correct responses correlated with: 
first cue left parietal N70 amplitude (P3RSpearman’s=0.65, p<0.001), first cue left parietal P100 
amplitude (P3RSpearman’s=0.56, p=0.002), first cue left parietal P150 amplitude 
(P3RSpearman’s=0.61, p<0.001), first cue left central N170 amplitude (C3RSpearman’s=0.51, 
p=0.006), and first cue left parietal N170 amplitude (P3RSpearman’s=0.67, p<0.001). The total 
number of omissions correlated with: first cue left parietal cortex N70 amplitude 
(P3RSpearman’s=-0.53, p<0.001) and target stimulus left parietal N170 amplitude (P3RSpearman’s=-
0.52, p=0.005). The total number of impulsive responses correlated with: first cue left 
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parietal N70 amplitude (P3RSpearman’s=-0.65, p<0.001), first cue left parietal P100 amplitude 
(P3RSpearman’s=-0.56, p=0.002), first cue left parietal P150 amplitude (P3RSpearman’s=-0.61, p= 
p<0.001), first cue left central N170 amplitude (C3RSpearman’s=-0.53, p=0.004), second cue left 
central N170 amplitude (C3RSpearman’s=-0.52, p=0.005), target stimulus left central N170 
amplitude (C3RSpearman’s=-0.50, p=0.007), and first cue left parietal N170 amplitude 
(P3RSpearman’s=-0.70, p<0.001). 
Within the SCZ for behavioural performance, number of correct responses correlated with 
the first cue left parietal P150 latency (P3RSpearman’s=0.50, p=0.008). Response time 
correlated with: target stimulus left central P300 latency (C3RSpearman’s=-0.57, p=0.002), 
target stimulus right central P300 amplitude (C4RSpearman’s=-0.54, p=0.004), target stimulus 
right parietal P300 latency (P4RSpearman’s=-0.51, p=0.006), second cue right central P300 
latency (C4RSpearman’s=-0.53, p=0.005), and second cue right parietal P300 latency 
(P4RSpearman’s=-0.52, p=0.006). The number of omissions correlated with the second cue right 
frontal P100 amplitude (F4RSpearman’s=-0.57, p=0.001). Then number of impulsive responses 
correlated with: target stimulus left parietal N70 latency (P3RSpearman’s=0.60, p=0.001) and 
second cue left parietal N70 latency (P3RSpearman’s=0.60, p<0.001). 
Within the MPD for behavioural performance, the number of omissions correlated with: 
first cue left frontal, P100 amplitude (F3RSpearman’s=0.66, p= p<0.001), first cue left central, 
P100 amplitude (C3RSpearman’s=0.62, p=0.002), first cue left parietal P100 amplitude 
(P3RSpearman’s=0.61, p=0.002), second cue right parietal P100 amplitude (P4RSpearman’s=0.55, 
p=0.008), and second cue right parietal P150 amplitude (P4RSpearman’s=0.57, p=0.005). 
3.3.4 Event- related potential wave component correlates with clinical scales 
Within SCZ for clinical scale scores, PANSS total correlated with the first cue: left central 
P300 amplitude (C3RSpearman’s=0.52, p=0.005), right central P300 amplitude 
(C4RSpearman’s=0.53, p=0.003), and left parietal P300 amplitude (P3RSpearman’s=0.62, p<0.001). 
PANSS negative subscale correlated with the first cue left parietal P300 amplitude 
(P3RSpearman’s=0.58, p=0.001). PANSS general psychopathology subscale correlated with: 
target stimulus right parietal P150 latency (P4RSpearman’s=-0.53, p=0.003), second cue right 
parietal P150 latency (P4RSpearman’s=-0.52, p=0.004), and first cue left parietal P300 
amplitude (P3RSpearman’s=0.56, p=0.002). Hamilton Depression Rating Scale correlated with: 
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first cue right frontal N170 latency (F4RSpearman’s=-0.51, p=0.006), first cue left parietal N170 
amplitude (P3RSpearman’s=0.60, p<0.001), first cue right parietal P300 latency (P4RSpearman’s=-
0.52, p=0.004), and target stimulus right parietal P300 amplitude (P4RSpearman’s=-0.52, 
p=0.004). Young Mania Rating Scale correlated with the first cue right central P100 latency 
(C4RSpearman’s=-0.61, p=0.006). Then Clinical Global Impression correlated with the first cue 
left parietal N170 latency (P3RSpearman’s=-0.50, p=0.006).  
Within BPD for clinical scale scores, PANSS total correlated with the first cue: left central 
P100 amplitude (C3RSpearman’s=0.54, p=0.002) and right central P100 amplitude 
(C4RSpearman’s=0.50, p=0.006). PANSS positive subscale correlated with the second cue right 
parietal N170 amplitude was (P4RSpearman’s=-0.50, p=0.005). PANSS negative subscale 
correlated with the first cue right parietal P300 amplitude (P4RSpearman’s=0.50, p=0.006). 
Calgary Depression Rating Scale correlated with the target stimulus right central N170 
amplitude (C4RSpearman’s=0.50, p=0.005). General Assessment of Function correlated with the 
target stimulus left prefrontal N170 amplitude (Fp1RSpearman’s=0.50, p=0.006), target stimulus 
right prefrontal N170 amplitude (Fp2RSpearman’s=0.55, p=0.002), second cue left prefrontal 
N170 amplitude (Fp1RSpearman’s=0.50, p=0.006), and second cue right prefrontal N170 
amplitude (Fp2RSpearman’s=0.51, p=0.005). 
Within MPD for clinical scale scores, PANSS negative subscale correlated with: second cue 
left parietal P100 amplitude (P3RSpearman’s=0.55, p=0.009), second cue left parietal P150 
amplitude (P3RSpearman’s=0.61, p=0.003), second cue right parietal P150 amplitude 
(P4RSpearman’s=0.57, p=0.006), second cue left parietal N170 amplitude (P3RSpearman’s=0.57, 
p=0.006), target stimulus right parietal P300 amplitude (P4RSpearman’s=0.61, p=0.003), second 
cue left central P300 amplitude (C3RSpearman’s=0.56, p=0.007), and second cue right parietal 
P300 amplitude (P4RSpearman’s=0.56, p=0.007). Calgary Depression Rating Scale correlated 
with: target stimulus left central P100 latency (C3RSpearman’s=-0.56, p=0.007), first cue left 
frontal N170 amplitude (F3RSpearman’s=-0.56, p=0.008), first cue left frontal P300 amplitude 
(F3RSpearman’s=-0.65, p=0.001), first cue right frontal P300 amplitude (F4RSpearman’s=-0.62, 
p=0.0026), and target stimulus left frontal P300 latency (F3RSpearman’s=0.56, p=0.007). 
Hamilton Depression Rating Scale correlated with: target stimulus left frontal P300 latency 
(F3RSpearman’s=0.55, p=0.008), and target stimulus right frontal P300 latency 
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(F4RSpearman’s=0.58, p=0.005). Clinical Global Impression correlated with the second cue right 
frontal P100 latency (F4RSpearman’s=-0.56, p=0.007). 
3.3.5 Event-related potential wave component correlated with illness duration and 
chlorpromazine equivalents 
There were no significant differences noted for chlorpromazine equivalent across groups 
however, differences were evident for illness duration within MPD. Within MPD duration of 
illness correlated with: target stimulus left frontal P100 latency (F3RSpearman’s=-0.56, 
p<0.001), first cue left parietal P100 latency (P3RSpearman’s=0.56, p=0.007), second cue the 
left frontal P100 latency (F3RSpearman’s=-0.57, p=0.006), and first cue left parietal P150 latency 
(P3RSpearman’s=0.70, p<0.001). 
3.4 Event-related potential wave component differences by medication 
To address the third aim, event-related potential wave component differences ‘on’ and ‘off’ 
a specific medication was determined by group the psychotic groups together. Then within 
each psychotic group ‘on’ and ‘off’ a medication where it was possible statistically 
(appendix D).  
3.4.1 First cue event-related potential wave component medication differences 
For the first cue ERP medication differences were found within all psychotic groups and 
then within SCZ and BPD only.  
In all psychotic groups prescription of FGAs increased left central P100 amplitude 
(z=3,14;p=0,001, on1.42(-1.07-7.26) off0.34(-4.19-3.04)), lengthened left central P100 latency 
(z=2,60;p=0,009, on134(50-150) off98(50-150)), increased right central P100 amplitude 
(z=2,58;p=0,009, on0.94(-1.20-4.21) off0.42(-5.88-4.20)), increased left parietal P100 amplitude 
(z=2,54;p=0,010, on1.38(-0.86-5.92) off0.48(-2.95-4.69)), increased right parietal P100 amplitude 
(z=2,26;p=0,023, on1.44(-0.87-4.69) off0.61(-4.42-5.38)), and lengthened right parietal N170 latency 
(F1,76=4,49;p=0,037, on220(100-250) off178(100-250)). In all psychotic groups prescription of SGAs 
shortened the left central P100 latency (z=2,88;p=0,003, on88(50-150) off122(50-150)), shortened 
the left parietal P100 latency (z=1,97;p=0,048, on92(50-150) off114(50-150)), increased the right 
prefrontal N170 amplitude (z=-2,63;p=0,008, on-1.27(-5.45-6.46) off-2.28(-14.34-2.05)), and increased 
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the right central N170 latency (z=-2,29;p=0,021, on190(100-250) off144(100-250)). In all psychotic 
groups prescription of mood stabilizers increased the left prefrontal P300 amplitude 
(F1,76=4,53;p=0,036, on2.29(2.68) off0.93(2.81)). In all psychotic groups prescription of 
anticholinergics increased the left prefrontal N170 amplitude (z=-2,25;p=0,023, on-1.38(-3.89-
3.29) off-2.20(-14.74-1.05)). In all psychotic groups prescription of any antipsychotic increased the 
right parietal N70 amplitude (z=2,08;p=0,037, on-0.71(-5.97-2.87) off-1.93(-6.52-2.45)), increased the 
left central P100 amplitude (z=2,35;p=0,018, on0.81(-4.19-7.26) off0.09(-3.39-2.53)), and increased 
the left parietal P100 amplitude (z=2,16;p=0,030, on1.09(-2.95-5.92) off0.35(-2.35-2.26)). In all 
psychotic groups prescription of clozapine reduced the right parietal N170 amplitude 
(F1,76=13,71;p<0,001, on-1.06(2.01) off-3.68(2.54)), increased the left frontal P300 amplitude 
(F1,76=4,09;p=0,046, on2.36(1.19) off1.19(-1.69)). In all psychotic groups prescription of risperidone 
increased the right prefrontal N170 amplitude (z=-1,98;p=0,047, on-1.21(-4.00-6.46) off-1.82(-14.34-
2.05)) and shortened the right parietal N170 latency (z=2,46;p=0,013, on158(108-216) off214(100-
250)). In all psychotic groups prescription of haloperidol lengthened the left central P100 
latency (z=-2,39;p=0,016, on134(56-150) off101(50-150)), lengthened the right frontal N170 latency 
(z=2,25;p=0,024, on118(100-200) off165(100-200)), lengthened the right parietal N170 latency (z=-
2,02;p=0,043, on225(100-250) off190(100-250)), lengthened the left prefrontal P300 latency (z=-
2,07;p=0,037, on378(218-400) off342(200-400)), lengthened the right frontal P300 latency (z=-
2,06;p=0,038, on370(228-400) off344(200-400)), and reduced the left central P300 latency 
(z=1,96;p=0,049, on361(300-400) off390(300-500)). In all psychotic groups prescription of lithium 
increased the left prefrontal P300 amplitude (F1,76=5,92;p=0,017, on3.20(-1.62-10.14) off1.68(-6.32-
6.36)).  
In SCZ prescription of FGAs increased left central P100 amplitude (z=2.13; P=0.032, 
on0.85(0.047) off0.32(-4.19-2.23)) and reduced left parietal P100 amplitude (z=2.44; P=0.014, 
on1.82(0.064-3.54) off0.24(-2.95-4.44)). In SCZ, clozapine lengthened left frontal P100 amplitude (z=-
2,75;p=0,005, on1.50(0.25-7.02) off-0.08(-3.75-3.10)).  
In BPD prescription of any antipsychotic medication increased right parietal N70 amplitude 
(z=2.49; P=0.012, on-0.69(-2.39-2.87) off-2.10(-6.52-0.30)) and increased left central P100 amplitude 
(z=1.98; P=0.047, on0.70(-1.21-2.82) off-0.33(-3.38-2.21)). Prescription of FGAs in BPD increased left 
central P100 amplitude (z=1.98; P=0.046, on1.76(-0.66-2.82) off0.30(-3.38-2.39)), while prescription of 
http://etd.uwc.ac.za/
60 
 
SGAs in BPD increased right prefrontal N170 amplitude (z=2.03; P=0.020, on-1.42(-3.99-6.46) off-
2.93(-9.97-0.78)). 
3.4.2 Second cue event-related potential wave component medication differences 
For the second cue ERP medication differences were found when all three psychotic groups 
were combined and within each of the psychotic disorders.  
In all psychotic groups prescription of FGAs increased the left prefrontal P300 latency 
(F1,76=5,43;p=0,022, on316.11(42.45) off298(202-388)). In all psychotic groups prescription of SGAs 
reduced the right parietal P150 amplitude (z=2,30;p=0,021, on1.13(-2.52-5.36) off2.12(-7.96-16.25)), 
increased the right central P300 latency (z=-2,87;p=0,004, on404(300-500) off368(300-484)), and 
increased the left parietal P300 latency (z=-2,59;p=0,009, on400(250-500) off374(250-500). In all 
psychotic groups prescription of mood stabilizers shortened the right prefrontal N170 
latency (z=2,64;p=0,008, on140(100-200) off156(100-200)). In all psychotic groups prescription of 
anticholinergics increased the left prefrontal N170 amplitude (F1,76=4,39;p=0,039, on0.35(2.39) 
off-1.46(2.67)). In all psychotic groups prescription of clozapine increased the right frontal P100 
amplitude (F1,76=7,91;p=0,006, on2.36(1.91) off0.09(2.44)), increased the left prefrontal N170 
amplitude (F1,76=4,31;p=0,041, on0.68(2.97) off-1.17(2.56)), increased the right frontal N170 
amplitude (F1,76=7,01;p=0,009, on-0.11(1.53) off-2.26(2.46)), increased the left prefrontal P300 
amplitude (F1,76=4,06;p=0,047, on4.99(3.77) off2.81(3.09)). In all psychotic groups prescription of 
risperidone lengthened the right central P300 latency (z=-2,98;p=0,002, on4.26(352-500) 
off372(300-500)). In all psychotic groups prescription of haloperidol increased the right parietal 
P100 amplitude (z=-2,13;p=0,032, on2.14(-7.96-13.39) off1.14(-3.07-7.11)), increased the right parietal 
P150 amplitude (z=-2,51;p=0,011, on3.35(-7.96-16.25) off1.51(-3.37-8.54)), shortened the left central 
P300 latency (z=2,44;p=0,014, on357(300-500) off396(300-500)), and shortened the right central 
P300 latency  (z=2,11;p=0,034, on336(300-484) off385(300-500)). In all psychotic groups prescription 
of sodium valproate increased the right parietal N70 latency (z=-2,13;p=0,032, on85(20-150) 
off72(20-150)), and increased the left prefrontal P300 latency (F1,76=4,10;p=0,046, on319.73(41.49) 
off295.67(202-398)).  
In SCZ, SGAs reduced right parietal P150 amplitude (z=2.03; P=0.042, on1.22(-2.19-5.35) 
off2.11(1.44-8.53)).  
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In BPD, SGAs lengthened left parietal P300 latency (z= -2.13; P=0.032, on439(312-500) off373(250-
452)). In BPD sodium valproate shortened left prefrontal P300 latency (F1.26=5,19; P=0.031, 
on316.93(41.67) off276.61(51.95)).  
In MPD, haloperidol increased right parietal P150 amplitude (z=-1.99; P=0.046, on5.20(-7.96-
16.25) off1.18(-2.51-4.86)). 
3.4.3 Target event-related potential wave component medication differences 
For the target stimulus ERP medication differences were found when all three psychotic 
groups were combined and within BPD only.  
In all psychotic groups prescription of SGAs reduced the right parietal P100 amplitude 
(z=3,01;p=0,002, on-1.10(-230-8.54) off1.27(-2.94-5.20)), reduced the left parietal P150 amplitude 
(z=2,47;p=0,013, on0.54(-4.35-7.53) off1.61(-3.11-6.60)), reduced the right parietal P150 amplitude 
(z=2,96;p=0,003, on0.43(-2.30-8.54) off2.11(-3.278.27)), lengthened the left central P300 latency (z=-
2,71;p=0,006, on404(300-500) off364(300-500)), lengthened the right central P300 latency (z=-
2,43;p=0,014, on406(300-500) off372(300-480)), and lengthened the left parietal P300 latency (z=-
3,25;p=0,001, on406(250-500) off37(250-500)). In all psychotic groups prescription of clozapine 
reduced the left parietal N70 amplitude (F1,76=4,42;p=0,038, on-3.10(2.23) off-1.75(1.83)), reduced 
the left parietal P100 amplitude (F1,76=4,47;p=0,037, on-0.32(2.02) off0.97(1.76)), increased the 
right prefrontal N170 amplitude (F1,76=6,74;p=0,011, on0.61(1.52) off-1.07(1.94)), increased the 
right frontal N170 amplitude (F1,76=4,41;p=0,039, on-0.51(1.38) off-1.77(1.81)). In all psychotic 
groups prescription of risperidone, lengthened the left central P300 latency (z=-
3,07;p=0,002, on4.26(362-500) off370(300-500)), lengthened the right central P300 latency (z=-
2,35;p=0,018, on408(352-500) off374(300-500)), and lengthened the left parietal P300 latency (z=-
2,46;p=0,013, on408(250-500) off378(250-500)). In all psychotic groups prescription of haloperidol 
increased the right parietal P100 amplitude (z=-2,19;p=0,028, on2.19(-2.88-5.20) off0.25(-2.94-8.58)), 
increased the right parietal P150 amplitude (z=-2,11;p=0,034, on2.33(-2.88-8.27) off0.88(-3.27-8.58)), 
and shortened the left central P300 latency (z=1,99;p=0,045, on357(300-500) off392(300-500)). In all 
psychotic groups prescription of lithium increased the left central N170 latency (z=-
2,19;p=0,028, on182(138-250) off159(100-250)), and increased the left parietal N170 latency (z=-
1,99;p=0,045, on188(100-250) off159(100-246)). In all psychotic groups prescription of sodium 
valproate shortened the left central P100 latency (z=2,10;p=0,035, on97(50-138) off113(50-150)), 
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and lengthened the left prefrontal P300 latency (F1,76=4,44;p=0,038, on324.55(35.70) 
off300(49.53)).  
In BPD, SGAs: reduced right parietal P100 amplitude (z=2.22; P=0.025, on-0.50(-182-2.17) off1.49(-
2.94-4.11)), reduced left parietal P150 amplitude (z=1.98; P=0.046, on0.10(-2.14-3.04) off1.70(-2.89-
4.53)), reduced right parietal P150 amplitude (z=2.46; P=0.010, on-0.04(-2.06-2.17) off2.09(-3.264.11)), 
lengthened left central P300 latency (z= -2.01; P=0.044, on431(300-500) off345(300-458)), and 
lengthened left parietal P300 latency (z= -2.85; P=0.004, on445(344-500) off373(250-450)). Then 
lithium in BPD lengthened left central N170 latency (z= -2.09; P=0.030, on182(138-250) off158(114-
220)).  
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Chapter 4 Discussion 
Our main findings for each of our aims are as follows: (1) sustained attentional performance 
is poorer in SCZ. Our study adds to previous studies showing attention processing deficits in 
SCZ are evident during cueing of a sustained attention tasks; (2) substance use was found to 
slow cognitive processing, education improved executive function and information 
processing, and symptom severity was associated with dysfunction of prefrontal and frontal 
cortices; (3) antipsychotic medication was related to improved processing of salient 
information.  
 The study included 103 participants (27 CON, 27 SCZ, 28 BPD and 21 MPD). Although our 
intent was to match demographics across groups, we found CON were younger in age 
compared to SCZ and BPD. MPD reported fewer years at school compared to CON, and 
MPD reported shorter total duration at school going compared to CON and BPD, reduced 
education in methamphetamine users has previously been reported (O’Brien & Anthony 
2009; Paulus 2017). Furthermore, SCZ weighed more than MPD and CON, then BPD 
weighed more than MPD and CON. Lastly SCZ BMI was greater than MPD and CON, and 
BPD BMI was greater than MPD and CON. These significant weight differences are likely due 
to psychotropic medication and their duration of use (Jibson 2017). The total substance 
involvement (TSI) score was higher in MPD compared to CON, SCZ and BPD. Tobacco ASSIST 
score was higher in MPD compared to CON, SCZ and BPD. Cannabis ASSIST score was higher 
in MPD compared to CON, SCZ and BPD. Methamphetamine use score was higher in MPD 
compared to CON, SCZ and BPD. It was expected that MPD would report high use of 
methamphetamine and other substances when compared to our other groups (McKetin et 
al. 2013). 
Clinically, SCZ and MPD reported higher positive and negative symptom scores compared 
with BPD. Then SCZ reported greater general psychopathology on the PANSS scale 
compared to BPD. These data suggest severity of illness, not only psychotic symptoms, was 
greater in SCZ when compared to BPD. This was supported by general clinical assessment of 
mental health, using the clinical global impression and global assessment of function scales, 
where scores were worse for SCZ compared with BPD. Extrapyramidal side effects score, 
using the Simpson Angus scale for Parkinsonism, was higher in SCZ compared to BPD. This is 
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likely due to clozapine being prescribed more in SCZ compared to BPD (Johnsen & Kroken 
2012). SGA’s generally have fewer extrapyramidal side effects as compared to FGA’s except 
for clozapine, olanzapine, and risperidone (Leucht et al. 2009). MPD reported shorter 
duration of illness when compared with SCZ and BPD. We suggest this difference is related 
to the transition in diagnosis from MPD to SCZ with time, this study however excluded 
participants with either a diagnosis of SCZ or BPD which may have had a causal link to the 
methamphetamine abuse. First generation antipsychotics, ergo haloperidol, were 
prescribed more in MPD compared to SCZ and BPD. This is due to the effectiveness of 
haloperidol in treating the effects of methamphetamine (Glasner-Edwards & Mooney 
2014). Second generation antipsychotics were prescribed more for SCZ compared to MPD. 
SCZ has longer duration of illness compared to MPD and therefore are given FGA’s for initial 
symptoms of psychosis and thereafter are given SGA’s for management of symptoms 
(Abou-Setta et al. 2012; Johnsen & Kroken 2012). Differences were found for clozapine; 
however specific group differences were not evident. Our results show that cognitive 
deficits in SCZ, are slightly improved with SGA’s. Mood stabilizers in general and lithium 
were prescribed more in BPD compared to MPD and SCZ. Then sodium valproate was 
prescribed more to BPD compared to MPD. This was to be expected as BPD is primarily a 
disorder of mood and medications prescribed are to improve mood stability (Malhi et al. 
2017). 
4.1 Groups differences in behavioural performance and event-related potential wave 
components 
Behaviourally, performance of the CPT task, SCZ performed poorer than the other groups. 
This included poorer accuracy, a greater number of incorrect responses, longer response 
times, and more errors of omission compared to CON, they also made more errors of 
omission than BPD. SCZ is known to have cognitive deficits compared to CON (Onitsuka et 
al. 2013). Increased N170 and P300 amplitudes along with lengthened latencies have 
previously been noted in SCZ (Onitsuka et al. 2013; Feuerriegel et al. 2015). The increased 
amplitudes and lengthened latencies in SCZ indicate that cueing and processing of 
sustained attention is different in SCZ when compared with CON. Albeit that it is known 
that SCZ present with cognitive deficits and deficits in processing target stimuli, this study 
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provides ERP evidence to cognitive differences during cue processing. The lack of difference 
in BPD and MPD compared with CON suggests that cueing and processing of the sustained 
attentional task applied in this study are not affected (Table 4.1).   
Table 4.1:Groups differences in behavioural performance and event -related 
potential wave components 
 
4.1.1 First cue event- related potential wave component group differences 
For the first cue, wave component differences were found only over the left hemisphere, 
for the P100 amplitude over frontal, P300 amplitude over the central cortex, and N170 
amplitude over the parietal cortex. The task our participants performed included repetition 
of stimuli to improve the signal to noise ratio of neural activity, task repetition is known to 
activate the left hemisphere, the inability to maintain processing has been related  to the 
inability to maintain engagement of the left hemisphere during repetitive tasks (Nemrodov 
et al. 2011). The P100 amplitude differences were not linked to specific group differences, 
i.e. the overall test found a significant difference, and post-hoc test did not yield specific 
Continuous Performance Task
Behavioural performance
Cue 1
Cue 2
Target
Group differences
left frontal P100 amplitude was > 
compared to CON
right frontal P100 amplitude was > 
compared to CON and BPD
left pre-frontal N170 latency was > 
compared to CON
SCZ had fewer correct responses compared to CON
SCZ response times were longer compared to CON
SCZ errors of ommission were more compared to CON and BPD
right pre-frontal P300 latency was > 
compared to CON
Schizophrenia Methamphetamine induced psychosis 
left frontal P100 amplitude was > 
compared to CON and BPD
left central P100 amplitude was > 
compared to CON
right central P100 amplitude was > 
compared to CON
left parietal N170 amplitude was < 
compared to MPD
right prefrontal N170 amplitude was > 
compared to CON, BPD and MPD
left frontal N170 amplitude was > 
compared to CON
right pre- frontal N170 latency 
left frontal P100 amplitude
left central P300 amplitude
right frontal N170 amplitude
left pre-frontal N170 latency was > 
compared to CON
right central N170 amplitude was > 
compared to CON
right parietal N70 latency
right frontal P100 amplitude was > 
compared to CON and BPD
left pre-frontal N170 latency was > 
compared to CON
right pre-frontal P300 latency was > 
compared to CON
right frontal N170 amplitude was  > 
compared to CON
The table denotes significant ANOVA, parametric (F-test) and non-parametric (H-test)  ERP differences across all groups with further ERP differences noted within 
CON, SCZ, BPD and MPD.  Significance P< 0,05
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group differences. Extraction of this wave component was supported by the literature, 
which states that the P100 is integrally involved in cognitive processes, however the exact 
neural mechanism during cognitive processing remain unknown (Campanella et al. 2006). It 
has been suggested that P100 amplitude decreases when the individual does not attend to 
a task (Bolton & Staines 2011). Due to the presence of an extractable P100 during early 
cueing, first cue, it suggests that our participants were engaged with the task while they 
were performing it and there were differences in the ability of participants to maintain 
early cognitive processes related to repetition.  
The N170 amplitude over the left parietal cortex was smaller in SCZ when compared to 
MPD during the first cue only. Previous studies have shown that N170 amplitude is reduced 
when the working memory capacity is at a max point (Morgan et al. 2008). This suggests 
that SCZ, compared to MPD, are unable to recruit working memory sufficiently and 
therefore have reduced ability to concentrate or maintain attention during the task. It has 
been noted in SCZ, that the N170 is attenuated when processing emotional stimuli (Lynn & 
Salisbury 2008; Feuerriegel et al. 2015; Cao et al. 2015; Maher et al. 2016). The N170 
usually shows dominance over the right hemisphere during a task which involves the 
presentation of faces showing different emotions (Tso et al. 2017). However our study did 
not involve face processing, but N170 related to letter processing (Stevens et al. 2013). In 
healthy adults a greater amplitude has been noted for the N170 in single letter processing. 
Our findings for the our first cue support these previous studies (Stevens et al. 2013; Begum 
et al. 2014). Taking this literature into consideration our findings suggest that individuals 
with SCZ and MPD have differences in the initiation of cue processing during a sustained 
attention task.   
4.1.2 Second cue event- related potential wave component group differences 
For the presentation of the second cue, differences noted for all groups were localised to 
the frontal and central brain regions and for P100 and N170 ERP waveforms. Left and right 
frontal and central P100 amplitude in SCZ was greater compared to CON. SCZ had greater 
left and right frontal P100 amplitude compared to BPD. Bolton and Steines (2011) 
suggested a decrease in P100 amplitude in the dorsal lateral prefrontal cortex contributes 
to processing and filtering of irrelevant information (Bolton & Staines 2011), with poorer 
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behavioural performance in SCZ  and increased P100 amplitude during the second cue this 
may suggest that are reported in the literature SCZ that they have a reduced ability to filter 
and process relevant stimuli compared to CON and BPD. Then CON had a shorter left pre-
frontal N170 latency when compared to SCZ and MPD. This suggests that visual processing 
is slower in SCZ and MPD. The lack of difference found for BPD suggests that deficits in cue 
processing is limited to SCZ (Heimrath et al. 2012; Stevens et al. 2013) and MPD. Lastly, SCZ 
N170 amplitude was greater when compared to CON These results indicate that there are 
possible sensory deficits which can influence target stimuli selection(Okena et al. 2006)  
4.1.3 Target stimulus event- related potential wave component group differences 
For the target stimulus wave component differences were found over the prefrontal, 
frontal and parietal brain regions. SCZ had a greater left and right frontal P100 amplitude 
compared to CON. SCZ had a greater right frontal P100 amplitude compared to BPD. The 
P100, involved in basic visual processing (Wynn et al. 2008), was found to be greater in SCZ 
compared to CON and BPD. As previously mentioned, the presence of the P100 during a 
cued task implies that the individual was engaged in the task. Also, the greater P100 
amplitude in SCZ for the presentation of target stimuli is indicative of differentiating 
between the target stimulus and potential distractors (Lynn et al. 2016), this suggests that 
SCZ requires enhanced processing of the P100 which may be related to ineffective filtering 
of what is relevant and what is not. 
SCZ N170 was found to differ, they reported greater right prefrontal N170 amplitude 
compared to CON, BPD and MPD, and greater left and right frontal N170 amplitude 
compared to CON. Then SCZ and MPD N170 latency was longer than reported in. For the 
first and second cue an increase in N170 amplitude and delayed latency was noted over the 
prefrontal and frontal cortex in SCZ. In a study conducted by Wynn et al, (2008) the N170 
showed delayed latency and increased amplitude in SCZ, supporting our findings. While, 
Campanella et al, (2006), and Morgan et al, (2008) reported delayed latency and decreased 
N170 amplitude, contrasting our current findings. Our results show that SCZ recognized the 
series of cues preceding the target but had a delay in responding to the target stimuli when 
it was presented. The enhanced amplitudes of P100 and N170 show that SCZ were engaged 
in the task and were applying significant effort. Campanella et al, (2006) suggested that 
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deficits in early (P100 and N170) visual processing underlies further dysfunction of the P300 
in SCZ. However, our data suggests that the cognitive deficits are more strongly related to 
later (P300) cognitive processing, following increased amplitude in P100 and N170 
waveforms which reflects the poor cognitive performance reported in SCZ.  
To support this, SCZ and MPD reported longer P300 latency over their right prefrontal 
cortex when compared with CON. The longer latency in SCZ and MPD suggests a longer 
temporality to completing cortical updating and orientating, supported by SCZ’s poorer 
behavioural performance (Sur & Sinha 2009). The differences found over the prefrontal and 
frontal regions indicate that there are impaired executive function in SCZ (Krishnadas et al. 
2014). Finding the P300 difference in MPD too, suggests that MPD share in part the 
executive function deficits seen in SCZ, and are related to later cognitive processing, further 
research is required to contrast the similarities reported in MPD with SCZ. 
4.2 Event- related potential wave component relationships 
Many relationships were found between demographics, drug use, and clinical variables and 
ERP wave components during the sustained visual attention task. Overall, for the first cue, 
education positively correlated with the N170 left parietal amplitude in CON and P300 right 
parietal amplitude in MPD. During the second cue, the left parietal N170 latency in SCZ 
correlated positively with education and the left central P300 latency correlated negatively 
with education in MPD. The age on the day of testing correlated negatively with the first 
cue right parietal N70 latency and correlated positively with the target left frontal P300 
latency in MPD (Table 4.2).  
  
http://etd.uwc.ac.za/
69 
 
Table 4.2: Event related wave component correlates with demographics  
 
A summary of these relationships are as follows: for the first cue, drug use negatively 
correlated with the CON left prefrontal, central and parietal N170 latencies and positively 
correlated with the right central N170 amplitude in BPD. In SCZ, correlations were noted for 
the P100 left frontal and parietal amplitude and latencies and the N170 frontal latency. In 
MPD there was a positive correlation with the right frontal N170 amplitude and right 
central P300 latency. For the second cue, drug use correlated positively with the right 
parietal N70, right prefrontal N170 and left frontal N170 amplitudes, and negatively 
correlated with the right frontal P100 latency in CON. A positive correlation was noted 
across left and right parietal P300 latency and negatively for the right parietal P100 
amplitude in SCZ. A positive correlation was noted for the left frontal N170 amplitude in 
BPD. In MPD, a negative correlation was noted across left and right prefrontal N170 and 
P300 amplitudes, and positive correlation for the left prefrontal P300 latency in MPD. For 
the target stimulus, correlations were evident for the right frontal P100 latency and P300 
amplitude and the left parietal P300 amplitude in CON. Left and right parietal N70, N170 
amplitudes, P300 latency, the right parietal P100 amplitude and left central P300 latency in 
SCZ correlated with drug use. Lastly the left parietal N170 amplitude in MPD correlated 
positively with drug use (Table 4.3).  
  
 Cue 1: Demographics
Age on day of imaging (yrs) -
+
Duration at school (yrs) +
Tertiary education (yrs) + +
 Cue 2: Demographics
Duration at school (yrs) + -
Total duration of education (yrs) +
Target: Demographics
Age on day of imaging (yrs) +
Duration at school (yrs) + left parietal N170 latency
Correlation differences across all four groups and further across psychotic groups (SCZ, BPD, MPD),  in demographics, behavioural performance, and 
drug use. + positive correlation - negative correlation. Spearman's rank order Rho ± 0,5 Significance P< 0,01
left frontal P300 latency
left parietal N170 latency left central P300 latency
left parietal N170 latency
left parietal N170 amplitude right parietal P300 amplitude
right parietal P300 amplitude
left parietal N170 amplitude
Control Schizophrenia 
Methamphetamine induced 
psychosis 
right parietal N70 latency
http://etd.uwc.ac.za/
70 
 
Table 4.3: Event related wave component correlates with drug use  
 
A summary of these relationships which pertained only to the psychotic groups are as 
follows: for the presentation of the first cue, the PANSS total correlated with the left and 
right central and parietal P300 amplitude in SCZ. The SCZ left parietal and right central P300 
amplitude correlated with the PANSS general. PANSS total correlated with the left and right 
central P100 amplitude and PANSS general correlated with the left parietal P100 amplitude 
in BPD. Then the BPD right parietal P300 amplitude correlated with the PANSS negative 
(Table 4.4, Table 4.5, Table 4.6).  
  
Cue 1: Drug use
TSI - -
Tobacco - + + +
+
-
Cannabis -
Alcohol +
Cue 2: Drug use
TSI + + +
+
Cannabis - -
+
Alcohol + -
+ -
-
-
Target: Drug use
TSI - -
-
-
-
-
+
+
Tobacco -
-
-
+
+
+
Cannabis -
-
Methamphetamine +
Alcohol +
Correlation differences across all four groups and further across psychotic groups (SCZ, BPD, MPD),  in demographics, behavioural performance, and drug use. + positive correlation - negative correlation. 
Spearman's rank order Rho ± 0,5 Significance P< 0,01
left parietal N170 amplitude
right frontal P300 amplitude
right frontal P100 latency
right frontal P300 amplitude
right parietal P300 latency
left parietal P300 latency
righ parietal P100 amplitude
left central P300 latency
left parietal P300 amplitude left parietal N70 amplitude
right parietal N70 amplitude
left parietal P300 latency
right parietal P300 latency
left parietal N170 amplitude
right parietal N170 amplitude
right parietal N70 amplitude
right parietal P100 amplitude
left prefrontal P300 amplitude
right prefrontal P300 amplitude
left parietal P300 amplitude left parietal N70 amplitude
right prefrontal N170 amplitude left prefrontal N170 amplitude
left frontal N170 amplitude right prefrontal N170 amplitude
right frontal P100 latency right parietal P100 amplitude
right parietal N70 amplitude
left parietal P300 latency left frontal N170 amplitude left prefrontal P300 latency
right parietal P300 latency
Control Schizophrenia Bipolar I disorder Methamphetamine induced psychosis 
left central N170 latency
right frontal N170 amplitude
left parietal P100 latency
left frontal N170 latency
left parietal N170 latency left parietal P100 latency
left prefrontal N170 latency left frontal P100 amplitude right central N170 amplitude right central P300 latency
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Table 4.4: Event related wave component correlates with clinical scales for the 
first cue 
 
  
Positive & Negative Syndrome Scale
Total score + +
+ +
+
Negative symptoms + +
General psychopathology + +
+
Calgary depression for schizophrenia -
-
-
Hamilton depression rating scale -
-
+
+
Young mania rating scale -
Clinical global impression of illness severity 
Global assessment of functioning scale
Bipolar I disorder 
Methamphetamine 
induced psychosis 
ERP wave form
 right central P300 A  
 
 
 
 right parietal  N170 A    
 right frontal  N170 T  
Schizophrenia 
ERP wave form ERP wave form
 left central P300 A   left central P100 A   
 left parietal P300 A  
 left parietal P100 A  
 
 
  
 right central P300 A  
 left parietal P300 A  
 right central P100 A  
 
 
 
 
 left frontal P300 A  
 
 
 right parietal P300 T  
 right central P100 T  
 right parietal P300 A  
 
 
 left parietal  N170 A  
 left parietal P300 A  
 
 
 
 
 left frontal  N170 A   
 
 left prefrontal  N170 A  
 left parietal  N170 T  
 
  right prefrontal  N170 A   
   right frontal P300 A  
 
Correlation differences across all four groups and further across psychotic groups (SCZ, BPD, MPD),  in 
demographics, behavioural performance, and drug use. + positive correlation - negative correlation. Spearman's 
rank order Rho ± 0,5 Significance P< 0,01
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Table 4.5: Event related wave component correlates with clinical scales for the 
second cue 
 
Table 4.6: Event related wave component correlates with clinical scales for the 
target stimulus 
 
4.2.1 Event- related wave component correlates with demographics 
Education was related to the first cue’s N170 and P300. The N170 and P300 waveforms 
have been shown to be affected by level of education (Begum et al. 2014). Within CON, 
years of tertiary education and number of years at school were positively correlated with 
Positive & Negative Syndrome Scale
Positive symptoms -
Negative symptoms +
+
+
+
+
+
General psychopathology -
Clinical global impression of illness severity -
Global assessment of functioning scale +
+
Schizophrenia Bipolar I disorder 
Methamphetamine 
induced psychosis 
   right parietal  N170 A  
ERP wave form ERP wave form ERP wave form
   left central P300 A  
 right parietal P150 T    
   right parietal P150 A  
   right frontal P100 T  
  left prefrontal  N170 A   
 
Correlation differences across all four groups and further across psychotic groups (SCZ, BPD, MPD),  in demographics, 
behavioural performance, and drug use. + positive correlation - negative correlation. Spearman's rank order Rho ± 0,5 
Significance P< 0,01
   right parietal P300 A  
   left parietal  N170 A  
   left parietal P100 A  
   left parietal P150 A  
 right prefrontal  N170 A   
Positive & Negative Syndrome Scale
Negative symptoms +
General psychopathology -
Calgary depression for schizophrenia + +
+
Hamilton depression rating scale - +
+
Global assessment of functioning scale +
+
 right parietal P150 T    
ERP wave form ERP wave form ERP wave form
Schizophrenia Bipolar I disorder 
Methamphetamine 
induced psychosis 
 right prefrontal  N170 A   
  
  right central  N170 A   left frontal P300 T  
 right parietal P300 A    left frontal P300 T  
 left central P100 T  
   right parietal P300 A  
   right frontal P300 T  
Correlation differences across all four groups and further across psychotic groups (SCZ, BPD, MPD),  in 
demographics, behavioural performance, and drug use. + positive correlation - negative correlation. Spearman's 
rank order Rho ± 0,5 Significance P< 0,01
  left prefrontal  N170 A   
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left parietal N170 amplitude, supporting the findings of Begum et al (2014). These findings 
suggest that CON with higher levels of education, showed recognition and attention that 
the cueing process has been initiated by the presentation of the first cue. Then MPD right 
parietal P300 amplitude positively correlated with level of tertiary education, suggesting 
that in MPD tertiary education was advantageous to cortical updating at this early cueing 
stage. Our study follows previous results conducted by (Begum et al. 2014) showing that 
education does indeed influence the N170 and P300 ERP waveforms. Further, increased 
education to be related with increased P300 amplitude during the cueing process suggests 
that individuals are more strongly involved in early frontal executive processes when in the 
cueing stages of the task versus cortical updating (Sur & Sinha 2009), this finding requires 
further investigation as there is an absence of cueing P300 research in MPD to contrast this 
finding. 
Duration of education was related to left hemisphere N170 latency in SCZ and MPD for the 
second cue. The total duration at school positively correlated with the left parietal N170 
latency in SCZ. Delayed N170 latency was previously found in SCZ indicating deficits in 
executive function and visual processing deficits. The N170 latency has been linked to 
damage of the prefrontal and frontal cortex, resulting in delayed processing of visual stimuli 
(Adams et al. 2017). Scott et al, (2007) found that SCZ and MPD have damage to the 
prefrontal and frontal cortices (Scott et al. 2007; Bonilha et al. 2008; Hazlett et al. 2008; 
Petit et al. 2012). The duration at school negatively correlated with the left central P300 
latency within MPD, also a positive correlation was noted with the left parietal N170 
latency in SCZ. As with the first cue, education influenced the N170 and the P300 
waveforms of the second cue.  
For the target stimulus; the left parietal N170 latency positively correlated with the 
duration at school in SCZ, low education level in SCZ has previously been reported to affect 
behavioural performance (Erick Messias, Chuan-Yu Chen 2009). The left frontal P300 
latency positively correlated with the age on the day of testing in MPD. These results 
indicate that age of MA use can influence cognition. These data suggest neural circuitry for 
the N170 to P300 are not only related to SCZ but are related to education and this 
association is apparent in SCZ and MPD. 
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4.2.2 Event- related wave component correlates with drug use 
Early cognitive processing was affected by substance involvement across all groups. For the 
first cue; total substance involvement correlated positively with the right central P100 
amplitude within BPD. A negative correlation was found for the left parietal N170 latency in 
CON, along with the left parietal P100 latency in SCZ with the total substance involvement. 
Slowed cognitive processing has previously been shown in substance abuse, this has been 
shown in CON and SCZ, and includes attentional processing and loading of working memory 
use (D’Souza et al. 2012; Petit et al. 2012; Thames et al. 2014), e.g. slowed P300 and reduce 
P300 latency (D’Souza et al. 2012). There is limited data reporting on early cognitive 
processing ERP waveforms, and further study is required to fully elucidate the relationships 
found with total substance use during the cueing process.  
Tobacco use has previously been shown to improve cognition and patient recovery at 
mental health institutions despite the adverse effects tobacco has on the human body 
(Weinberger & Sofuoglu 2009). Tobacco use positively correlated with the left frontal P100 
amplitude, left parietal P100 latency, and negatively correlated with the frontal N170 
latency in SCZ. The right central N170 amplitude in BPD, and right central P300 latency in 
MPD correlated positively with tobacco use. Tobacco use in SCZ has previously been 
positively related to negative symptoms within SCZ (Patkar et al. 2002). Despite the strong 
correlation to negative symptoms in SCZ, amplitude reduction following tobacco use has 
shown an enhanced ability in individuals to ignore irrelevant stimuli as well as follow 
habituation (Veltri et al. 2017). This enhancement has been shown in previous studies 
which added alertness, verbal working memory and attention accuracy to the list of 
enhancements (Wesnes & Warburton 1983; Heishman et al. 2010; Kleykamp et al. 2011).  
Alcohol use correlated positively with the right central N170 amplitude in MPD only. A 
previous study reported a similar finding in detoxified alcoholics (Matheus-Roth et al. 
2016), a second found delayed latency of the N170 (Zhang et al. 2017). It is known that the 
abuse of alcohol affects frontal and more severely the subcortical brain structures (Moselhy 
et al. 2001; Brumback et al. 2007). Our finding support’s the reported literature and likely 
addresses the damage in of gating neural activity, a result of alcohol abuse. Cannabis use 
correlated negatively with the left central N170 latency in CON. Van Tricht et al, (2013) and 
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Troup et al (2016) reported attenuated amplitudes and longer latencies in cannabis users 
(van Tricht et al. 2013; Troup et al. 2016). The current findings in part support the 
literature, however finding increased P100 and N170 amplitude contradict previous studies. 
Winton- Brown et al, (2015) indicated cannabis use in high psychosis risk patients have 
reduced sensory gating and overall reduced cortical function. Alcohol, tobacco and 
cannabis use reduced early sensory gating which therefore indicates a reduced ability to 
filter irrelevant information with use of these substances. 
The second cue revealed substance involvement affected early and late cognitive 
processing across all groups. Total substance involvement scores positively correlated with 
the left and right parietal P300 latency in SCZ, the left frontal N170 amplitude in BPD and 
the left prefrontal P300 latency in MPD. Cannabis use correlated positively with the right 
parietal N70 latency and negatively with the right frontal P100 latency within CON, and 
right parietal P100 amplitude in SCZ. Cannabis use affected executive functioning along 
with movement and speech (D’Souza et al. 2009). These relationships suggest that cannabis 
use affected cue processing in CON, and minimally affected cue processing in psychotic 
disorders. Alcohol positively correlated with the left frontal N170 amplitude and right 
prefrontal N170 amplitude in CON, the left and right prefrontal N170 and P300 amplitude in 
MPD. Alcohol is known to affect the prefrontal and frontal cortex function (Moselhy et al. 
2001). There is a single study which has addressed the effects of alcohol on N170 latency, 
however this study investigated hazardous drinkers and found longer N170 latencies in 
facial processing (Zhang et al. 2017). Further study is required to understand the 
mechanisms in which alcohol shortens the N170 latency during early cueing processes. 
During target processing, substance use strongly correlated with wave components over 
parietal regions across all groups, then unique relationships within CON, SCZ and MPD were 
found. Total substance involvement correlated negatively with the right parietal P100 
amplitude, negatively with both the left and right parietal N70 amplitude and N170 parietal 
amplitude in SCZ, as well as negatively with the left parietal P300 amplitude in CON. The 
total substance involvement correlated positively with left and right parietal P300 latency in 
SCZ. Methamphetamine use positively correlated with the left parietal N170 amplitude in 
MPD. MA has previously been shown to have an attenuated P300 amplitude during early 
MA abstinence (Berman et al. 2009). This reduction in amplitude is from the disruption of 
http://etd.uwc.ac.za/
76 
 
catecholaminergic neurotransmission in individual with chronic MA use (Nordahl et al. 
2003). Tobacco use correlated negatively with the left parietal P300 amplitude in CON, then 
negatively with both the left and right parietal N70 amplitude and positively with the left 
and right parietal P300 latency, then positively correlated with the left central P300 latency 
and negatively with the right parietal P100 amplitude in SCZ. Our result adds to a previous 
study conducted on the effects of tobacco use in SCZ which has been shown to enhance 
parietal cognitive processing (Giessing et al. 2006). Our data extend these findings as we 
report a link between tobacco use and reliability of cue updating during attentional 
processing. Alcohol use correlated positively with the right parietal N170 latency across all 
groups and negatively with the right prefrontal P300 amplitude in CON. Cannabis use 
correlated negatively with the left frontal P100 latency and right frontal P300 amplitude in 
CON. Troup et al, (2016) explained that delayed latency and was noted when attention was 
directed at the emotional cues. Also, a reduction in amplitude was noted with an increase 
in cannabis dose (Troup et al. 2016). These results support the current literature, that with 
substance use recognition and perception of target stimuli, and attentional deficits are 
apparent and more strongly affect parietal cortices function (Kleykamp et al. 2011; Troup et 
al. 2016; Troup et al. 2017; Ehlers et al. 2003). 
4.2.3 Event- related wave component correlates with behavioural performance 
Behavioural performance was related to the early wave components of the first cue’s ERP. 
By accessing the number of correct responses, impulsive responses, omissions and 
commissions, a record of attention can be recorded. Omissions assess the attention given 
to the task at hand whereas commission assesses impulsive behaviour (Table 4.7).  
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Table 4.7: Event related wave component correlates with behavioural 
performance 
 
In CON, the number of correct responses positively correlated with the left parietal N70, 
P100, P150 and N170 amplitude, and left central N170 amplitude. While the number of 
impulsive responses correlated negatively with the left parietal N70, P100, P150 and N170 
and the left central N170 amplitude of CON. Then the number of omissions negatively 
correlated with CON left parietal N70 amplitude. These relationships suggest that during 
early processing of initial cueing, increased amplitudes are related to improved behavioural 
performance, while decreased amplitudes are related to impulsive behavioural response. In 
SCZ, the number of correct responses positively correlated with left parietal P150 latency 
and SCZ performed significantly worse than the CON. This relationship suggests that with 
slower P150 processing, behavioural performance in SCZ may improve. The P150 in SCZ has 
previously been noted to potentially underlie severity of negative symptoms (Higashima et 
al. 2004). However, further research is required to fully understand the role the P150 has in 
SCZ behavioural performance.  
Cue 1: Behavioural performance
Correct responses + +
+
+
+
+
Total number of omissions - +
+
+
Total number of impulsive responses -
-
-
-
-
Cue 2:Behavioural performance
Response time -
-
Total number of omissions - +
+
Total number of impulsive responses - +
Target: Behavioural performance
Response time -
-
-
Trick stimulus responses +
Total number of omissions -
Total number of impulsive responses - +
Correlation differences across all four groups and further across psychotic groups (SCZ, BPD, MPD),  in demographics, behavioural performance, and drug use. + 
positive correlation - negative correlation. Spearman's rank order Rho ± 0,5 Significance P< 0,01
left parietal N170 amplitude
left central N170 amplitude left parietal N70 latency
right parietal P300 latency
left frontal P100 latency
left central P300 latency
right central P300 amplitude
right parietal P150 amplitude
left central N170 amplitude left parietal N70 latency
right parietal P300 latency
right frontal P100 amplitude right parietal P100 amplitude
left parietal N170 amplitude
right central P100 latency
left parietal P150 amplitude
left central N170 amplitude
left parietal N70 amplitude
left parietal P100 amplitude
left parietal N70 amplitude left frontal P100 amplitude
left central P100 amplitude
left parietal P100 amplitude
left central N170 amplitude
left parietal N170 amplitude
left parietal P100 amplitude
left parietal P150 amplitude
Control Schizophrenia Methamphetamine induced psychosis 
left parietal N70 amplitude left parietal P150 latency
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Lastly, in MPD the number of omissions positively correlated with left frontal P100 
amplitude, and left parietal P100 amplitude in BPD, suggesting omissions in MPD and BPD 
are related to P100 processes however in relation to different cortical brain area 
functioning. Behavioural performance was related to the early wave components of the 
first cue’s ERP, further research is required to elucidate these findings. 
For the second cue, behavioural performance was related to the fronto-parietal 
relationship across all groups. The number of impulsive responses negatively correlated 
with the left central N170 amplitude in CON and positively correlated with the left parietal 
N70 latency in SCZ. The number of omissions negatively correlated with the right frontal 
P100 amplitude in SCZ and positively correlated with the right parietal P100 and P150 
amplitude in MPD. Featherstone et al, (2007) suggested there are deficits in attentional 
performance with increased omissions, and reduced response accuracy. These relationships 
with poor behavioural performance suggest that during the cueing process, attentional 
processes related to the P100 and P150 were attenuated in SCZ and MPD, i.e. reduced 
engagement at this stage of cueing (Bolton & Staines 2011). Overall, response time 
negatively correlated with the right central P100 and right parietal P300 latency in SCZ. The 
P300 reflects cortical updating which is generally attenuated in SCZ (Ethridge et al. 2015). 
Overall response time reflected shortened cortical processing (i.e. early visual and 
attentional) over the right hemisphere central and parietal regions. This shows that the 
second cue ERP wave form is partially impaired in SCZ and that there is a slight preparative 
measure before the arrival of the target stimulus (Dufau et al. 2009; Ethridge et al. 2015). 
Together, the ERP wave component findings for the second cue suggest a disengagement of 
attentional processes in SCZ, while MPD only showed early processing deficits. 
For the target stimulus, the total number of impulsive responses positively correlated with 
the left parietal N70 latency in SCZ. Hoptman et, (2015) and Reddy et al, (2014) suggested 
that impulsivity in SCZ leads to attentional deficits, however no relationships between 
impulsive responses and ERP wave components were found in SCZ. In CON the total 
number of impulsive responses negatively correlated with the left central N170 latency and 
the number of omissions negatively correlated with the left parietal N170 latency of CON. 
Increased omissions and incorrect responses leads to a decrease in response time, 
indicating that errors are more likely due to impulsive responses in individuals with 
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cognitive deficits (Hebert 2015). The overall response time negatively correlated with the 
right central P300 amplitude and the left central P300 latency for CON, and the right 
parietal P300 latency for SCZ. A previous study with similar results indicated a negative 
frontocentral ERP waveform occurred after an error of omission (Garofalo et al. 2014). 
These data suggest increased N170 amplitudes may impact the P300 wave form and 
attentional processing in SCZ, i.e. the shift from early to late cognitive processing needs 
further investigation as the neural connectivity from N170 to P300 is dysfunctional in SCZ 
and may underlie impulsive responding. 
4.2.4 Event- related wave component correlates with clinical scales 
The clinical scales scores revealed correlations with the first cue’s wave components in the 
psychotic groups. For the Positive and Negative Syndrome Scale (PANSS) BPD showed 
relationships with early cognitive processing and cortical updating over parietal cortex, 
while SCZ showed relationships with cortical updating over central and parietal cortex. In 
BPD PANSS total score correlated positively with left and right central P100 amplitudes; 
then its subscale, PANSS general psychopathology correlated positively with left parietal 
P100 amplitude; and PANSS negative symptom subscale correlated positively with right 
parietal P300 amplitude. In SCZ PANSS total score correlated positively with left and right 
central P300 amplitudes and the left parietal P300 amplitude; then its subscale, PANSS 
general psychopathology score correlated positively with right central and left parietal P300 
amplitude; and PANSS negative symptom subscale correlated positively with the left 
parietal P300 amplitude. Increased PANSS scores have been strongly related to poor 
attentional performance including the reduction in amplitude of early (P100) and late 
(P300) event- related wave components during target processing (Chang et al. 2014; 
Campanella et al. 2006; Iwanami et al. 1995). Finding these relationships during cueing may 
suggest that cognitive resources are being inappropriately applied, i.e. increased 
amplitudes over central and parietal cortices reflect good performance during the 
presentation of the stimulus and not cueing processes.  
The remaining clinical scales showed relationships predominantly with latency of wave 
components of the first cue’s ERP. Latency is the time it takes for a specific wave 
component to reach its maximal amplitude, latency therefore addresses the speed of 
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processing (Clayson et al. 2013; Polich 1992). Longer latencies were related to severity of 
clinical symptoms across the psychotic groups for right central P100 (Young mania rating 
scale) and P300 (Calgary depression rating scale; Hamilton depression rating scale) wave 
components. Within SCZ longer latencies were also related to severity of clinical symptoms 
for right central P100 (Young mania rating scale), right frontal N170 (Hamilton depression 
rating scale), left parietal N170 (Clinical global impressions scale), right parietal P300 
(Hamilton depression rating scale). However shorter latencies were also found with 
increased severity of clinical symptoms, within SCZ right parietal P150 (Hamilton depression 
rating scale). It has been noted in the literature that more severe clinical symptoms are 
associated with delayed cognitive processing, i.e. longer latencies (Zamani et al. 2014; 
Tripathi et al. 2015), and the majority of our findings support these, further study is 
required to understand the shorter latency of the P150, but it may be related to bypassing 
P100 which led to greater activation of circuitry related to P150. And within MPD decreased 
amplitudes were related to severity of depression scores as they were negatively correlated 
with left and right frontal P300 amplitudes. Tripathi et al. (2015) showed similar results 
indicating that attenuated amplitudes are associated with more severe symptoms of 
depression. Then damage to reward systems with use of MA has been related to depressive 
symptoms (Petit et al. 2012). A result of MA preventing and reversing DA reuptake causing 
a reduction in DA production, this has previously been related to  negative symptoms in SCZ 
and depression (Spitzer et al. 1978; Volkow et al. 2001; Zacher & Holmes 2012). In SCZ left 
and right parietal N170 amplitude was positively related to the Hamilton depression rating 
scale. The parietal region in SCZ has been linked to emotional expression (Onitsuka et al. 
2013) and further emotional interference (García-Pacios et al. 2015). Emotional 
interference is the body’s predisposition to mentally block out emotion in order to focus on 
relevant information (García-Pacios et al. 2015). This last finding suggests that negative and 
depressive  symptoms, i.e. emotional interference, impacts early cognitive processing in 
SCZ  (Kim et al. 2013). Our cohort were stable outpatients, these correlates suggest that 
even with low clinical scale scores the first cue wave components are affected. 
With the second cue, clinical scales scores were correlated with wave components across 
the psychotic groups. In MPD, the PANSS negative symptom score, positively correlated 
with left parietal P100 amplitude, left parietal N170 amplitude, left and right parietal P150 
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amplitude, left central P300 amplitude, and right parietal P300 amplitude. This array of 
relationships in MPD, suggest that the presentation of negative symptoms in MPD bear a 
significant role in cue recognition and cognitive interference (Kim et al. 2013). These results 
also suggest that negative symptoms not only affect later cognitive processing but early 
cognitive processing in MPD. PANSS positive symptom score negatively correlated with the 
right parietal N170 amplitude within BPD. The N170 amplitude, as mentioned previously, 
has been found to increase with attentional based dysconnectivity in BPD (Kraguljac et al. 
2016). Lastly, the clinical global impression scale negatively correlated with the right frontal 
P100 latency in MPD. These results support the idea suggesting a deficit in early visual 
processing within BPD and MPD (Earls et al. 2016; Campanella et al. 2006). 
The global assessment of functioning scale positively correlated with left and right N170 
amplitude, which supports the findings in MPD with respect to the PANSS correlations, 
where symptom severity is related to deficits in early visual processing and early cognitive 
processing. 
Psychotic symptom severity was related to wave components of target stimulus. For the 
PANSS, PANSS negative symptom score correlated positively with the right parietal P300 
amplitude in MPD. Negative symptoms have been shown to influence cognitive deficits 
(Trotman et al. 2013). PANSS general psychopathology score negatively correlated with the 
right parietal P150 latency in SCZ. As seen during the cueing ERP wave components group 
difference and relationships with symptom severity strongly related to early cognitive 
processes, including early visual processing being specifically related to negative symptoms, 
then later wave component P300 psychosis symptom relationships are restricted to MPD 
group, suggesting symptom severity more strongly affects MPD orientating and cortical 
updating.  
The target stimulus wave components showed relationships with mood- related clinical 
scales, specifically scores from depression scales. The Hamilton depression rating scale 
correlated positively with the left and right frontal P300 amplitude in MPD and then 
negatively with the right parietal P300 amplitude in SCZ. It was previously found that 
depression was associated with cognitive deficits (Ravnkilde et al. 2002). The Calgary 
depression rating scale correlated positively with the right central N170 amplitude in BPD, 
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and the left frontal P300 latency and negatively with the left central P100 latency in MPD. 
These results indicate cognitive deficits can be related to nominal presentation of 
depressive symptoms, more so in BPD compared to MPD, which may be due to BPD being a 
mood disorder (Harvey 2011). An additional relationship found for N170 wave form, where 
the global assessment of functioning scale, a measure of general symptom severity within 
an affected individual (Aas 2011), was positively correlated with left and right prefrontal 
N170 latency in BPD. In a previous study, the global assessment of functioning scale 
relationship with the N170 suggested that early visual processing deficits were present in 
patients with SCZ (Ibáñez et al. 2012). In SCZ, recognition of the target was affected due to 
cortical processing being delayed in affected individuals (Rehse et al. 2016). From our 
results we can conclude that depressive symptoms in psychotic disorders are associated 
with dysfunction in the prefrontal and frontal cortices (Hoshino et al. 2005). 
4.3 Event-related potential wave component differences by medication 
Medication was found to affect ERP wave components during the sustained visual attention 
task. For the first cue FGA’s increased the left central P100 amplitude in both SCZ and BPD 
and decreased the left parietal P100 amplitude in SCZ only. The use of antipsychotics 
increased the right parietal N70 and left central P100 amplitudes in BPD, specifically the 
right prefrontal N170 amplitude was increased with the use of SGA’s. Then clozapine use 
increased the left frontal P100 amplitude in SCZ. These results suggest improved early 
cognitive processing in SCZ and BPD with the use of antipsychotics.  For the second cue, 
SGA’s decreased the right parietal P150 amplitude in SCZ but in MPD the right parietal P150 
amplitude was increased with haloperidol use, and FGA. The opposing results for the P150 
amplitude in SCZ and MPD suggests that haloperidol improved symptom severity and 
cognitive functioning in MPD but not in SCZ. SGA’s increased the left parietal P300 latency 
in BPD and sodium valproate decreased the left prefrontal P300 latency. For the target 
stimulus, SGA’s decreased the right parietal P100, P150 and left parietal P150 amplitudes 
and increased the left central P300 latency in BPD. These results indicate that SGA’s 
improved visual processing in BPD but decreased attention.  
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4.3.1 First cue event- related potential wave component medication differences  
For the first cue, prescription of antipsychotic medication increased the right parietal N70 
amplitude across the psychotic groups and within BPD. Increased N70 amplitude and 
delayed latency was previously reported in a study conducted on patients diagnosed with 
SCZ (Arnfred et al. 2006). Another study involving a flashing pattern task, suggested the N70 
relates to late processing and sensory focus (Saint-Amour et al. 2005). This suggests early 
visual processing in SCZ and BPD is improved with antipsychotic medication use (Adams et 
al. 2017), refer to section 1.8. Across psychotic groups the left central and left parietal P100 
amplitude was also increased with the prescription of antipsychotic medication, and the left 
central finding was also found within BPD. Very few studies have focused on medication 
effects on the P100 ERP waveform. An attenuated P100 ERP waveform depicts deficits early 
visual processing (Campanella et al. 2006). Degabriele et al (2011) found the P100 
amplitude is increased in BPD, during the presence of the target cue. However various 
studies have used emotional cues (i.e. happy and sad faces) to determine differences in the 
P100 ERP waveform (Earls et al. 2016). The data presented suggests that the use of any 
antipsychotic medication enhances early visual processing, and this was more evident in 
BPD (Table 4.8).   
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Table 4.8: First cue event- related potential wave component medication 
differences 
 
Prescription of FGA’s for the presentation of the first cue showed similar effects to the 
prescription of any antipsychotic medication however, both the left and right central and 
parietal regions reported differences in amplitudes and latencies across all psychotic groups 
and within SCZ. Individuals prescribed FGA’s left central P100 amplitudes were greater, this 
increase was also apparent within SCZ and BPD. FGA’s also increased the left parietal P100 
amplitude across all groups, however within SCZ the left parietal P100 amplitude was 
slightly decreased. Lastly, FGA’s increased the left and right central P100 amplitude, left 
central P100 latency, left and right parietal P100 amplitude and right parietal P100 latency 
across all psychotic groups. Barch and Sheffield (2014) described various studies showing 
deficits in cognitive performance as opposed to BPD and other depressive disorders (Barch 
& Sheffield 2014). These differences suggest that FGA’s also improved early cognitive 
processing during the cueing process (Goff et al. 2011). Across all group’s haloperidol an 
Medication
First generation antipsychotics
Second generation antipsychotics
Mood stabilizers
Anticholinergics
any antipsychotic
Clozapine
Risperidone
Haloperidol
Lithium
˄ left central P100 latency v left parietal P100 amplitude
˄ left prefrontal P300 amplitude
˄ left parietal P100 amplitude
˄ right central N170 amplitude
˄ right parietal N70 amplitude ˄ right parietal N70 amplitude
n = 76 n = 27 n = 28
32 females/44 males 11 females/16 males 12 females/16 males
v left central P100 latency
˄ right prefrontal N170 amplitude
˄ right parietal P100 amplitude
v left parietal P100 latency
˄ right prefrontal N170 amplitude
˄ right parietal P100 latency
All Psychotic Groups Schizophrenia Bipolar I disorder 
˄ right central P100 amplitude
˄ left parietal P100 amplitude
˄ left central P100 amplitude ˄ left central P100 amplitude ˄ left central P100 amplitude
˄ left central P100 amplitude
˄ left prefrontal N170 amplitude
v right parietal N170 latency
˄ right prefrontal N170 amplitude
˄ left central P100 latency
˄ left prefrontal N170 amplitude
v right parietal N170 amplitude ˄ left frontal P100 amplitude
˄ left central P100 amplitude
˄ right frontal P300 latency
˄ right frontal N170 latency
˄ right parietal N170 latency
˄ right prefrontal P300 latency
v left central P300 latency
Medication differences analysis was conducted on whether participants were "on" or "off" a specific medication.  ˄ increased amplitude/lengthened latency   ˅  
decreased amplitude/reduced latency. Mann- Whitney U testing was applied. Significance P<0,05
˄ left prefrontal P300 amplitude
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FGA, lengthened the latencies over right parietal N170, right frontal N170, right frontal 
P300, right prefrontal P300, and the left central P100 and shortened the left central P300 
latency. These findings in part contrast FGAs overall. Haloperidol was previous found to 
reduce metabolism in the prefrontal and frontal cortex (Oranje et al. 2009). Suggesting 
haloperidol use decreased cue processing speed, and slowed neuronal activity in the brain 
may be the reason why (Yael et al. 2013). 
During the first cue SGA’s shortened the left central and left parietal P100 latencies across 
all psychotic groups. Furthermore, SGA’s increased the right central N170 and right 
prefrontal N170 amplitudes across all groups, then the right prefrontal N170 amplitude was 
increased in BPD. In a study conducted on FGA’s verses SGA’s, SGA’s outperformed FGA’s in 
cognition (including attention). The use of SGA’s decreased the latency over the left 
hemisphere indicating possible improvement in working memory and executive function 
(Zhang et al. 2013; Bombaci 2016).  
An SGA, clozapine, often prescribed to treat resistant psychosis (Marder et al. 1991; Jibson 
2015), decreased the right parietal N170 amplitude and increased the left prefrontal N170 
amplitude across all psychotic groups. Further, the left frontal P100 amplitude in SCZ was 
increased after clozapine use. According to previous studies conducted, SCZ has attenuated 
amplitudes in the parietal regions (Johnson et al. 2005; Campanella et al. 2006; Earls et al. 
2016). These findings suggest that there may be dysfunctional connectivity across the 
parietal cortex resulting in cognitive impairment in SCZ. Our results follow previous studies 
which showed early visual processing which affected later processing in parietal regions 
after clozapine administration in SCZ (Micoulaud-Franchi et al. 2015; Campanella et al. 
2006). An FGA, risperidone, increased the right prefrontal N170 amplitude and decreased 
the right parietal N170 latency across all groups. Kraguljac et al, (2016) found increased 
amplitude and latency across the fronto-parietal region to be a characteristic of executive 
and attentional based dysconnectivity. Contradicting results were observed in the present 
study indicating after risperidone use, attention and processing speed enhanced (Umbricht 
et al. 1999).  
Mood stabilizers were associated with increased left prefrontal P300 amplitude and then 
the use of lithium, a mood stabilizer, showed increased left prefrontal P300 amplitude 
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across all groups. Chun et al, (2003) conducted a study in SCZ and BPD and found the P300 
latency was delayed in BPD and the amplitude in SCZ was increased. Our findings indicate 
that mood stabilizers improved cognitive performance in BPD (Polich & Herbst 2000).  
Lastly, anticholinergics prescribed to reduce extrapyramidal side effects, were found to 
increase the left prefrontal N170 amplitude across the psychotic disorders. A study 
conducted on the effects of anticholinergic use found that cognitive function improved with 
the use of antipsychotics across psychotic disorders (Rehse et al. 2016). Our findings 
suggest that high dose antipsychotics should try to be avoided to reduce the need for 
anticholinergics, and thereby reduce potential negative effects of chronic antipsychotic 
medications (Rehse et al. 2016). 
Overall antipsychotics, FGA’s and SGA’s improved the cueing processing across the 
psychotic groups, and this was pronounced in SCZ. It is evident that prescribed medication 
for the management of psychotic symptoms can improve the processing of salient 
information, this is particularly noted during the first cue of our sustained performance 
task.  
4.3.2 Second cue event- related potential wave component medication differences   
When all antipsychotic medication was grouped no effects on the second cue ERP wave 
components were found, however FGA’s and SGA’s in isolation did. Prescription of FGA’s 
increased the left prefrontal P300 latency across all groups, suggesting improved cue 
loading, i.e. activation of working memory improved after the use of FGA’s (Lencer et al. 
2008). The P150 has been related to processing spatial information and a decrease in the 
amplitude and latency  can result in early visual processing deficits (Van Der Lubbe & 
Woestenburg 1997). Haloperidol, an FGA, increased the right parietal P150 amplitude 
across groups, specifically in MPD. Further haloperidol increased the right parietal P100 
amplitude and decreased the left and right central P300 latency across all groups. These 
results suggest haloperidol improved cue processing. As was found with FGA’s in general, 
haloperidol improved early cognitive processing, and improved cortical updating over 
central brain areas (Table 4.9).   
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Table 4.9: Second cue event- related potential wave component medication 
differences 
 
The prescription of SGA’s increased the left parietal P300 latency across all groups and 
within BPD. The right parietal P150 amplitude was decreased across all groups, more so in 
SCZ with the use of SGA’s, suggesting that with SGA’s cue updating is enhanced in SCZ over 
parietal cortices while delayed cortical updating in BPD is over the parietal cortices (Lencer 
et al. 2008). The use of clozapine, an SGA, increased the right frontal P100 amplitude, left 
prefrontal and right frontal N170 amplitude, left prefrontal P300 amplitude across all 
groups. An increase in electrical brain activity after clozapine use has previously been noted 
by Purkayastha et al, (2012). Our data supports this as increased amplitudes are reflective 
of increase or stronger activation of neural circuitry that is recruited for a cognitive task. 
The use of risperidone, also an SGA, increased the right central P300 latency across all 
groups, suggesting a delay in the activation of P300 neural circuitry activation. A previous 
study found P300 amplitude to decrease with risperidone in SCZ and related this to reduced 
ability to cortically update task information. They did not report a difference in P300 
latency (Nieman et al. 2002). Further study is needed as this study is the first to interrogate 
the role of medications during the sustained attentional cueing. Antipsychotic medication 
possibly helped in the processing of the second cue by activating working memory in 
preparation of the target stimulus and this was more strongly supported in SCZ (Luck et al. 
2014). 
Medication
First generation antipsychotics
Second generation antipsychotics
Mood stabilizers
Anticholinergics
Clozapine
Risperidone
Haloperidol
Sodium valproate
n = 76 n = 27 n = 28 n = 21 
32 females/44 males 11 females/16 males 12 females/16 males
All Psychotic Groups Schizophrenia Bipolar I disorder Methamphetamine induced psychosis 
 ^right frontal N170 amplitude
 ^left prefrontal P300 amplitude
 ^left prefrontal N170 amplitude
v right central P300 latency
v left prefrontal P300 latency ^right parietal N70 latency
 ^right parietal P150 amplitude
 ^left prefrontal P300 latency
Medication differences analysis was conducted on whether participants were "on" or "off" a specific medication.  ˄ increased amplitude/lengthened latency   ˅  decreased amplitude/reduced latency. Mann- 
Whitney U testing was applied. Significance P<0,05
v left central P300 latency
 ^right parietal P100 amplitude  ^right parietal P150 amplitude
 ^right central P300 latency
 ^left parietal P300 latency
v right parietal P150 amplitude v right parietal P150 amplitude  ^left parietal P300 latency
 ^left prefrontal P300 latency
v right prefrontal N170 latency
 ^right frontal P100 amplitude
 ^left prefrontal N170 amplitude
9 females/12 males
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During the second cue mood stabilizers decreased the right prefrontal N170 latency across 
the psychotic disorders. Across all groups sodium valproate, used as a mood stabilizer, 
increased the right parietal N70 latency and the left prefrontal P300 latency, while the left 
prefrontal P300 latency was decreased in BPD. The decrease in latency indicates that 
attentional processing was efficiently processed by the use of mood stabilizers (Hileman et 
al. 2011). Then prescription of risperidone and sodium valproate increased the latency of 
the P300 causing a delay in cortical updating and this may potentially be related to reduced 
assessment in predicting a target stimuli (Lencer et al. 2008). Overall, mood stabilizers have 
been shown to decrease mania in BPD but also enhances executive function and emotional 
control (Altinay et al. 2018). These data suggest that in BPD the impact of emotional 
interference is reduced by administration of mood stabilizers. Lastly, anticholinergics 
increased the left prefrontal N170 amplitude across the psychotic disorders. This result 
follows from previous studies showing reductions in working memory (Zhou et al. 2011; 
Kocsis et al. 2014). 
Overall antipsychotics, FGA’s and SGA’s improved the cueing processing across the 
psychotic groups, as shown from the first cue. From these results it is evident that cue 
processing was enhanced by prescribing medication for the management of psychotic 
symptoms. 
4.3.3 Target stimulus event- related potential wave component medication differences   
Antipsychotic medications and mood stabilizers were related to wave components of the 
target stimulus, these relationships were evident across the psychotic groups and within 
BPD. The only FGA which showed relationships with target ERP wave components was 
haloperidol. Haloperidol increased the right parietal P100 and right prefrontal P150 
amplitude and decreased the left P300 latency across all groups. As noted previously, 
increased amplitude in early ERP waveforms shows haloperidol improving cortical updating 
and working memory. Further, these results indicate that improved cue processing. SGA’s 
decreased the right parietal P100 amplitude and left and right parietal P150 amplitude of all 
groups, and within BPD. SGA’s also increased the left parietal P300 latency and left and 
right central P300 latency was noted across all groups, however only the left central P300 
latency was decreased in BPD. Very few studies were found with the link between 
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antipsychotic medication and the effects on ERP wave components in BPD, further research 
is needed (Table 4.10) 
Table 4.10: Target stimulus event- related potential wave component 
medication differences 
  
Clozapine, an FGA, decreased the left parietal N70 and P100 amplitude across all groups. 
These results indicate that early visual processing is altered with the use of clozapine.  
However, increases in the right prefrontal N170 and frontal N170 amplitude were evident, 
indicating that there is potential improvement in attention- dependent information 
processing and reduced interference of emotion after clozapine use (Umbricht et al. 1998). 
Then, risperidone, an SGA, increased the left parietal P300 latency and both the left and 
right central P300 latency in all psychotic groups. Risperidone delayed information 
Medication
Second generation antipsychotics
Clozapine
Risperidone
Haloperidol
Lithium
Sodium valproate
Medication differences analysis was conducted on whether participants were "on" or "off" a specific medication.  ˄ 
increased amplitude/lengthened latency  ˅ decreased amplitude/reduced latency. Mann- Whitney U testing was applied. 
Significance P<0,05
n = 76 n = 28
32 females/44 males 12 females/16 males
All Psychotic Groups Bipolar I disorder 
v left parietal P150 amplitude v left parietal P150 amplitude
v right parietal P150 amplitude v right parietal P150 amplitude
v right parietal P100 amplitude v right parietal P100 amplitude
v left parietal P100 amplitude
v left parietal N70 amplitude
 ^left parietal P300 latency
 ^left central P300 latency
 ^left central P300 latency
 ^left central P300 latency
 ^left central P300 latency
 ^right parietal P100 amplitude
 ^right prefrontal N170 amplitude
 ^right central P300 latency
 ^left central P300 latency
 ^right frontal N170 amplitude
 ^left parietal N170 latency
 ^left prefrontal P300 latency
v left central P100 latency
 ^right central P300 latency
 ^left central N170 latency
 ^right parietal P150 amplitude
v left central P300 latency
 ^left central N170 latency
 ^left parietal P300 latency
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processing as shown by increased latencies. Our results contrast with previous studies 
showing decreased latencies after risperidone use (Umbricht et al. 1999).  
A mood stabilizer, lithium, increased the left central N170 latency across all groups and 
within BPD, and left parietal N170 latency was increased across groups. Importantly, lithium 
was primarily prescribed to BPD (see table 4.14). Previously, it has been reported that 
lithium use enhances the N170 ERP waveform in BPD resulting in dysfunction to the 
cognitive networks (Ilhan Atagün et al. 2015). Therefore, lithium should only be prescribed 
in emergency cases for psychotic episodes and not as a daily maintenance regime. Then 
sodium valproate, also mood stabilizer, increased the left prefrontal P300 latency and 
shortened the left central P100 latency. It is important to note that subtle changes by a 
slight decrease in amplitude or increase in latency were found to differ across the scalp 
from posterior to anterior, further research is needed to fully appreciate the effects of 
these mood stabilizers in cognitive processing.  
Overall, information processing was improved after haloperidol and sodium valproate use 
for the target. It was also found that clozapine, risperidone and lithium resulted in reduced 
information processing and reduced emotion interference. 
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Chapter 5 Conclusion 
The aim of this study was to determine whether there are specific group differences 
between CON and three psychotic disorders: SCZ, MPD and BPD, then to determine 
differences between these psychotic disorders. This included differences in behavioural 
performance and prominent electrophysiological event- related potential (ERP) wave 
components during cueing and target processing of a visual sustained attention task. 
Further we aimed to characterize ERP waveform component relationships across and within 
these groups for demographics, drug use, behavioural performance, and clinical variables, 
the last limited to the psychotic groups. Lastly, we investigated the effects of prescribed 
medications on ERP wave components within the psychotic groups. 
Behaviourally, performance of the CPT task, SCZ performed poorer than the other groups. 
SCZ is known to have cognitive deficits compared to CON (Onitsuka et al. 2013). The 
increased amplitudes and lengthened latencies in SCZ indicated that cueing and processing 
of sustained attention is different in SCZ when compared with CON. The lack of difference 
in BPD and MPD compared with CON suggests that cueing and processing of the sustained 
attentional task applied in this study are not affected 
Substance use  was shown to slowed cognition in CON and SCZ, this includes attentional 
processing and loading of working memory use (D’Souza et al. 2012; Petit et al. 2012; 
Thames et al. 2014), e.g. slowed P300 and reduce P300 latency (D’Souza et al. 2012). 
Furthermore, across psychotic groups symptom severity was shown to negatively affect 
cognitive performance. There is limited data reporting on early cognitive processing ERP 
waveforms, and further study is required to fully elucidate the relationships found with 
total substance use during the cueing process. 
Also, an outcome of the study showed that SCZ, MPD and BPD differentiated by medication 
as well. This research is important in understanding the adverse effects antipsychotic 
medications can have on an individual, and to further help the patient manage their disease 
better. The results of our study help in understanding behavioural and electrophysiological 
event- related differences across SCZ, BPD and MPD. Further studies looking into specific 
electrophysiological differences in MPD with comparison to SCZ is warranted. The inclusion 
of other biological markers, e.g. genetics and neuro-immunology of SCZ and MPD may 
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provide the missing links to understanding the deficits and differences in the ERP wave 
components. These studies will support elucidating what underlies dysfunctional neural 
networks identified in SCZ and MPD cortical functioning. 
Several limitations are apparent in the current study. First, the number of individuals 
recruited for the study could have been more case matched. However, despite the low 
MPD numbers, significant differences were still found. This indicates that inclusion of more 
MPD individuals could have made the results stronger.  
Using the information obtained in the present study, further research can be conducted to 
develop a panel of electrophysiological and neuroimmune markers for each of the 
psychotic disorders (Upthegrove et al. 2014; Dimitrov et al. 2014). Dimitrov et al, (2014) 
explained that IL-6 is increased in individuals who are at risk in developing psychosis. 
Similarly, Upthegrove et al, (2014) found increased inflammatory markers in individuals 
with SCZ. The discovery of specific neuroimmune markers along with the 
electrophysiological markers can be useful for diagnostic and treatment of the specific 
psychotic disorders. Furthermore, it was found that antipsychotic medication can influence 
the cytokine levels within an individual (Drzyzga et al. 2006). By conducting studies on the 
medication used for each psychotic disorder, relationships between medication use and 
EEG frequency and ERPs can be conducted in MPD as very few information is available. 
Lastly, a metanalysis can be conducted in SCZ and MPD, comparing neuroimmune markers, 
EEG frequency, ERP waveforms. As noted in the current study, the metanalysis will be 
informative as to the differences underlying the two disorders. 
There is currently a lack of literature which has investigated the cueing process via the use 
of ERP waveforms, this is apparent in CON and within each of the psychotic disorders 
investigated. Our findings show that there are prominent differences in early cueing and 
target ERP waveforms which are unique to specific psychotic disorders. Relationships with 
demographics and clinical variables, including medication, do influence these early cueing 
and target ERP waveforms. The results presented show that further ERP studies are sorely 
needed to address these differences and relationships found, to distinguish differences in 
cognitive processing which may serve to provide a clearer understanding to which neural 
circuitry is uniquely dysfunctional in each of these psychotic disorders. This study provides 
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new insights to early processing deficits during the cueing and processing of a visual 
sustained attention task in the psychotic disorders and addresses the effects of medication 
through ERP wave component analysis.   
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Appendices 
Appendix A Participant information sheet and consent form 
The participant was supplied with an information sheet containing details of the research 
study and the tests they will undergo. A consent form was asked to be filled in and signed if 
the participant was willing to partake in the research study. 
Cortical inhibition and attentional modulation a study of psychosis 
University of Cape Town Human Ethics reference number:  192/2010 
Participant information sheet 
Attention is when you are able to focus on information. Like when you think of what you are going to wear, 
needs a level of attention. A person may find this difficult if they have other thoughts that don’t allow them to 
pay attention. This is only one example, but applies to feelings as well. Like if you are worried about something, 
you cannot pay attention to something that may really need your attention. The ability to pay attention is 
different for everyone and may be more difficult for some. 
The present study is not clinical. This study would like to understand how interfering or too many thoughts 
lower a person’s ability to pay attention. This will be done through brain imaging techniques that allow us to 
record electrical activity (electroencephalography), the level of brain chemicals (magnetic resonance 
spectroscopy, MRS), and changes in electrical activity (electroencephalography with transcranial magnetic 
stimulation). 
Recruitment into the present study will occur through referral from a medical practitioner who is informed as 
to your psychiatric illness. Participants without a history of psychosis will also be recruited as controls to 
compare findings. The control participants will be interviewed by a psychiatrist to determine inclusion (can 
participate). The controls will not undergo the brief repetitive transcranial magnetic stimulation (brTMS) but 
will have a ‘fake’ treatment referred to as sham TMS treatment. 
Basic exclusion (cannot participate) criteria for the present study are as follows. Individuals who: are under the 
age of 18, or older than 40; have a history of, or have first-degree relatives (father, mother, brothers and/or 
sisters) with a history of, epilepsy or seizures; have a history of stroke or brain aneurism; have a chronic medical 
condition, including Parkinson’s disease, Huntington’s chorea, multiple sclerosis, and dementia; have cardiac 
devices, implanted medication pumps, intracardial lines, or cardiac disease; have apparent mental retardation; 
have a history of treatment with TMS therapy; have extensive tattoos on their face; or have orthodontic braces, 
will not be included in the study.   Woman who are known or suspected to be pregnant or who are breast 
feeding will also be excluded from the study.  Each participant will be checked off against a set of criterion from 
the TMS adult safety screen (Keel et al., 2000) by the researcher involved, and a magnetic resonance imaging 
(MRI) safety screen by a radiographer at the Cross-University Brain Imaging Centre (CUBIC).  
Individuals who are suitable and willing to participate in the present study will need to be available for one 
working day from 08h30 to 17h30. Each participant will receive shopping vouchers for food to the value of 
R200, and will receive R50 toward travel expenses. Lunch will be provided on the day of participation.  
Each participant is free to withdraw from the present study at any time. This study is for research purposes only 
and is not funded by a pharmaceutical (drug) company. Participant’s details will be anonymous, as each 
participant will be assigned a participant number on the day of the recording session.  
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If you have any questions with respect to the present study do not hesitate to contact the principal 
investigator,   Dr Fleur Howells at fleur.howells@uct.ac.za  
If you would like to participate in the present study please contact us through any of the following: 
Email: participant.CIAM@gmail.com, Cell number: 082 749 5223, Landline number: 021 404 5488 
 
Please see the next page for further information of the brain imaging modalities that will be used in the present 
study. 
Additional information for participant: 
 
Magnetic Resonance Imaging (MRI) is a form 
of medical imaging that needs you lie on a 
scanner bed and be placed into a short 
tunnel (open at both ends) in line with a 
strong magnetic field (Fig 1). A device is 
placed over your head with a mirror system 
attached (Fig 2). You can relax during the 
scanning session by watching a movie or 
taking a nap, but you do need to keep as 
still as possible. Fig 1              Fig 2 
The magnetic field attracts (pulls) metal objects. Therefore an MRI safety checklist is required to prevent 
cancellation of the scan once scheduled. These precautions are for your safety and to ensure optimal image 
data. Prior to entering the scan room the Radiographer will go through a checklist to ensure your safety.  There 
are no known side effects of undergoing an MRI if you are seen as suitable by a Radiographer.  
 
In addition, should you pass the first checkpoint, we will ask that you remove all metal objects for the period of 
scanning: no jewelry, watches, metal piercing (this includes all forms of piercing), pens, coins, cell phones etc. 
lockable change rooms and hospital gowns will be available, but we suggest you wear more suitable clothing 
such as a t-shirt & track pants that are preferably not nylon (with no zips, buckles etc). Any clothing that 
contains metal wire, buttons, and zips will need to be removed.  
 
Once the scan commences you will hear a continuous loud noise for the duration of the sequence and each 
sequence lasts about 6-9 minutes each. Each of the sequences will make a different set of noises. You will be 
provided with earplugs and headphones to protect your ears from this noise. You will be under constant 
supervision verbally and visually for the duration of the entire scan (± 1hour in total).  
 
The MRI scanning will be done at the Cross-University Brain Imaging Centre (CUBIC), Tygerberg hospital. You 
(the participant) will be transported to Tygerberg and back by a research assistant.  
 
Transmagnetic cranial stimulation (TMS), works by placing a magnet next to the brain 
(over the scalp). When the magnetic coil is charged it changes the electrical activity 
of the surface area of the brain that is targeted. After one pulse from the magnetic 
coil the brain area is briefly inactive and this is a measure of the brain’s ability to 
inhibit activity (cortical inhibition).  This inhibition of activity is decreased in 
individuals with a history of psychosis. All participants with and without a history of 
psychosis will undergo the cortical inhibition protocol.  
 
Brief repetitive transmagnetic cranial stimulation (brTMS) is used to increase communication between neurons. 
In doing this, we aim to improve attentional information processing. brTMS has been associated with brief 
headaches, which is as a result of nerves and muscles on the scalp. In addition the participant may show 
symptoms of temporary mania or depression, but this is very very rare.  Only the participants with a history of 
psychosis will have brTMS as we would like to see whether we can improve their attention. The TMS machine 
makes a clicking noise, but not as loud at the MRI scanner. Earplugs will be provided to reduce the noise. The 
results from this study are for research purposes only and not a form of therapy. 
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During the cortical inhibition protocol and the brTMS continuous 
electroencephalographic (EEG) data will be collected. EEG records brain wave 
activity by placement of an electrode cap (similar to a swimming cap) that records 
electrical activity from the scalp. The participants’ will complete computerized tasks 
of attention with breaks between the different protocols.  
 
The EEG, cortical inhibition and brTMS will take place in the EEG suite of the 
educational center at Valkenberg Hospital, Observatory. 
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Participant Name _________________________________   Participant Number 
_________________________ 
Cortical inhibition and attentional modulation a study of psychosis 
University of Cape Town Human Ethics reference number:  192/2010 
CONSENT FORM 
I voluntarily agree to participate in the present study: Cortical inhibition and attentional modulation a study of 
psychosis, which includes magnetic resonance imaging (MRI), cortical inhibition protocol through 
transmagnetic cranial stimulation (TMS) pulses, and electroencephalography (EEG). 
 
YES NO 
 
In addition I voluntarily agree to undergo brief repetitive transmagnetic cranial stimulation (bRTMS) for 
research purposes only. (Only participants with a history of psychosis.) 
 
YES NO 
 
I am aware that brief repetitive transmagnetic cranial stimulation (brTMS) may lead to a brief headache as a 
result of stimulating nerves and muscles on the scalp and/or short-term symptoms of mania or depression. 
 
YES       NO 
 
I have been informed of the procedures and have a copy of the study’s information sheet (attached). 
 
YES NO 
 
 
I have been allowed the opportunity to ask questions that relate to the present study and they have been 
answered (else please ask these questions of the researcher before you sign this consent form). 
 
YES NO 
 
 
I ……………………………………………………………….……….. (Participant’s full name) am voluntarily participating in the 
present study and am aware that at any point I may stop participating in the present study. If I stop 
participating there will be no impact (effect) on my current or future medical treatment.  
 
 
Participant’s signature: ………….………………………………                    date:  DAY / MONTH / YEAR 
 
Participant’s email and/or contact number: ……………………………………………………………………………………………………. 
 
 
 
 
I ……………………………………………………………..(researcher’s full name) have gone through the consent form and 
answered any questions that the participant has asked 
 
Researcher’s signature …………………………………………  date:     DAY / MONTH / YEAR 
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Appendix B Ethical clearance 
Ethical clearance document for the conducting of the study was approved by the Human 
research ethical council (HREC/192).
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Appendix C Clinical scales 
C 1. PANSS questionnaire 
Absent Minimal Mild Moderate
Moderate-
severe Severe Extreme Absent Minimal Mild Moderate
Moderate-
severe Severe Extreme
Positive scale General psychopathology scale
P1 Delusions 1 2 3 4 5 6 7 G1 Somatic concern 1 2 3 4 5 6 7
P2 Conceptual disorganization 1 2 3 4 5 6 7 G2 Anxiety 1 2 3 4 5 6 7
P3 Hallucinatory behaviour 1 2 3 4 5 6 7 G3 Guilt feelings 1 2 3 4 5 6 7
P4 Excitement 1 2 3 4 5 6 7 G4 Tension 1 2 3 4 5 6 7
P5 Grandiosity 1 2 3 4 5 6 7 G5 Mannerisms & posturing 1 2 3 4 5 6 7
P6 Suspiciousness 1 2 3 4 5 6 7 G6 Depression 1 2 3 4 5 6 7
P7 Hostility 1 2 3 4 5 6 7 G7 Motor retardation 1 2 3 4 5 6 7
Negative scale G8 Uncooperativeness 1 2 3 4 5 6 7
N1 Blunted effect 1 2 3 4 5 6 7 G9 Unusual thought content 1 2 3 4 5 6 7
N2 Emotional withdrawal 1 2 3 4 5 6 7 G10 Disorientation 1 2 3 4 5 6 7
N3 Poor rapport 1 2 3 4 5 6 7 G11 Poor attention 1 2 3 4 5 6 7
N4 Passive/apathetic social withdrawal 1 2 3 4 5 6 7 G12 Lack of judgment & insight 1 2 3 4 5 6 7
N5 Difficulty in abstract thinking 1 2 3 4 5 6 7 G13 Disturbance of volition 1 2 3 4 5 6 7
N6 Lack of spontaneity & flow of conversaiton 1 2 3 4 5 6 7 G14 Poor impulse control 1 2 3 4 5 6 7
N7 Stereotyped thinking 1 2 3 4 5 6 7 G15 Preoccupation 1 2 3 4 5 6 7
G16 Active social avoidance 1 2 3 4 5 6 7
Scale Total Percentile Range
Positive scale
Negative scale
General psychopathology
Number of symptoms rated > 3: Positive Negative
Typological classification
Instructions: Circle the appropriate rating for each dimension following the specified clinical interview. Refer to the rating manual for item definitions, description of anchoring points, and scoring procedure
Kay SR, Opler LA, Lindenmayer J-P (1988). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry research, 23:99-110
Positive and negative syndrome scale (PANSS) - Rating Form
Participant number                                                                                             Date of completion
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C 2. Calgary depression rating scale 
  
1 Depression 4 Guilty ideas of reference 7 Early wakening
0 Absent 0 Absent 0 Absent No early wakening.
1 Mild 1 Mild 1 Mild
2 Moderate 2 Moderate 2 Moderate
3 Severe 3 Severe 3 Severe
2 Hopeless ness 5 Pathological guilt 8 Suicide
0 Absent 0 Absent 0 Absent
1 Mild 1 Mild 1 Mild
2 Moderate 2 Moderate 2 Moderate
3 Severe 3 Severe 3 Severe
3 Self depreciation 6 Morning depression 9 Observed depression
0 Absent 0 Absent No depression 0 Absent
1 Mild 1 Mild 1 Mild
2 Moderate 2 Moderate 2 Moderate
3 Severe 3 Severe 3 Severe
Persitent sense of being accused. When challenged acknowledges 
that it is not so
Subject appears sad and mournful throughout the interview, with 
gloomy monotonous voice and is tearful or close to tears at times
Subject chokes on distressing topics, frequently sighs deeply and 
cries openly, or is persistently in a state of frozen misery
Frequent thoughts of being better off dead, or occcasional thoughts 
of suicide
Deliberately considered suicide with a plan, but made no attempt.
Suicidal attempt apparently designed to end in death (i.e., accidental 
discovery or inefficient means).
Based on interviewer's observations during the entire interview. The question 'Do 
you feel like crying?' used at appropriate points in the interview may elicit 
information useful to this observation
Subject appears sad and mournful even during parts of the 
interview involving affectively neutral discussion
Calgary depression rating scale
Subject feels worthless more than 50% of the time. May be 
challenged to acknowledge otherwise
Distinct depressed mood persisting up to half the time 
over last 2 weeks; present daily
Markedly depressed mood persisitng daily over half the 
time interfering with normal motor and social functioning
How do you see the future for youself? Can you see any future? - or has 
life seemed quite hopeless? Have you given up or does there still seem 
some reason for trying?
Has at times felt hopeless over the last week but still has 
some degree of hope for the future
Persistent, moderate sense of hopelessness over last 
week. Can be persuaded to acknowledge possibility of 
things being better
Do you tend to blame youself for little things you may have done in the past? Do 
you think you deserve to be so concerned about this?
Persisting and distressing sense of hopelessness
What is your opinion of yourself compared to other people? Do you feel 
better or not as good or about the same as most? Do you feel inferior or 
even worthless?
Some inferiority; not amounting to feeling of 
worthlessness.
Subject feels worthless, but less than 50% of the time
Depression present but no diurnal variation
Depression spontaneously mentioned to be worse in the a.m.
Depression markedly worse in a.m., with impared functioning 
which improves in p.m.
Do you wake earlier in the morning than is normal for you? How many times does 
this happen?
Participant number                                                                                             Date of completion
How would you describe your mood over the last 2 weeks: Do you keep 
reasonably cheerful or have you been very depressed or low spirited 
recently? In the last 2 weeks how often have you (own words) every 
day? All day?
Expresses some sadness or discouragement on 
questioning
Interviewer: Ask the first question as written. Use follow up probes or qualifiers at your discretion. Time frame refers to last 2 weeks unless stipulated. N.B. the last item, #9, is based on observations of the entire review
Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6:201-208
Occassionally wakes (up to twice weekly) 1 h or more before 
normal time to wake or alarm time.
Often wakes early (up to five times weekly) 1 h or more before 
normal time to wake or alarm.
Daily wakes 1 h or more before normal time.
Have you felt that life wasn't worth living? Did you ever feel like ending it all? What 
did you think you might do? Did you actually try?
Subject sometimes feels over guilty about some minor peccadillo, 
but less than 50% of time
Subject usually (over 50% of time) feels guilty about past actions 
the significance of which s/he exaggerates
Subject usually feels s/he is to blame for everything that has gone 
wrong, even when not his/her fault
When you have felt depressed over the last 2 weeks have you noticed the 
depression being worse at any particular time of day?
Do you have the feeling that you are being blamed for something or even wrongly 
accused? What about? (Do not include justifiable blame or accusation. Exclude 
delusions of guilt.)
Subject feels blamed but not accused less than 50% of the time
Persisting sense of being blamed, and/or occasional sense of being 
acused.
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C 3. Hamilton depression rating scale  
. HAMILTON DEPRESSION RATING SCALE (HAM-D)  
(HAM)  
Participant number ...................................    Date of Completion .................................. 
 
 
TICK APPROPRIATE BOX FOR EACH ITEM  
1. Depressed mood  
This item covers both the verbal and the non-verbal communication of sadness, depression, despondency, helplessness and hopelessness.  
 
WHAT HAS YOUR MOOD BEEN LIKE IN THE LAST WEEK? 
0 - Neutral mood.  □  
1 – When it is doubtful whether the patient is more despondent or sad than usual. E.g. the patient vaguely indicates to be more depressed than usual.  □  
2 – When the patient more clearly is concerned with unpleasant experiences, although he still is without helplessness or hopelessness.  □  
3 – The patient shows clear non-verbal signs of depression and/or is at times overpowered by helplessness or hopelessness.  □  
4 – The patient’s remark on despondency and helplessness or the non-verbal ones dominate the interview in which the patient cannot be distracted.  □  
2. Self-depreciation and guilt feelings  
This item covers the lowered self-esteem with guilt feelings.  
 
DO YOU FEEL YOU ARE LETTING PEOPLE DOWN?  
0 – No self-depreciation or guilt feelings.  □  
1 – Doubtful whether guilt feelings are present, because the patient is only concerned with the fact that he during the actual illness has been a burden to the family or colleagues due to reduced work 
capacity.  □  
2 – Self-depreciation or guilt feelings are more clearly present because the patient is concerned with incidents in the past prior to the actual episode. E.g. the patient reproaches himself small omissions or 
failures, not to have done his duty or to have harmed others.  □  
3 – The patient suffers from more severe guilt feelings. He may express that he feels that the actual suffering is some sort of a punishment. Score 3 as long as the patient intellectually can see that his 
view is unfounded.  □  
4 – The guilt feelings are firmly maintained and resist any counterargument, so that they have become paranoid ideas.  □  
3. Suicidal impulses  
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DO YOU FEEL LIFE IS NOT WORTH LIVING? HAVE YOU THOUGHT ABOUT TAKING YOUR OWN LIFE? 
0 – No suicidal impulses.  □  
1 – The patient feels that life is not worthwhile, but he expresses no wish to die.  □  
2 – The patient wishes to die, but has no plans of taking his own life.  □  
3 – It is probable that the patient contemplates to commit suicide.  □  
4 – If during the days prior to the interview the patient has tried to commit suicide or if the patient in the ward is under special observation due to suicidal risk.  □  
4. Initial insomnia  
 
HOW HAVE YOU BEEN SLEEPING IN THE LAST WEEK? 
0 – Absent  □  
1 – When the patient 1 (-2) out of the last 3 nights has had to lie en bed for more than 30 minutes before falling asleep.  □  
2 – When the patient all 3 nights has been in bed for more than 30 minutes before falling asleep.  □  
6. Delayed insomnia = Premature awakening  
The patient wakes up before planned by himself or his surroundings.  
 
DO YOU WAKE UP EARLIER THAN YOU INTEND TO? 
0 – Absent  □  
1 – Less than 1 hour (and may fall asleep again).  □  
2 – Constantly – or more than 1 hour too early.  □  
7. Work and interests  
This item includes both work carried out and motivation. Note, however, that the assessment of tiredness and fatigue in their physical manifestations is included in item 13 (general somatic symptoms) and in 
item 23 (tiredness and pain).  
A. At first rating of the patient  
 
ARE YOU HAVING DIFFICULTIES AT WORK? HAVE YOU BEEN PRODUCTIVE AT WORK? 
0 – Normal work activity.  □  
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1 – When the patient expresses insufficiency due to lack of motivation, and/or trouble in carrying out the usual workload, which the patient, however, manages to do without reduction.  □  
2 – More pronounced insufficiency due to lack of motivation and/or trouble in carrying out the usual work. Here the patient has reduced work capacity, cannot keep normal speed, copes with less job or 
in the home; the patient may stay home some days or may try to leave early.  □  
3 – When the patient has been sick-listed, or if the patient has been hospitalized (as day-activities).  □  
4 – When the patient is fully hospitalized and generally unoccupied without participation in the ward activities.  □  
B. At weekly ratings  
0 – Normal work activity. a) The patient has resumed work at his/her normal activity level. b) When the patient will have no trouble to resume normal work.  □  
1 a) The patient is working, but at a reduced activity level, either due to lack of motivation or due to difficulties in the accomplishment of his normal work. b) The patient is not working and it is still doubtful 
that he can resume his normal work without difficulties.  
2 – The patient is working, but at a clearly reduced level, either due to episodes of non-attendance or due to reduced work time. The patient is still hospitalized or sick-listed, participates more than 3-4 
hours per days in ward (or home) activities, but is only capable to resume normal work at a reduced level. If hospitalized the patient is able to change from full stay to day-patient status.  □  
3 – When the patient has been sick-listed, or if the patient has been hospitalized (as day-activities).  □  
4 – When the patient is fully hospitalized and generally unoccupied without participation in the ward activities.  □  
8. Retardation (general)  
 
OBSERVATION 
0 – Normal verbal activity, normal motor activity with adequate facial expression.  □  
1 – Conversational speed doubtfully or slightly reduced and facial expression doubtfully or slightly stiffened (retarded).  □  
2 – Conversational speed clearly reduced with intermissions; reduced gestures and slow pace.  □  
3 – The interview is clearly prolonged due to long latencies and brief answers; all movements were slow.  □  
4 – The interview cannot be completed, retardation approaches (and includes) stupor.  □  
9. Agitation  
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OBSERVATION 
0 – Normal motor activity with adequate facial expression.  □  
1 – Doubtful or slight agitation. E.g. tendency to changing position in chair or at times scratching his head.  □  
2 – Fidgeting; wringing hands, changing position in chair again and again. Restless in ward, with some pacing.  □  
3 – Patient cannot stay in chair during interview and/or much pacing in ward.  □  
4 – Interview has to be conducted “on the run”. Almost continuous pacing. Pulling off clothes, tearing his hair.  □  
10. Anxiety (psychic) This item includes tenseness, irritability, worry insecurity, fear and apprehension approaching overpowering dread. It may often be difficult to distinguish between the patient’s experience 
of anxiety (“psychic” or “central” anxiety phenomena) and the physiological (“peripheral”) anxiety manifestations, which can be observed, e.g., hand tremor and sweating. Most important is the patient’s report 
on worry, insecurity, uncertainty, and experiences of dreadfulness i.e. the psychic (“central”) anxiety.  
 
ARE YOU WORRYING ABOUT THINGS MORE THAN USUAL? 
0 – The patient is neither more nor less insecure or irritable than usual.  □  
1 – It is doubtful whether the patient is more insecure or irritable than usual.  □  
2 – The patient expresses more clearly to be in a state of anxiety, apprehension or irritability, which he may find difficult to control. It is thus without influence on the patient’s daily life, because the 
worrying is still about minor matters.  □  
3 – The anxiety or insecurity is at times more difficult to control, because the worrying is about major injuries or harms, which might occur in the future. E.g.: the anxiety may be experienced as panic, 
i.e. overpowering dread. Has occasionally interfered with the patient’s daily life.  □  
4 – The feeling of dreadfulness is present so often that it markedly interferes with the patient’s daily life.  □  
11. Anxiety (somatic) This item includes physiological concomitants of anxiety: All feeling states should be rated under item 10 and not here.  
 
HAVE YOU GOT ANY PHYSICAL SYMPTOMS AT THE MOMENT? (If due to meds, are then symptoms not due to meds?) 
0 – When the patient is neither more nor less prone than usual to experience somatic concomitants of anxiety feeling states.  □  
1 – When the patient occasionally experiences slight manifestations like abdominal symptoms, sweating or trembling. However, the description is vague and doubtful.  □  
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2 – When the patient from time to time experiences abdominal symptoms, sweating trembling etc. Symptoms and signs are clearly described, but are not marked or incapacitating, i.e. still without 
influence on the patient’s daily life.  □  
3 – Physiological concomitants of anxious feeling states are marked and sometimes very worrying. Interfere occasionally with the patient’s daily life.  □  
4 – The feeling of dreadfulness is present so often that it markedly interferes with the patient’s daily life.  □  
12. Gastro-Intestinal Symptoms may stem from the entire gastro-intestinal tract. Dry mouth, loss of appetite, and constipation are more common than abdominal cramps and pains. Must be distinguished from 
gastro-intestinal anxiety symptoms (“butterflies in the stomach”) or loose bowel movements) and also from nihilistic ideas (no bowel movements for weeks or months; the intestines have withered away) which 
should be rated under 15 (Hypochondriasis).  
 
WHAT IS YOUR APPETITE LIKE? 
0 – No gastro-intestinal complaints (or symptoms unchanged from before onset of depression).  □  
1 – Eats without encouragement by staff, and food intake is about normal, but without relish (all dishes taste alike and cigarettes are without flavour). Sometimes constipated.  □  
2 – Food intake reduced, patient has to be urged to eat. As a rule clearly constipated. Laxatives are often tried, but are of little help.  □  
13. General Somatic Central is feelings of fatigue and exhaustion, loss of energy. But also diffuse muscular achings and pains in neck, back or limbs, e.g. muscular headache.  
 
HAVE YOU GOT ANY ACHES AND PAINS? WHAT IS YOUR ENERGY LEVEL LIKE? 
0 – The patient is neither more nor less tired or troubled by bodily discomfort than usual.  □  
1 – Doubtful or very vague feelings of muscular fatigue or other somatic discomfort.  □  
2 – Clearly or constantly tired and exhausted, and/or troubled by bodily discomforts, e.g. muscular headache.  □  
14. Sexual Interests This subject I often difficult to approach, especially with elderly patients. In males try to ask questions concerning sexual preoccupation and drive, in females responsiveness (both to 
engage in sexual activity and to obtain satisfaction in intercourse).  
 
MEN: HAVE YOU BEEN THINKING ABOUT SEX MORE THAN USUAL? HAS YOUR SEX DRIVE CHANGED (INCREASED OR DECREASED) IN THE LAST WEEK? 
WOMEN: HAS YOUR INTEREST IN SEX CHANGED IN THE LAST WEEK?               
 
0 – Not unusual.  □  
1 – Doubtful or mild reduction in sexual interest and enjoyment.  □  
2 – Clear loss of sexual appetite often functional impotence in men and lack of arousal or plain disgust in women.  □  
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15. Hypochondriasis  
Preoccupation with bodily symptoms or functions (in the absence of somatic disease).  
 
OBSERVED 
0 – The patient pays no more interest than usual to the slight bodily sensations of every day life.  □  
1 – Slightly or doubtfully more occupied than usual with bodily symptoms and functions.  □  
2 – Quite worried about his physical health. The patient expresses thoughts of organic disease with a tendency to “somatise” the clinical presentation.  □  
3 – The patient is convinced to suffer from a physical illness, which can explain all his symptoms (brain tumour, abdominal cancer, etc.), but the patient can for a brief while be reassured that this is not 
the case.  □  
4 – The preoccupation with bodily dysfunction has clearly reached paranoid dimensions. The hypochondriacal delusions often have a nihilistic quality or guilt associations: to be rotting inside; insects 
eating the tissues; bowels blocked and withered away, other patients are being infected by the patient’s bad odour or his syphilis. Counter-argumentation is without effect.  □  
16. Loss of insight  
This item has, of course, only meaning if the observer is convinced that the patient at the interview still is in a depressive state.  
 
IF DEPRESSION SUSPECTED: HAVE YOU BEEN FEELING DEPRESSED? 
0 – The patient agrees to have depressive symptoms or a “nervous” illness.  □  
1 – The patient still agrees to being depressed, but feels this to be secondary to non-illness related conditions like malnutrition, climate, overwork.  □  
2 – Denies being ill at all. Delusional patients are by definition without insight. Enquiries should therefore be directed to the patient’s attitude to his symptoms of Guilt (item 2) or Hypochondriasis (item 15), but 
other delusional symptoms should also be considered.  
17. Weight loss Try to get objective information; if such is not available be conservative in estimation.  
A. At first interview this item covers the whole actual period of illness  
 
HAS YOUR WEIGHT CHANGED NOTICEABLY IN THE LAST MONTH? 
0 – No weight loss.  □  
1 – 1-2.5 kg weight loss.  □  
2 – Weight loss of 3 kg or more.  □  
B. At weekly interviews  
0 – No weight loss.  □  
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1 – ½ kg pr week.  □  
2 – 1 kg or more per week.  □  
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C 4. Young mania rating scale 
Young Mania Rating Scale (YMRS) 
1. Elevated Mood   0 Absent 
1 Mildly or possibly increased on questioning 
2 Definite subjective elevation; optimistic, self-confident; cheerful; appropriate to content 
3 Elevated; inappropriate to content; humorous 
4 Euphoric; inappropriate laughter; singing 
 
2. Increased Motor Activity-Energy 0 Absent 
1 Subjectively increased 
2 Animated; gestures increased 
3 Excessive energy; hyperactive at times; restless (can be calmed) 
4 Motor excitement; continuous hyperactivity (cannot be calmed) 
 
3. Sexual Interest    0 Normal; not increased 
1 Mildly or possibly increased 
2 Definite subjective increase on questioning 
3 Spontaneous sexual content; elaborates on sexual matters; hypersexual by self-report 
4 Overt sexual acts (toward patients, staff, or interviewer) 
 
4. Sleep    0 Reports no decrease in sleep 
1 Sleeping less than normal amount by up to one hour 
2 Sleeping less than normal by more than one hour 
3 Reports decreased need for sleep 
4 Denies need for sleep 
 
5. Irritability   0 Absent 
2 Subjectively increased 
4 Irritable at times during interview; recent episodes of anger or annoyance on ward 
6 Frequently irritable during interview; short, curt throughout 
8 Hostile, uncooperative; interview impossible 
 
6. Speech (Rate and Amount) 0 No increase 
2 Feels talkative 
4 Increased rate or amount at times, verbose at times 
6 Push; consistently increased rate and amount; difficult to interrupt 
8 Pressured; uninterruptible, continuous speech 
 
7. Language-Thought Disorder  0 Absent 
1 Circumstantial; mild distractibility; quick thoughts 
2 Distractible, loses goal of thought; changes topics frequently; racing thoughts 
3 Flight of ideas; tangentiality; difficult to follow; rhyming, echolalia 
4 Incoherent; communication impossible 
 
8. Content   0 Normal 
2 Questionable plans, new interests 
4 Special project(s); hyper-religious 
6 Grandiose or paranoid ideas; ideas of reference 
8 Delusions; hallucinations 
 
9. Disruptive-Aggressive Behavior  0 Absent, cooperative 
2 Sarcastic; loud at times, guarded 
4 Demanding; threats on ward 
6 Threatens interviewer; shouting; interview difficult 
8 Assaultive; destructive; interview impossible 
 
10. Appearance   0 Appropriate dress and grooming 
1 Minimally unkempt 
2 Poorly groomed; moderately disheveled; overdressed 
3 Disheveled; partly clothed; garish make-up 
4 Completely unkempt; decorated; bizarre garb 
 
11. Insight    0 Present; admits illness; agrees with need for treatment 
1 Possibly ill 
2 Admits behavior change, but denies illness 
3 Admits possible change in behavior, but denies illness 
4 Denies any behavior change 
 
 
 
Participant number …………………………………..  Date of completion ……………………………….. 
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C 5. Clinical global impression severity rating scale and global assessment of functioning 
scale  
  
Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?
0 Not assessed
1 Normal, not at all ill
2 Borderline mentally ill 
3 Mildly ill 
4 Moderately ill
5 Markedly ill
6 Severely ill
7 Among the most extremely ill patients
91 - 100
81 - 90
71 - 80
61 - 70
51 - 60
41 - 50
31 - 40
21 - 30
11 - 20
0 - 10
Clinical global impression severity scale (CGI-S)
Global Assessment of Functioning(GAF) scale (DSM - IV Axis V)
Person has no problems OR has superior functioning in several areas OR is admired and sought after by others due to 
positive qualities
Person has few or no symptoms. Good functioning in several areas. No more than "everyday" problems or concerns.
Person has symptoms/problems, but they are temporary, expectable reactions to stressors. There is no more than 
slight impairment in any area of psychological functioning.
Persistent danger of harming self or others OR persistent inability to maintain personal hygiene OR person has made 
a serious attempt at suicide.
Mild symptoms in one area OR difficulty in one of the following: social, occupational, or school functioning. BUT, the 
person is generally functioning pretty well and has some meaningful interpersonal relationships.
Moderate symptoms OR moderate difficulty in one of the following: social, occupational, or school functioning.
Serious symptoms OR serious impairment in one of the following: social, occupational, or school functioning.
Some impairment in reality testing OR impairment in speech and communication OR serious impairment in several 
of the following: occupational or school functioning, interpersonal relationships, judgment, thinking, or mood.
Presence of hallucinations or delusions which influence behavior OR serious impairment in ability to communicate 
with others OR serious impairment in judgment OR inability to function in almost all areas.
There is some danger of harm to self or others OR occasional failure to maintain personal hygiene OR the person is 
virtually unable to communicate with others due to being incoherent or mute.
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C 6. Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)  
 
 
ASSIST - Drug Use Frequency Questionaire
YES NO
Tobacco
Alcoholic Beverages (beer, wine etc)
Cannabis (dagga, marijuana)
Cocaine (rocks, coke, crack)
Amphetamine Type Stimulants (Tik)
Inhalants (nitrous glue, petrol)
Sedatives or sleeping pills (
Hallucinogens (LSD, acid, mushrooms, PCP, special K)
Opioids (heroin, morphine, methadone, unga)
Other (eg Mandrax, Buttons)
Never Once or Twice Monthy Weekly Daily or Almost Daily
Tobacco 0 2 3 4 6
Alcoholic Beverages (beer, wine etc) 0 2 3 4 6
Cannabis (dagga, marijuana) 0 2 3 4 6
Cocaine (rocks, coke, crack) 0 2 3 4 6
Amphetamine Type Stimulants (Tik) 0 2 3 4 6
Inhalants (nitrous glue, petrol) 0 2 3 4 6
Sedatives or sleeping pills 0 2 3 4 6
Hallucinogens (LSD, acid, mushrooms, PCP, special K) 0 2 3 4 6
Opioids (heroin, morphine, methadone, unga) 0 2 3 4 6
Other (eg. Mandrax/Buttons) 0 2 3 4 6
I am going to ask you some questions about your experience of using  substances across your l ifetime and in the past three months. These substances can be smoked, swallowed, snorted, 
inhaled, injected or taken in the form of pil ls. Some of the substances listed may be prescribed by a doctor (l ike amphetamines, sedatives, pain medications). For this interview, we will  not record 
medications that are used as prescribed by your doctor. However, if you have taken such medications for reasons other than prescription, or taken them more frequently or at higher doses than 
prescribed, please let me know. While we are also interested in knowing about your use of various il l icit drugs, please be assured that information on such use will  be treated as strictly 
confidential
Probe if all answers are negative: "Not even when you were in school?", If "No" to all 
items, skip substance use questionaire. If "Yes" to any of these items, ask Question 2 
for each substance ever used. 
Question 2: In the past three months, how often have you used the substances you mentioned (FIRST DRUG, SECOND DRUG, ETC)
If "Never" to all items in Question 2, skip to Question 6. If any substances in Question 2 were used in the previous three months, continue with Questions 3, 4 & 5 for each substance  used.
Question 1: In your life, which of the following substances have you used.
Question 3: During the past three months, how often have you had a strong desire or urge to use?
Never Once or Twice Monthy Weekly Daily or Almost Daily
Tobacco 0 3 4 5 6
Alcoholic Beverages (beer, wine etc) 0 3 4 5 6
Cannabis (dagga, marijuana) 0 3 4 5 6
Cocaine (rocks, coke, crack) 0 3 4 5 6
Amphetamine Type Stimulants (Tik) 0 3 4 5 6
Inhalants (nitrous glue, petrol) 0 3 4 5 6
Sedatives or sleeping pills 0 3 4 5 6
Hallucinogens (LSD, acid, mushrooms, PCP, special K) 0 3 4 5 6
Opioids (heroin, morphine, methadone, unga) 0 3 4 5 6
Other (eg.  Mandrax/Buttons) 0 3 4 5 6
Question 4: During the past three months, how often has your use of substances led to health, social, legal or financial problems? (please circle)
Never Once or Twice Monthy Weekly Daily or Almost Daily
Tobacco 0 4 5 6 7
Alcoholic Beverages (beer, wine etc) 0 4 5 6 7
Cannabis (dagga, marijuana) 0 4 5 6 7
Cocaine (rocks, coke, crack) 0 4 5 6 7
Amphetamine Type Stimulants (Tik) 0 4 5 6 7
Inhalants (nitrous glue, petrol) 0 4 5 6 7
Sedatives or sleeping pills 0 4 5 6 7
Hallucinogens (LSD, acid, mushrooms, PCP, special K) 0 4 5 6 7
Opioids (heroin, morphine, methadone, unga) 0 4 5 6 7
Other (eg. Mandrax/Buttons) 0 4 5 6 7
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Never Once or Twice Monthy Weekly Daily or Almost Daily
Tobacco 0 5 6 7 8
Alcoholic Beverages (beer, wine etc) 0 5 6 7 8
Cannabis (dagga, marijuana) 0 5 6 7 8
Cocaine (rocks, coke, crack) 0 5 6 7 8
Amphetamine Type Stimulants (Tik) 0 5 6 7 8
Inhalants (nitrous glue, petrol) 0 5 6 7 8
Sedatives or sleeping pills 0 5 6 7 8
Hallucinogens (LSD, acid, mushrooms, PCP, special K) 0 5 6 7 8
Opioids (heroin, morphine, methadone, unga) 0 5 6 7 8
Other (eg. Mandrax/Buttons) 0 5 6 7 8
Ask Questions 6 & 7 for all substances ever used (i.e. those endorsed in Question 1)
No, Never Yes, in the past 3 months Yes, but not in the past 3 
months
Tobacco 0 6 3
Alcoholic Beverages (beer, wine etc) 0 6 3
Cannabis (dagga, marijuana) 0 6 3
Cocaine (rocks, coke, crack) 0 6 3
Amphetamine Type Stimulants (Tik) 0 6 3
Inhalants (nitrous glue, petrol) 0 6 3
Sedatives or sleeping pills 0 6 3
Hallucinogens (LSD, acid, mushrooms, PCP, special K) 0 6 3
Opioids (heroin, morphine, methadone, unga) 0 6 3
Other (eg. Mandrax/Buttons) 0 6 3
Question 6: Has a friend or relative or anyone else ever expressed concern about your use of specific substances?
Question 5: During the past three months, how often have you failed to do what was normally expected of you because of your use of substance use? (please circle)
No, Never Yes, in the past 3 months Yes, but not in the past 3 
months
Tobacco 0 6 3
Alcoholic Beverages (beer, wine etc) 0 6 3
Cannabis (dagga, marijuana) 0 6 3
Cocaine (rocks, coke, crack) 0 6 3
Amphetamine Type Stimulants (Tik) 0 6 3
Inhalants (nitrous glue, petrol) 0 6 3
Sedatives or sleeping pills 0 6 3
Hallucinogens (LSD, acid, mushrooms, PCP,special K) 0 6 3
Opioids (heroin, morphine, methadone, unga) 0 6 3
Other (eg.  Mandrax/Buttons) 0 6 3
No, Never Yes, in the past 3 months Yes, but not in the past 3 
months
0 2 1
Total Score Drug 1: __________                                                                                                             Total Score Drug 2: __________ Total Score Drug 3: _________   
Total Score drug 4: _________ Total Score Drug 5: __________ Total Score Drug 6: __________                                                                                                               
Participant Number: Date of completion:
Question 7: Have you ever tried and failed to control, cut down or stop using specific drugs?
Question 8: Have you ever used any drug by injection? 
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C 7. Simpson angus extrapyrimidal symptom scale 
 
Simpson-Angus Rating Scale for Extrapyramidal Side Effects
Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212:11-19, 1970
1
0 Normal
1 Diminution in swing while the patient is walking
2 Marked diminution in swing with obvious rigidity in the arm
3 Stiff gait with arms held rigidly before the abdomen
4 Stopped shuffling gait with propulsion and retropulsion
2
0 Normal, free fall  with loud slap and rebound
1 Fall slowed slightly with less audible contract and little rebound
2 Fall slowed, no rebound
3 Marked slowing, no slap at all
4 Arms fall  as though against resistance; as though through glue
3
0 Normal
1 Slight stiffness and resistance
2 Moderate stiffness and resistance
3 Marked rigidity with difficulty in passive movement
4 Extreme stiffness and rigidity with almost a frozen shoulder
4
0 Normal
1 Slight stiffness and resistance
2 Moderate stiffness and resistance
3 Marked rigidity with difficulty in passive movement
4 Extreme stiffness and rigidity with almost a frozen joint
5
0 Normal
1 Slight stiffness and resistance
2 Moderate stiffness and resistance
3 Marked rigidity with difficulty in passive movement
4 Extreme stiffness and rigidity with almost a frozen wrist
Instructions: The exam should be conducted in a room where the subject can wlak a sufficient distance to allow him/her to get into a 
natural rhythm (e.g., 15 paces). Each side of the body should be examined. If one side shows more pronounced pathology than the 
other, this scoure should be noted and this taken. Cogwheel rigidity may be palpated when the examination is carried out for items, 3,4, 
5, and 6. It is not rated separately and is merely another way to detect rigidity. It would indicate that a minimum score of 1 would be 
mandatory. 
Shoulder Shaking: The subject's arms are bent at a right angle at the elbow and are taken one at a time by the examiner who 
grasps one hand and also clasps the other around the patient's elbow. The subject's upper arm is pushed to and fro and the 
humerus is externally rotated. The degree of resistance form normal to extreme rigidity is scored as follows:
Elbow Rigidity: The elbow joints are separately bent at right angles and passively extended and flexed, with the subject's biceps 
observed and simulataneously palpated, The resistance to this procedure is rated. (The presence of cogwheel rigidity is noted 
separately.)
Wrist rigidity or Fixation of position: The wrist is held in one hand and the fingers held by the examiner's other hand, with the 
wrist moved to extension, flexion and ulnar and radial deviation.
Gait: The patient is examined as he walks into the examining room, his gait, the swing of this arms, his general posture, all  form 
the basis for an overall  score for this item. This is rated as follows:
Arm Dropping: The patient and the examiner both raise their arms to sholder height and let them fall  to their sides. In a normal 
subject, a stout slap is hear as the arms hit the sides. In the patient with extreme Parkinson's syndrome, the arms fall  very 
slowly:
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6
0 The legs swing freely
1 Slight diminution in the swing of the legs 
2 Moderate resistance to swing
3 Marked resistance and damping of swing
4 Complete absence of swing
7
0 The head falls completely with a good thump as it hits the table
1 Slight slowing in  fall, mainly noted by lack of slap as head meets the table
2 Moderate slowing in the fall  quite noticeable to the eye
3 Head falls stiffly and slowly
4 Head does not reach the examining table
8
0 0-5 blinks
1 6-10 blinks
2 11-15 blinks
3 16-20 blinks
4 21 and more blinks
9
0 Normal
1 Mild finger tremor, obvious to sight and touch
2 Tremor of hand or arm occurring spasmodically
3 Persistent tremor of one or more limbs
4 Whole body tremor
10
0 Normal
1 Excess salivation to the extent that pooling takes place if the mouth is open and the tongue is raised. 
2 When excess salivation is present and might occasionally result in difficulty in speaking
3 Speaking with difficulty because of excess salivation
4 Frank drooling
Total Score: 
Date:Participant Number:
Glabella Tap: Subject is told to open eyes wide and not to blink. The glabella region is tapped at a steady, rapid speed. The 
number of times patient blinks in succession is noted
Tremor: Patient is observed walking into examining room and is then re-examined for this item
Salivation: Patient is observed while talking and then asked to open his mouth and elevate his tongue. The following ratings are 
given:
Leg Pendulousness: The patient sits on a table with his legs hanging down and swinging free. The ankle is grasped by the 
examiner and raised until  the knee is partially extended. It is then allowed to fall. The resistance to fall ing and the lack of 
swinging form the basis of the score on this item.
Head Dropping: The patient l ies on a well-padded examining table and his head is raised by the examiner's hand. The hand is 
then withdrawn and the head allowed to drop. In the normal subject the head will  fall  upon the table. The movement is delayed 
in extrapyramidal system disorders and in extreme parkinsonism it is absent. The neck muscles are rigid and the head does not 
reach the examining table. 
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C 8. Edinburgh handedness questionnaire  
Edinburgh Handedness Questionnaire
Oldfield,RC. (1971). The assessment and analysis of handedness: The edinburgh inventory. Neuropsychologia. 9:97-113
Right Both Left Which hand do you write with?
Right Both Left Which hand do you draw with?
Right Both Left When throwing a ball, which hand do you use?
Right Both Left When using scissors, which hand does the cutting?
Right Both Left When brushing or combing your hair, which hand holds the brush/comb?
Right Both Left When brushing your teeth, which hand holds the toothbrush?
Right Both Left When cutting a loaf of bread, which hand holds the knife?
Right Both Left When eating soup, which hand holds the spoon?
Right Both Left When using a hammer, which hand hammers the nail into the wood?
Right Both Left When using a screwdriver, which hand turns the screwdriver to tighten the screw?
Right Both Left When playing tennis, which hand holds the racket?
Right Both Left When using both a knife and a fork, which hand holds the fork?
Right Both Left When hitting a ball with a cricket bat, which hand is at the top of bat? 
Right Both Left when hitting a golf ball with a golf stick, which hand is at the top of the club?
Right Both Left When sweeping with a broom, which hand is at the top of the broom?
Right Both Left When raking leaves up with a rake, which hand is at the top of the rake?
Right Both Left When striking a match, which hand is holding the match?
Right Both Left When opening the match box to get a match, which hand takes the match out?
Right Both Left When dealing cards, which hands deals to the players?
Right Both Left When threading and needle, which hand is used to put the thread through the eye of the needle?
Date of Completion:
Which Hand?
Participant Number:
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Appendix D Statistical data 
Table D 1 Demographic mean and standard deviation   
 
Table D 2 Behavioural mean and standard deviation  
 
  
Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. Mean Std.Dev.
Age on day of imaging (yrs) * 25,74 3,75 29,67 5,43 29,64 4,91 26,05 5,47
Duration at school (yrs) 11,56 1,25 10,70 1,81 11,39 1,07 # 10,24 1,64
Tertiary education (yrs) 2,30 3,15 1,48 1,95 1,71 1,82 0,57 1,35
Total duration of education (yrs) 13,85 3,78 12,19 3,23 13,11 2,51 @ 10,80 2,38
Weight (kg) * 69,17 7,96 85,48 24,30 83,83 14,57 & 68,77 15,18
BMI * 23,28 3,00 29,24 7,96 28,75 5,24 & 23,34 3,69
Handedness (left:right)
Controls
n=27
Schizophrenia 
1:26 3:24 2:26 3:19
Methamphetamine induced psychosis 
n=21
Bipolar I disorder 
n=27 n=28
* CON vs SCZ and BPD; # CON vs MPD; @ MPD vs CON and BPD & MPD vs SCZ and BPD.  Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. Mean Std.Dev.
Continuous Performance Task 
Correct responses (χ/60) 53,59 10,71 * 44,23 13,27 51,82 10,91 46,52 14,83
Overall response time (msec) 231,56 103,55 * 459,96 233,98 315,43 141,22 330,19 142,42
Errors of commission 4,81 8,05 7,77 9,33 6,29 10,19 11,29 13,98
Errors of omission 1,59 4,84 # 8,00 11,93 1,89 4,08 2,19 3,36
Trick S responses 0,63 2,51 1,19 2,83 0,43 0,96 0,67 1,20
* CON vs SCZ # SCZ vs CON and BPD.  Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
Controls Schizophrenia Bipolar I disorder Methamphetamine induced psychosis 
n=27 n=27 n=28 n=21
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Table D 3 Clinical scales mean and standard deviation  
 
  
Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. Mean Std.Dev.
Positive & Negative Syndrome Scale
Total score 43 30-100 48 30-100 * 35 30-73 45 30-77
Positive symptoms 8 7-25 # 12 7-24 7 7-25 7 7-19
Negative symptoms 11 7-30 13 7-30 * 9 7-20 12 7-27
General psychopathology 22 16-50 # 23 16-50 19 16-37 22 16-38
Calgary depression for schizophrenia 1 0-13 2 0-8 0 0-13 1 0-9
Hamilton depression rating scale 1 0-20 2 0-10 0 0-20 2 0-5
Young mania rating scale 2 0-16 3 0-15 1 0-16 2 0-12
Clinical global impression of illness severity 2 1-4 # 3 1-4 2 1-4 2 1-4
Global assessment of functioning scale 65 5-90 # 60 30-85 71 5-85 65 31-90
Simpson Angus scale for parkinsonism 0 0-16 # 1 0-16 0 0-1 0 0-9
 * BPD vs SCZ, and MPD ; # SCZ vs BPD. Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
n=76 n=27 n=28 n=21
Psychotic groups 
combined
Schizophrenia Bipolar I disorder 
Methamphetamine 
induced psychosis 
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Table D 4 ASSIST scores mean and standard deviation  
  
Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. Mean Std.Dev.
Total substance involvement score 17 13 27 26 27 22 * 60 25
Tobacco score 6,07 8,10 12,96 12,91 12,68 11,21 * 22,29 6,25
Alcohol score 5,81 4,95 5,93 6,24 6,96 5,36 8,48 6,40
Cannabis score 3 3 3 5 5 7 * 9 7
Cocaine score 1 1 0 0 1 1 1 2
Methamphetamine score 0 1 2 6 0 1 * 13 10
Inhalants score 0 1 1 2 0 0 0 1
Sedatives sleeping pill score 0 1 1 2 1 3 1 2
Hallucinogens score 0 1 0 1 1 2 1 1
Opioids score % 0 1 0 1 0 1 1 1
Mandrax score 0 1 1 2 0 1 * 4 4
  * MPD vs all other groups;  % Denotes significant differences but not between groups. Non- parametric Kruskal Wallis (H- test), Significance P<0,05.
Controls Schizophrenia Bipolar I disorder Methamphetamine induced psychosis 
n=76 n=27 n=28 n=21
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Table D 5 Medication mean and standard deviation  
 
 
 
 
  
Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. Mean Std.Dev.
Duration of psychotic disorders (years) 6,30 5,35 7,41 5,60 7,59 5,27 3,13 3,83
Chlorpromazine equivalents 210,03 299,27 330,56 438,77 151,34 178,79 133,33 108,78
Positive & Negative Syndrome Scale
Total score 23,03 6,95 52,33 17,46 $ 39,04 10,78 46,62 11,86
Positive symptoms 45,86 14,76 # 12,22 5,02 9,07 4,09 8,95 3,09
Negative symptoms 10,16 4,44 14,89 6,53 $ 9,21 3,12 14,43 5,63
General psychopathology 12,67 5,82 # 25,22 8,10 20,75 5,76 23,24 6,11
Calgary depression for schizophrenia 2,34 2,88 2,70 2,49 2,00 3,12 2,33 3,10
Hamilton depression rating scale 1,96 3,42 4,52 4,46 3,46 5,01 3,33 3,26
Young mania rating scale 3,80 4,36 2,22 2,69 2,04 4,86 1,52 1,50
Clinical global impression of illness severity scale 2,43 1,04 # 2,93 1,07 2,00 0,90 2,38 0,92
Global assessment of functioning scale 64,30 13,51 61,17 11,36 @ 67,30 15,01 64,31 13,68
Simpson Angus scale for parkinsonism 1,17 2,57 # 2,15 3,46 0,07 0,26 1,38 2,46
n=76 n=27 n=28 n=21
* MPD vs SCZ, and BPD; # SCZ vs MPD ;% Denotes significant differences but not between groups; & BPD vs SCZ, and  MPD  ;$ BPD vs MPD.  Non- parametric Kruskal Wallis (H- test), Significance 
P<0,05.
Psychotic groups 
combined
Schizophrenia Bipolar I disorder Methamphetamine induced psychosis 
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Appendix E Spearman rank order correlations 
Table E 1 Spearman rank order correlations for demographics  
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Table E 2 Spearman rank order correlations for behavioural data  
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Table E 3 Spearman rank order correlations for the ASSIST scores  
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Table E 4 Spearman rank order correlations for the clinical scales  
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Appendix F Spearman rank order correlation graphical representation 
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